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ABSTRACT
Melesse, Michael Ph.D., Purdue University, December 2015. Characterization of
mitotic regulators Acm1 and Cdc14. Major Professor: Mark C. Hall.
Mitotic exit and cytokinesis are driven by a complex set of processes that serve to
reset the eukaryotic cell cycle and allow entry into the subsequent cycle. These steps
are driven by a combination of molecular events that lead to the termination of high
cyclin dependent kinase (Cdk) activity and reversal of Cdk mediated phosphorylation.
Proteasomal degradation of cyclins is essential for terminating Cdk activity and active
dephosphorylation of Cdk mediated phosphorylation is important for the appropriate
completion of the cell cycle.
The anaphase promoting complex (APC) is a ubiquitin ligase responsible for promoting events in late mitosis by polyubiquitinating, among other substrates, cyclins
and targeting them for degradation. Cdh1 is a highly conserved activator of the
APC and its activity is regulated by, among other mechanisms, a pseudosubstrate
inhibitor, Acm1. I have demonstrated that Acm1 degradation in G1 is mediated by
a non-canonical proteasomal degradation mechanism that does not require polyubiquitin conjugation. I also show that expression of an Acm1 mutant resistant to this
degradation mechanism (Acm1N ∆52 ) leads to reduced cell fitness.
The activity of mitotic phosphatases is essential for the reversal of Cdk phosphorylation at the end of the cell cycle. Cdc14 activity is essential in budding yeast.
However, it is only recently that its role in ordering late mitotic events has begun to
be appreciated. By characterizing Cdc14 substrate selectivity, using phosphopeptide
substrates, it has become clear that Cdc14 preferentially dephosphorylates a subset of Cdk phosphorylation sites. Here I show that Cdc14 substrate selectivity is
conserved across diverse species and this selectivity can be used to gain insight into

xv
Cdc14 substrates in these organisms, where there is limited understanding of Cdc14
function.
The substrate selectivity observed for Cdc14 enzymes holds the potential for the
development of selective inhibitors. I was able to show that unphosphorylated peptide
containing an optimal substrate sequence is able to inhibit Cdc14 activity. This observation points to the possibility of developing inhibitors that incorporate substrate
like characteristics and can take advantage of the active site architecture. I have also
developed a high throughput screening strategy and utilized it to screen 50,000 small
molecules for the ability to inhibit Cdc14 activity. Specific Cdc14 inhibitors hold the
potential to study the effects of Cdc14 loss in organisms that have multiple paralogs
of the enzyme or in which genetic manipulations are a challenge.
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1. INTRODUCTION
1.1

Overview of cell division
Successful cell division requires the coordination of multiple molecular events

within a cell. Precise timing of events driving cell division is an essential requirement
of all dividing eukaryotic cells. In the absence of strict regulation of cell division, the
potential for highly deleterious events is likely to culminate in genetic instability and
cell death.
An important goal of the cell cycle is the error free transmission of genetic information from one cell to the next generation. In order to avoid errors during division,
eukaryotic cells employ multiple checkpoint mechanisms that monitor proper completion of sequential steps [1]. The timing of duplication of the genome and the
subsequent partition of identical copies to the new daughter cells are subject to multiple layers of regulation. Eukaryotic species share several molecular mechanisms for
controlling the process of cell division. These mechanisms include regulation by protein phosphorylation and control over protein stability throughout the various stages
of the cell cycle.
Understanding the mechanisms that control progress of the cell cycle is essential
for understanding disease states that can occur when the regulatory mechanisms fail.

1.2

The eukaryotic cell cycle
This chapter will discuss the regulation of cell division in the budding yeast (Sac-

charomyces cerevisiae), a model organism that has historically been essential for
understanding the fundamental mechanisms of cell cycle regulation [2]. For the most
part, the mechanisms that regulate the yeast cell cycle apply across multiple eukary-
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otes. Deviations from this will be highlighted, when appropriate, throughout this
chapter.

1.2.1

Stages of the cell cycle

The cell cycle is, for the most part, a unidirectional process in which the order of
events allows cells to divide and multiply while maintaining a consistent complement
of genetic and cellular contents [3]. A large body of research exists characterizing
the mechanisms that drive the processes of the cell cycle based on the foundational
studies of the budding yeast Saccharomyces cerevisiae [2] and fission yeast Schizosaccharomyces pombe [4] cell cycles. The regulatory systems that drive the eukaryotic
cell cycle are highly conserved across species [5] and the advancements in the understanding of the yeast cell cycle have been critical in elucidating control mechanisms
in higher eukaryotes.
The cell cycle involves two major nuclear events, namely, chromosome replication
during S phase and chromosome segregation during M phase. These stages are separated by two gap (G) phases: G1 and G2. G1 separates the end of one cycle from
the start of the next, whereas G2 separates S phase and M phase. These gap phases
give cells the opportunity to monitor the appropriate completion of the process in
the preceding cell cycle stage and ensure conditions are appropriate to proceed to the
subsequent stage [6]. In Saccharomyces cerevisiae, a decision point known as START
during G1 allows cells to either commit to another cell cycle and initiate S phase
entry when nutrient conditions are favorable or exit the cell cycle [7].
The progress from S phase to M phase is also under the regulation of surveillance
processes that monitor the appropriate completion of DNA duplication [8]. Mitosis
begins only after DNA synthesis has been completed. Mitosis consists of 4 phases:
prophase, metaphase, anaphase, and telophase. At prophase, replicated chromosomes
begin to condense and at metaphase, the sister chromatid pairs attach to spindle
microtubules from both spindle poles, which align the chromosomes along the center of
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the spindle apparatus. When all kinetochores are properly attached to microtubules,
the cohesin complex linking sister chromatids is cleaved by separase, permitting the
transition from metaphase to anaphase. During anaphase, the mitotic spindle pulls
sister chromatids to opposite poles of the spindle. The final step in cell division,
cytokinesis, is the physical division of the cytoplasm. A contractile ring pinches the
cell into two daughter cells which inherit a complete set of chromosomes and cellular
organelles.
Upon the completion of mitosis, the cell cycle is reset to the G1 state before the
commencement of the subsequent cell cycle in a highly regulated manner. In fact,
there are multiple checkpoints that prevent progress of the cell cycle if events do not
proceed appropriately. Examples of such events include DNA damaging insults or
inappropriate spindle assembly [1].

1.2.2

Cyclin dependent kinase activity drives the cell cycle

The eukaryotic cell cycle is driven by the oscillating activity of cyclin dependent
kinases (Cdks) [9,10]. All Cdks require association with a cyclin subunit for enzymatic
activity, hence, the regulation of this association is the major method by which their
activity is controlled. In budding yeast, there is a single cyclin dependent kinase,
Cdc28, and at least 11 different cyclins, which are responsible for driving the cell
cycle (Figure 1.1) [11].
All Cdks are proline-directed kinases which preferentially phosphorylate the minimal consensus sequence Ser/Thr-Pro [12]. The distinct cyclin-Cdk subclasses (Figure
1.1) exhibit minor differences in their specificities outside of this minimal consensus
that contribute to substrate selection [13]. The three major switch points during the
cell cycle that are controlled by cyclin-Cdk activity are the START (G1/S), mitotic
entry, and the metaphase-anaphase transitions [14].
Cdc28 expression varies little throughout the cell cycle [11]. Cdc28 activity and
target substrates vary substantially between cell cycle stages, owing, in large part, to
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Fig. 1.1.: The cell cycle is driven by Cdk activity.
In budding yeast, distinct sets of cyclins activate Cdc28, a cyclin-dependent kinase
(Cdk), to drive progress through the cell cycle. In G1, the cyclins Cln1, 2, and 3
promote budding and activate the S phase cyclins in preparation for S phase. In
S-phase, cyclins Clb 5 and 6 promote DNA replication. The mitotic cyclins (Clb1-4)
promote spindle formation and mitotic initiation and inhibit mitotic exit and cell
division.
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the periodic presence and/or absence of cyclins. In the cell cycle there are cyclins that
prevail during G1 (Cln1, Cln2 and Cln3), S phase (Clb5 and 6) and mitosis (Clb1
and 2) [15]. Cyclin abundance at particular stages of the cell cycle is a result of the
combined effects of regulated expression as well as degradation by the proteasome
[16, 17]. Cdc28 activity is also regulated by post-translational modifications, namely,
an inhibitory phosphorylation by the Wee1/Swe1 kinase [18], which attenuates Cdc28
activity. Cdc28 activity can also be reduced by cyclin-dependent kinase inhibitors
(CKIs) such as Sic1 [15] and Far1 [19].
In budding yeast, mitotic entry is driven by the activity of B-type cyclin bound
Cdc28. Mitotic Cdk activity is negatively regulated by Swe1 and activated by Mih1.
Swe1 phosphorylates Cdc28, on a conserved tyrosine, to prevent premature activation
until Cdc25 (Mih1 in S. cerevisiae) [9,20] reverses the phosphorylation during mitotic
entry. Reversal of the inhibitory Cdk phosphorylation by Mih1 and association with
the B type cyclins promote maximal Cdk activation. An illustration of the effects
of this regulatory system is clearly observed in fission yeast as Wee1 mutants have a
shortened G2 caused by premature activation of Cdk1, whereas Cdc25 mutants never
accumulate sufficient Cdk1 activity to enter mitosis [21–23].
During the metaphase-anaphase transition, Cdk1 is responsible for phosphorylating and activating the Anaphase Promoting Complex (APC), the essential E3
ubiquitin ligase required for chromosome segregation [24]. Mitotic Cdk activity also
prevents mitotic exit and cytokinesis to ensure complete spindle assembly and kinetochore attachment before cells divide [17].

1.3

Mitotic exit
Mitotic exit refers to the reversal of the mitotic state to an interphase state fol-

lowing successful chromosomal segregation. It includes disassembly of the spindle
apparatus, decondensation of chromosomes, and, in species with an open mitosis,
reformation of the nuclear envelope [25]. Like all other steps of the cell cycle, mitotic
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exit is under strict regulation. It is essential for cells to appropriately and equally distribute the genome duplicated during S phase to opposite poles prior to mitotic exit,
since cytokinesis occurs immediately after [26]. Mitotic exit requires the elimination
of all pro-mitotic signals, including Cdk activity.
As discussed above, mitotic entry is driven by increasing Cdk activity. In contrast, mitotic exit requires the reduction of Cdk activity. The requirement for Cdk
inactivation prior to cytokinesis ensures that cytokinesis does not occur before completion of chromosome segregation, a process that requires Cdk activity [17]. There
is increasing evidence that reduction in Cdk activity alone is not sufficient to allow
mitotic exit [27]. Skoufias et al. demonstrated that in the absence of proteasomal
activity, loss of Cdk1 is not sufficient for mitotic exit and that phosphatases that
oppose Cdk activity are required. Failure to dephosphorylate mitotic Cdk substrates
has been shown to inhibit cytokinesis in budding yeast [28]. It is becoming more evident that active reversal of Cdk phosphorylation is essential to allow cells to undergo
cytokinesis and reset the cell cycle.

1.3.1

Mitotic exit requires mitotic cyclin degradation

Inactivation of Cdk activity is achieved primarily by the regulated reduction of
cyclin abundance in the cell through the action of the ubiquitin proteasome system
(UPS, Figure 1.2) [29]. In a variety of eukaryotes, failure to degrade mitotic cyclins
leads to an arrest in mitosis [30]. The Anaphase Promoting Complex (APC) is responsible for targeting mitotic cyclins to the proteasome and is essential for mitotic
exit [31].

1.3.2

Reversal of Cdk mediated phosphorylation is essential for mitotic
exit

Mitotic phosphatases are required for proper progression through mitotic exit.
Protein phosphatase 2A (PP2A), protein phosphatase 1 (PP1), and Cdc14 all play
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roles in reversing Cdk1 mediated phosphorylation and promoting cytokinesis to varying degrees, depending on the species [32–35].

1.4

The Ubiquitin Proteasome System (UPS)
As discussed in the previous subsection, the cell cycle is driven by the activity of

Cdks that phosphorylate their cognate targets [36]. Controlling the levels of cyclins
controls Cdk activity which in turn determines the level of phosphorylated protein
substrates. Cyclin level control is achieved both by controlling their gene transcription
[37] as well as their proteolysis [29]. The majority of cyclin proteolysis is carried out
by the UPS [29].
In eukaryotes, ubiquitin-mediated proteolysis is the major mechanism that eliminates proteins in a highly regulated manner, at specific times to allow progress of
the cell cycle. The eukaryotic UPS is responsible for the rapid and specific degradation of cyclins, among other things, ensuring a unidirectional cell cycle. Since the
characterization of the role of polyubiquitination mediated protein degradation of
cyclins [29, 38], the study of the UPS has played a major role in the study of cell
cycle regulation. Beyond cell cycle regulation, the UPS plays essential roles in a wide
variety of biological processes including apoptosis and immune response [38].
The 26S proteasome is a multimeric, ATP-dependent protease made up of two
distinct sub-complexes: one 20S and two 19S particles [39]. The 20S particle is made
up of a stack of four heptameric rings containing six proteolytic active sites in the
interior of the barrel [40]. The two ends of the barrel are each capped by a 19S
particle, restricting access to the active sites (Figure 1.2).
The 19S particle is composed of two sub-complexes, the base and the lid. The
26S proteasome structure requires that polypeptides being degraded are unfolded
and enter the barrel as extended chains. The base contains six ATPase subunits and
mediates the substrate unfolding step [41]. The lid covers the base and is involved in
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Fig. 1.2.: The ubiquitin proteolysis system.
Ubiquitin (Ub) is first activated in an ATP-dependent reaction to form a thioester
bond with the E1 activating enzyme. Ubiquitin is then transferred to a conjugating (E2) enzyme. Substrates targeted for polyubiquitination are then modified, in
conjunction with an E3 ubiquitin ligase enzyme. The E3 ligase provides selectivity
and determines the identity of substrates being polyubiquitinated. Ubiquitin is covalently attached to the substrate, via an isopeptide bond, between the carboxyl group
of the C-terminal Gly and the -primary amino group of a Lys residue in the substrate. Polyubiquitinated substrates are subsequently recognized by 26S proteasome
and degraded. Deubiquitinating enzymes (DUBs) serve to recycle ubiquitin.
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the recognition of ubiquitin chains on substrates before their translocation into the
20S core [42].

1.4.1

Ubiquitination targets proteins to the proteasome

Substrate selectivity of the proteasome is largely a product of restricted access
to the proteolytic active sites [43]. A common mechanism by which substrates are
targeted to the proteasome is via the attachment of polyubiquitin chains (Figure 1.2).
Polyubiquitination is achieved by the covalent attachment of multiple ubiquitins to a
substrate, mainly on lysine residues in a selective process. A minimum chain length of
4 ubiquitins is required for substrates to access the 26S proteasome active site [43,44].
This observation has more recently been challenged by Ying Lu, et al., who have
demonstrated that APC substrates with multiple ubiquitinated lysines are better
proteasome substrates than those with the same number of ubiquitins conjugated,
but have fewer and longer ubiquitin chains [45].
Polyubiquitinated substrate selectivity is a product of the specificity of E3 ubiquitin ligases that function downstream of E2 (ubiquitin conjugating enzymes) which
are downstream of E1 (ubiquitin activating) enzymes [46] (Figure 1.2). E1 enzymes
activate ubiquitin by forming a high energy thioester bond in an ATP-dependent
reaction. Ubiquitin is then transferred to an E2 conjugating enzyme via a transthiolation reaction in an E1-Ub dependent reaction to form a high-energy thioester bond
between ubiquitin and the cognate E2. In Saccharomyces cerevisiae, there is a single
E1 [47], a dozen E2s, and diverse classes of E3 ligases [46].
There are three major classes of E3 ubiquitin ligases identified thus far, the HECT
(homologous to E6-associated protein C-terminus), RING (really interesting new
gene) domain, and U-box (modified RING motif) E3s [48]. HECT E3 ligases contain
both a substrate recognition element as well as a ubiquitin ligation active site. In
contrast, RING E3s do not directly participate in the chemical transfer of ubiquitin.
RING E3s are thought to function as scaffolds that bring E2 conjugating enzymes
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and substrate proteins into proximity and promote the transfer of Ub directly from
E2s [49].

1.4.2

Polyubiquitin-independent proteasomal degradation

Although it has been well established that ubiquitination is the major mechanism
for targeting proteins to the proteasome, it is clear that alternative mechanisms exist.
A well-established ubiquitin independent mechanism is the proteasomal degradation
of ornithine decarboxylase (ODC) [50, 51]. ODC, the first enzyme in polyamine synthesis, is targeted for degradation to the proteasome by its interaction with antizyme,
a protein that becomes abundant during high cellular polyamine concentration. It has
been postulated that antizyme is able to engage the 19S particle of the proteasome
and deliver ODC for degradation. Outside of ODC degradation, Antizyme has been
demonstrated to target Aurora-A for degradation in HeLa cells [52].

1.4.3

The Anaphase Promoting Complex (APC) during mitotic exit

In the context of the cell cycle, there are two major E3 ligases that function in cell
cycle regulation, Skp1-Cullin-1-F-box protein (SCF) and the APC [53]. In budding
yeast, the SCF ubiquitinates substrates to promote S phase, including the Cdk inhibitor Sic1, which allows for the activation of S phase Cdk/cyclin complexes [54,55].
The APC, on the other hand, is responsible for driving mitotic progress, namely sister chromatid segregation and mitotic exit as well as establishing and maintaining
G1 [56].
The APC is responsible for ubiquitin-mediated proteolysis of numerous proteins
to drive mitotic exit [57]. At the metaphase to anaphase transition the APC targets
Securin (Pds1 in yeast), an inhibitor of chromosome segregation, for destruction [58].
Pds1 degradation allows for the activation of the protease separase (Esp1 in budding
yeast) which is responsible for cleaving the cohesin rings that tie sister chromatids
together [26,58]. The APC is also essential for the destruction of mitotic cyclins such
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as Clb2 to terminate Cdk activity, allowing exit from mitosis [59]. APC also promotes
destruction of components of the mitotic spindle apparatus such as Fin1, Ase1, and
Cin8 in yeast to disassemble the spindle at the end of mitosis [60–62].

APC co-activators determine substrate recognition
The APC is a large, ≈ 1.5MDa, multi-subunit E3 ubiquitin ligase complex (Figure
1.3). The human APC consists of 12 identified core subunits and the budding yeast
APC has 13 [63]. The Core APC has two sub-complexes; one sub-complex contains
Apc2 and Apc11 that are essential for ligase activity as well as Doc1 that is required
for processive ubiquitination of substrates (Figure 1.3) [64]. The cullin domain of
Apc2 interacts with the RING domain of Apc11 which is suggested to be responsible
for association with both E2 ubiquitin-conjugating enzyme and a substrate [65, 66].
The other sub-complex contains three TPR (tetra-trico-peptide repeat domain) proteins, Cdc27, Cdc16, and Cdc23 that mediate protein-protein interactions between
subunits. Both sub-complexes are held together by the largest subunit, Apc1. Both
Apc4 and Apc5 connect Apc1 to the TPR sub-complex via Cdc23.
In addition to the core subunits, APC activity requires transient association with
a co-activator subunit. The core APC is present constitutively during the entire cell
cycle; but association with one of its co-activators, either Cdc20 or Cdh1, in a cell
cycle-dependent manner limits APC activity to mitosis and G1 [59, 67–69].
The Cdc20 and Cdh1 co-activators are structurally related proteins responsible
for APC’s substrate selectivity [67]. These co-activators bind sequentially to the
core APC as cells progress through mitosis. In budding yeast, Cdc20 is essential
for anaphase onset and Pds1 degradation [70]. Most known substrates of the APC
have destruction motifs (degrons) such as D-box (RxxLxxxxN) and/or KEN, which
are required for their ubiquitination-dependent proteolysis [71–73]. Other sequence
elements such as A-box (in Aurora A) [74], CRY box (Cdc20 in GV-stage mouse

Fig. 1.3.: APC function is essential for mitotic exit. The APC binds to its coactivators (Cdc20 and Cdh1) sequentially
during mitosis. APCCdc20 activity is required for anaphase transition. In late mitosis, Cdc20 is degraded by APCCdh1 following Cdh1 dephosphorylation and its association with the core APC. APCCdh1 remains active during G1 and is inactivated
as Cdk activity returns during S phase entry.
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oocytes) [75], or O-box (degradation of ORC1 in D. melanogaster ) [76] have also
been demonstrated as recognition motifs in substrates by the APC.
Although the mechanisms by which APC and a co-activator recognize substrates
and how co-activators discriminate between destruction motifs are still unclear, it is
known that the co-activators are major targets for regulating APC activity. A combination of phosphorylation and protein degradation are employed to regulate APC
activity. Both APC co-activators (Cdc20 and Cdh1) are highly regulated through
phosphorylation by Cdk and Cdc5/Polo kinase. Cdc20 activity is largely limited to
the initiation of mitotic exit, when Cdk activity is high [77] and its phosphorylation promotes Cdc20 association with the core APC resulting in the degradation of
substrates like Pds1, Clb5, and Dbf4 [68, 78]. Cdc20 is also involved in the activation of Cdh1 as it degrades mitotic cyclins leading to lowered mitotic Cdk activity.
The reduction in mitotic Cdk activity, in combination with Cdc14 phosphatase mediated dephosphorylation, leads to the reduction in the inhibitory phosphorylation of
Cdh1 [79] and increased Cdh1 association with the core APC [34, 80].

Multiple mechanisms regulate APCCdh1 activity
Cdh1 is an APC activating subunit that is homologous to Cdc20, and is able to
complement Cdc20 mutants when expressed in high copy number [59]. In contrast
to Cdc20, Cdh1 deletion in budding yeast is not lethal but the degradation of many
proteins, like Ase1, which leads to spindle disassembly and Clb2, which ,in turn,
results in inactivation of mitotic cyclins, is impaired [59, 67]. APCCdh1 function is
also important to establish conditions necessary for DNA replication in S phase.
Cdh1 and Sic1 have been demonstrated to promote efficient origin firing at origins of
replication during S phase entry [81]. In mice, loss of APCCdh1 has been associated
with genomic instability resulting in embryonic lethality [82].
Regulation of Cdh1 is different from that of Cdc20 as Cdh1 protein abundance
is fairly stable throughout the cell cycle and it is a target of multiple kinases that
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regulate its activity [80,83]. Cdh1’s ability to activate APC is inhibited by Cdk phosphorylation beginning in late G1 until late mitosis. Cdh1 is unable to bind the APC
when phosphorylated in early mitosis and requires dephosphorylation by Cdc14 phosphatase at mitotic exit for its activation [84]. It has been shown that overexpression
of an unphosphorylatable Cdh1 mutant (cdh1-m11 ) is lethal in yeast [62]. This phosphoregulation ensures that APCCdc20 is activated and has degraded mitotic cyclins
before APCCdh1 is able to drive late mitotic events. Failure to inactivate APCCdh1
also prevents accumulation of mitotic cyclins and results in G2/M phase arrest.

Acm1 is a pseudosubstrate inhibitor of APCCdh1
Several pseudosubstrate inhibitors which use degron motifs, similar to those found
in APC substrates, to bind to APC and interfere with substrate binding, have been
identified. Examples include Mad3, a subunit of the spindle assembly checkpoint.
Mad3 is a pseudosubstrate inhibitor of the APCCdc20 responsible for delaying anaphase
when errors occur in chromosome attachment to the mitotic spindle by preventing the
degradation of Pds1 [85]. In vertebrates, APCCdh1 can be inhibited by Emi1, which
is important for the stabilization of cyclin A and S phase entry [86].
In budding yeast, APCCdh1 is inhibited by a pseudosubstrate called Acm1. Acm1
forms a ternary complex with Cdh1 and the 14-3-3 homologs Bmh1 and Bmh2 [88].
Acm1 inhibits APCCdh1 mediated polyubiquitination of Clb2, Hsl1, and Fin1 in vitro
[88–90]. The overexpression of Acm1 is also able to rescue the toxicity of Cdh1-m11
overexpression [88].
Acm1 binds tightly to Cdh1 via conserved D and KEN boxes which interact with
the Cdh1 WD40 domain (Figure 1.4) [88, 89, 91, 92]. The reasons why Acm1 can
bind Cdh1 via its degron sequences, in the same manner as substrates, but avoid
polyubiquitination and degradation are not known. There is preliminary evidence
that suggests there are additional sequence elements within Acm1, proximal to its
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Fig. 1.4.: Acm1 is a pseudosubstrate inhibitor of APCCdh1
A. Acm1 contains D and KEN box sequences that are commonly found in APCCdh1
substrates. These sequences are necessary for Acm1 binding to Cdh1 and its ability
to inhibit substrate degradation. The ABBA motif shown is also a sequence that is
known to contribute to Cdh1 binding [87].
B. Acm1 inhibits APCCdh1 by competing for substrate binding sites on Cdh1.
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second D box, that distinguish it from substrates, but the mechanisms are not yet
clear (L. Qin, unpublished results).
Deletion of Acm1 does not result in inappropriate activation of APCCdh1 , due to
the robust effect of Cdk phosphorylation. Instead, Acm1 is important for preventing
premature binding of Cdh1 to substrates, particularly the bud neck kinase Hsl1, which
can impair their functions. Loss of Acm1 leads to premature accumulation of Cdh1
at the bud neck, via interaction with Hsl1, resulting in improper positioning of the
mitotic spindle along the mother-bud axis prior to nuclear division which normally
ensures one set of chromosomes ends up in the bud [93].
Consistent with Acm1’s role as a Cdh1 inhibitor, Acm1 protein abundance changes
with the cell cycle. Acm1 is found at higher abundance from late G1 to late mitosis [88, 89, 92] when APCCdh1 is inactive. Multiple mechanisms result in Acm1
degradation, one of which is dependent on the APCCdc20 [91]. However, complete
degradation of Acm1 at the end of mitosis requires an additional APC-independent,
proteasome-dependent mechanism [89, 94].

Unphosphorylatable Acm1 mutant is constitutively degraded
Acm1 is a phosphoprotein and is a target of Cdk [92, 94]. Mass spectrometric
analysis revealed that Acm1 is phosphorylated at Cdk consensus sequences. Mutation
of five Cdk sites to alanine leads to a significant reduction in Acm1 stability in all
phases of the cell cycle [94]. These data illustrate that phosphorylation of Acm1
is necessary for its stability and dephosphorylation in late mitosis leads to its rapid
degradation. Inhibition of the yeast proteasome with drug treatment causes abnormal
Acm1 protein stability [92]. The mechanism that targets Acm1 for degradation by
the proteasome is non-canonical and is discussed in Chapter 2.
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1.5

Mitotic phosphatases reverse Cdk phosphorylation
Beyond the inactivation of mitotic Cdks, mitotic exit and cytokinesis require active

reversal of Cdk phosphorylation by mitotic phosphatases [27]. Recent developments
are beginning to shed light on the complexity of the mechanisms regulating the activity of mitotic phosphatases [35]. The protein phosphatases Cdc14, PP1 and PP2A
play significant roles in reversing Cdk-dependent protein phosphorylation [32–35].

1.5.1

PP1 and PP2A contribute to mitotic exit

PP1 and PP2A are multimeric members of the serine/threonine phosphoprotein
phosphatase (PSP) family of phosphatases. As is the case for many PSPs, PP1 and
PP2A are regulated and their specificity defined through combinatorial interactions
between a common catalytic subunit and various regulatory subunits [95]. Both have
been implicated in the reversal of Cdk mediated phosphorylation, which is important
for mitotic exit [35].
PP1 functions typically as a dimer consisting of a catalytic subunit (PP1c), which
is encoded by GLC7 in budding yeast [96] and is one of many regulatory subunits. The
catalytic subunit is highly conserved among all eukaryotes with about 70% identity
across any pairwise alignments [95]. Many of the regulatory subunits bind to PP1c
through a highly conserved RVXF/W docking motif [97]. The regulatory subunits
determine in vivo substrate specificity by either directing the holoenzyme subcellular
localization and/or altering its substrate selectivity.
PP2A is a heterotrimeric complex consisting of a structural A subunit, a regulatory
B subunit and a catalytic C subunit [98]. The B-regulatory subunits regulate both
localization and substrate selectivity of the PP2A complex. The two B-regulatory
subunits in budding yeast (Cdc55 and Rts1) bind PP2A in a mutually exclusive
manner. PP2ACdc55 is required for the spindle assembly checkpoint [98,99] and targets
Cdc25 (Mih1) for dephosphorylation during mitosis leading to increased Cdk1 activity
[100].
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1.5.2

Cdc14 activity counteracts Cdk1 mediated phosphorylation

Cdc14 is a member of the dual specificity phosphatase (DSP) family, a subgroup
of the larger PTP super family [101, 102]. Cdc14 phosphatases contain the active
site sequence CX5 R, which is a hallmark for the protein tyrosine phosphatase (PTP)
superfamily (Figure 1.5) [103]. In budding yeast, Cdc14 is the major phosphatase
required for mitotic exit and remains sequestered in the nucleolus until early anaphase
at which point it is able to dephosphorylate various Cdk1 substrates [34, 104].
Chromosome segregation, spindle disassembly and cytokinesis are late mitotic
events requiring reversal of Cdk mediated phosphorylation. Beyond the inactivation
of Cdk activity by the degradation of cyclins, Cdk substrates are need to be dephosphorylated [33]. The budding yeast phosphatase Cdc14 has, for a long time, been
recognized as an essential regulator of mitotic exit. cdc14 mutants arrest in late
mitosis in a telophase like state [105]. Cdc14 triggers mitotic exit by reversal of Cdkmediated phosphorylation [34]. Cdc14 dephosphorylates Swi5, a transcription factor
for the Cdk inhibitor Sic1 [106], Sic1 itself, leading to its stabilization [34] and the
APC co-activator Cdh1 [80], which targets mitotic cyclins for degradation. Dephosphorylation of Swi5 also leads to the transcriptional activation of other genes at the
M/G1 transition, such as Egt2 [107], required for normal septation. Iqg1 has also
recently been identified as an important Cdc14 substrate in regulating actomyosin
ring contraction during cytokinesis [108]. Cdc14 function is also important for formation of the pre-replication complex (pre-RC) via dephosphorylation of the replication
initiation proteins Orc2, Orc6, Cdc6, and Mcm3, to allow DNA replication in the subsequent S phase [109]. Cdc14 also regulates the localization and enzymatic activity of
Yen1, a Holiday junction resolvase that plays a role in DNA damage repair [110,111].

Cdc14 activity is tightly regulated
In accordance with its essential role in mitotic exit, Cdc14 activity is under strict
regulation. Its activity is regulated both by the binding of a competitive inhibitor
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as well as by its subcellular localization. For most of the cell cycle until metaphase,
Cdc14 is sequestered and inhibited in the nucleolous by Net1, as part of the regulator
of nucleolar silencing and telophase (RENT) complex [112–114]. Cdc14 disassociation
from its inhibitor and its resulting spread, first, to the nucleoplasm in early anaphase,
and then, throughout the cytoplasm in late anaphase/telophase occurs via two distinct and sequential regulatory mechanisms: the Cdc fourteen early anaphase release
(FEAR) and Mitotic Exit Network (MEN) pathways, respectively. The FEAR network initiates Cdc14 release within the nucleus and its association with the spindle
pole body as well as the mitotic spindle, mainly to promote proper chromosome segregation. The MEN is activated during telophase and results in the spread of Cdc14
to the cytoplasm where it drives mitotic exit and cytokinesis [35].
There is an increasing body of evidence that Cdc14’s intrinsic selectivity is a driver
for the order of mitotic substrate dephosphorylation. It has been shown that Cdc14
substrates are targeted in two distinct windows of time [115]. Jin et al. tested whether
early Cdc14 substrates were targets of FEAR released Cdc14 and were preferentially
phosphorylated by Cdk1-Clb5 and later substrates of MEN Cdc14 were Cdk1-Clb2
substrates. They observed that the release mechanism does not determine Cdc14
specificity, illustrated by the dephosphorylation of Sld2, an early anaphase substrate,
by both FEAR and MEN released Cdc14, in nocodazole arrested cells. Although
the decrease in Clb5 activity contributes to the steady state levels of early Cdc14
substrates and high Clb2 activity delays the loss of phosphorylation of late substrates,
it does not completely account for the observed timing of substrate dephosphorylation
[104]. Bouchoux et al. show that Cdh1 and Orc6, which are preferential Cdk1-Cdc5
substrates, are late Cdc14 substrates. They also show that ectopic Cdc14 expression
in cells arrested in metaphase does not change the order in which Cdc14 substrates are
dephosphorylated, suggesting a central role for Cdc14 as the main driver of sequential
substrate dephosphorylation, independent of other mitotic events. The study also
demonstrated the catalytic efficiency of Cdc14 towards Fin1, an early Cdc14 substrate
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was 20 times grater than that of Orc6 [104]. The underlying reasons for this substrate
preference have not yet been completely elucidated.

1.5.3

Cdc14 is conserved across multiple species

Although the Cdc14 gene is highly conserved (Figure 1.5), the reversal of mitotic
phosphorylation in other eukaryotes does not strictly require Cdc14. Cdc14 homologs
are found in multiple eukaryotes spanning a large evolutionary space. Studies in a
variety of organisms suggest that Cdc14 is not required for Cdk inactivation or for
bulk Cdk substrate dephosphorylation [116, 117]. Although these phosphatases play
roles during mitotic exit, they are only essential in budding yeast. An interesting
observation pointing to a functional conservation is that the two human Cdc14 paralogs (A and B) are able to rescue the cdc14 phenotype in both budding [118, 119]
and fission yeast [120]. The specific biological functions of Cdc14 in organisms other
than budding yeast are still poorly characterized and the extent to which functions
might be conserved across divergent eukaryotes remains unclear. A discussion of the
current data is presented below.
Schizosaccharomyces pombe Cdc14 orthologue, Clp1, is kept sequestered in the
nucleolus as is the case for budding yeast. However, unlike S. cerevisiae Cdc14, Clp1
is not essential for normal cell cycle progression and is released from the nucleolus earlier in mitosis [121]. Clp1 is mainly responsible for regulating cytokinesis and affects
the timing of mitotic entry [122, 123]. Clp1 promotes mitotic exit by promoting the
dephosphorylation and subsequent degradation of Cdc25. Clp1∆ cells display cytokinesis defects and advance prematurely into mitosis but continue to grow. Meanwhile,
cells overproducing Clp1 delay Cdk1 activation but are able to progress through mitosis [122].
There are inconclusive reports regarding the function of Cdc14 in Caenorhabditis
elegans. One group has reported that depletion of C. elegans Cdc14 results in embryonic lethality [124]. However, another study demonstrated that cdc14 heterozygous
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null worms are viable and fertile [125]. It was also shown that CeCdc14 localizes to
the central spindle during anaphase and the midzone during telophase suggesting a
role in mitotic events.
In contrast to S. cerevisiae Cdc14, either of the two human paralogs (hCDC14A
and B) are dispensable for the cell cycle. Ectopic expression of hCDC14A results
in the dephosphorylation of Wee1 and its degradation by the proteasome [126] and
delays mitotic entry by counteracting Cdk1-Cyclin B1 activity [120]. Overexpression
of hCDC14B has been shown to transform cells [127]. As an indicator of functional
divergence between the two paralogs, this same study demonstrated that overexpression of hCDC14A did not result in transformation. hCDC14A and B also appear to
localize differently during interphase; hCDC14A at the centrosome and hCDC14B at
the nucleolus [128]. Specific functions and molecular targets of human Cdc14 enzymes
remain poorly understood.

1.5.4

S. cerevisiae Cdc14 is highly selective for a subset of Cdk phosphorylation sites

The crystal structure of hCDC14B shows that it is made up of two structurally
similar domains arranged in tandem [102]. The N-terminal domain (domain A, aa
44-198), thought to contribute to substrate selectivity, has no sequence similarity to
other dual specificity phosphatases. The C-terminal domain (domain B, residues 213368) contains the PTP motif. The hCDC14B active site is within the groove at the
domain A and B interface.
Cdc14 phosphatases are unique, in that, despite being members of the PTP family,
they have evolved to specifically dephosphorylate a subset of Cdk substrates. Cdks
phosphorylate Ser/Thr-Pro sites. Cdc14 phosphatases have a strict selectivity for
Cdk phosphoSer-Pro (pS-P) sites. Moreover, they strongly prefer sites followed by
a basic residue at the +3 position (pS-P-X-K, where X represents any amino acid)
with additional downstream basic residues enhancing activity [129, 130].
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Our enzymatic studies and the crystal structure solved for hCDC14B in complex
with a peptide indicate that Cdc14 substrate selectivity is primarily determined by
the active site region [102]. The residues thought to contribute to catalysis and
substrate binding (the acidic groove, +1 Pro binding, +3 lysine binding and pSer
selectivity) highlighted in Figure 1.5 are highly conserved across multiple species.
Unlike other mitotic phosphatases previously discussed, Cdc14 does not function as
part of a multimeric complex. Taken together, these observations suggest that Cdc14
enzymes could display similar substrate selectivity across multiple species and may
be amenable to the development of highly specific competitive inhibitors.
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Fig. 1.5.: (Caption on next page)
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Fig. 1.5.: (Previous page) Cdc14 catalytic and substrate interacting motifs are
conserved. Alignment of Cdc14 protein sequences from an evolutionarily diverse set
of organisms. The observed conservation of sequences responsible for catalysis and
substrate selectivity indicates that the enzymatic behavior observed in budding yeast
Cdc14 is likely to be conserved across multiple species.

1.6

Mitotic exit as a therapeutic target
One of the central characteristics of cancer cells is the loss of proliferative control

[131]. This can take the form of either adaptations that allow cells to keep growth
signals active or result from deactivation of growth limiting mechanisms. Inability to
regulate mitotic exit and failure to achieve appropriate temporal control of mitotic
exit events is a potential driving factor in the progression of cancer [132].
A chemotherapeutic strategy that has been clinically relevant in treating cancer for
some time has been the chemical perturbation of mitotic spindle function by taxanes
and vinca alkaloids (reviewed in [133, 134]). The strategy relies on the activation of
the spindle assembly checkpoint (SAC) in the presence of a defective spindle, which
inhibits APCCdc20 -mediated securin and cyclin B degradation, and causes an arrest
at metaphase. The sustained mitotic arrest eventually leads to programmed cell
death [134]. It has been observed that cells can undergo mitotic slippage and escape
from arrest by slowly degrading cyclin B1 even though the SAC is activated by these
drugs [135]. Cancerous cells often develop the ability to overcome the microtubuletargeted mitotic arrest by inappropriately inducing mitotic exit, which further leads
to genome instability. Thus, one of the major challenges with developing effective
chemotherapies that disrupt mitotic spindle function has been avoiding slippage or
other mechanisms of resistance [136].
An alternative therapeutic strategy that has been proposed is the inhibition of
APC activity, because securin and cyclin B degradation by the APC is an essential
step in mitotic exit [137]. The genetic ablation of Cdc20, the APC activating subunit,
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in cancerous cells has been demonstrated to reduce proliferation by preventing mitotic
exit [138]. Sackton et al. have also shown that a combination of two chemicals
is able to block the interaction of APC with Cdc20 as well as Cdc20 with D box
containing substrates, resulting in blockage of mitotic exit [139]. Another study has
demonstrated that coupling microtubule disrupting drugs with the depletion of Cdc20
is capable of reducing the probability of mitotic slippage [136]. This study also found
Cdc20 knockdown more effective at inducing a longer mitotic blockage, compared to
spindle-perturbing drugs, which led to increased apoptosis. These studies suggest
targeting mitotic exit processes is a viable and potentially more effective therapeutic
strategy.

1.6.1

Utility of Cdc14 inhibitor development

As discussed above, targeting mitotic exit for chemotherapy results in improved
therapeutic efficacy, especially when spindle function is simultaneously disrupted
[136]. Inhibiting Cdc14 activity, which plays a role in mitotic exit, in combination with spindle disrupting drugs, might also prove to be an effective therapeutic
approach. Cdc14 is also known to play a role in the G2 DNA damage response checkpoint [140]. This raises the possibility of improving the effectiveness of DNA damaging chemotherapeutic agents like doxorubicin by simultaneously inhibiting Cdc14 to
prevent an effective DNA damage checkpoint response.

1.6.2

Cdc14 inhibitors as research tools

As discussed in previous sections, the role of Cdc14 in regulating the cell cycle
has only been extensively studied in budding yeast, where it is essential for cell
cycle progress, and in fission yeast, where it is not essential and phenotypes observed
are somewhat mild. Outside of these unicellular organisms, there have not been
definitive results from efforts to understand Cdc14 function. The fact that most
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higher eukaryotes have multiple paralogs of the enzyme makes it more difficult to
study its role, because it is not known if these paralogs are functionally redundant.
The development of a specific and high affinity inhibitor of Cdc14 has the potential
to be useful in elucidating Cdc14 roles in higher eukaryotes, including humans. Such
an inhibitor would allow the simultaneous inhibition of all Cdc14 activity in cells,
which has, thus far, not been achieved by genetic approaches.
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2. ACM1 IS DEGRADED VIA AN UNCONVENTIONAL
MECHANISM
2.1

Introduction
1

Proper execution of the eukaryotic cell division cycle depends heavily on ubiquitin-

mediated proteolysis, involving the conjugation of polyubiquitin chains to substrate
proteins by E3 ubiquitin ligases and their subsequent recognition and degradation by
the 26S proteasome [38]. Coupled with transcriptional regulation, proteolysis helps
establish cell cycle-dependent protein expression profiles for many key regulators of
cell division, contributing to precise control of the initiation and order of cell cycle
events [53, 137]. Two large ubiquitin ligase complexes are responsible for the majority of regulated proteolysis during the cell division cycle [53, 141, 142]. One, the
Skp1/cullin/F-box protein complex (SCF) is well known for promoting the degradation of G1 cyclins, cyclin-dependent kinase (Cdk) inhibitors, and numerous other
substrates, and is thought to be constitutively active. However, recognition of most
SCF substrates requires their cell cycle-dependent phosphorylation [143]. The second, the anaphase-promoting complex (APC), or cyclosome, targets the chromosome
segregation inhibitor securin, S and M phase cyclins, and many other proteins for
degradation during mitosis and G1 [144, 145]. In contrast to SCF, the activity of
APC is cell cycle-regulated by several mechanisms including phosphorylation of, and
inhibitor binding to, its activator proteins Cdc20 and Cdh1 [146]. Following conjugation of polyubiquitin chains to substrate lysines by SCF and APC, recognition by
1

This chapter has been reprinted from Melesse M, Choi E, Hall H, Walsh MJ, Geer MA,
Hall MC (2014) Timely Activation of Budding Yeast APCCdh1 Involves Degradation of Its
Inhibitor, Acm1, by an Unconventional Proteolytic Mechanism. PLoS ONE 9(7): e103517.
doi:10.1371/journal.pone.0103517 under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a
letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.
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the 26S proteasome results in their irreversible degradation, and helps drive the cell
cycle forward.
In this report, we describe an unconventional proteolytic mechanism, independent
of SCF and APC, that helps establish the strict cell cycle expression profile of the
APC inhibitor Acm1 in budding yeast. Acm1 was identified several years ago by
our lab as a tight binding partner and inhibitor of the APC activator Cdh1 [88,
90]. Acm1 uses substrate-like degron sequences to competitively inhibit substrate
binding to Cdh1, making it one of several pseudosubstrate inhibitors of the APC
identified in diverse eukaryotes. One important function of Acm1 appears to be
ensuring proper positioning of the nucleus along the mother-bud axis prior to nuclear
division. Acm1 does this by limiting the premature accumulation of Cdh1 at the bud
neck via interaction with its high affinity substrate Hsl1 [93], although the details of
how this contributes to proper nuclear orientation remain unclear.
Acm1 expression is very tightly cell cycle-regulated. Acm1 protein is absent from
G1 cells, appears around the onset of S phase, and rapidly disappears in late mitosis,
after anaphase onset [88, 90, 91]. The ACM1 promoter is also cell cycle regulated as
part of a large collection of genes turned on at the beginning of S phase [147]. Two
distinct proteolytic mechanisms have been reported to clear cells of Acm1 at the end
of mitosis. First, consistent with the cell cycle profile of Acm1 being reminiscent of
APC substrates, Acm1 was shown to be a target of APCCdc20 during anaphase [91].
In other studies, Acm1 was shown to be very sensitive to an APC-independent
proteolytic mechanism in G1 [92, 94]. This APC-independent mechanism is inhibited
by Cdk phosphorylation on Acm1 such that Acm1 is stable only during the cell cycle
window of high Cdk activity. The results presented here provide confirmation of both
proteolytic mechanisms but demonstrate that the APC-independent mechanism is
both necessary and sufficient for complete elimination of Acm1 during mitotic exit.
Interestingly, several lines of evidence suggest that this mechanism is independent of
the conventional ubiquitin conjugation pathway, although it is still mediated by the
26S proteasome. This is one of the first examples of a strict cell cycle expression
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pattern established by proteolytic mechanisms independent of SCF and APC. The
existence of two distinct degradation pathways for Acm1 suggests it is critical for
yeast cells to relieve Cdh1 inhibition in a timely manner to promote mitotic exit,
cytokinesis, and establishment of the ensuing G1 and we provide evidence to support
this.

2.2

Results

2.2.1

APCCdc20 activity is not sufficient for complete Acm1 degradation

Acm1 was reported to be effectively eliminated via APCCdc20 prior to mitotic
exit [91]. However, we originally identified Acm1 as a Cdh1 binding partner at the late
anaphase arrest point of a cdc15-2 strain [88] and therefore suspected that APCCdc20
might not be sufficient for complete elimination of Acm1. To test this rigorously
we had a polyclonal antibody raised against recombinant Acm1 so we could monitor
endogenous Acm1 protein without addition of an epitope tag. Synchronized dbf2-2
cultures were released from α-factor-induced G1 arrest into fresh medium at 37 ◦ C so
they would arrest in late anaphase, a point where APCCdc20 has been activated and
has targeted its substrates for degradation (Figure 2.1A and 2.1B). As expected, the
levels of the well-characterized Cdc20 substrates Clb5 and Pds1 rapidly dropped as
cells reached the arrest point. In contrast, the Acm1 level decreased more slowly and
a substantial fraction (>30%) of Acm1 remained after a lengthy arrest.
Next, to definitively test for the presence of an APC-independent proteolytic mechanism acting on endogenous Acm1 protein in late mitosis and G1, we probed for Acm1
in extracts from synchronized cultures of a yeast strain (apc2∆ apc11∆ cdc20∆ cdh1∆
pds1∆ clb5∆ SIC110x ) engineered to survive in the complete absence of APC activity by deletion of the essential APC substrate genes CLB5 and PDS1, and 10-fold
overexpression of the Cdk inhibitor Sic1 [148]. When compared with a control strain
containing wild-type APC, Acm1 levels cycled normally (Figure 2.1C), being absent
from G1 cells as previously reported [88]. In contrast, the APC substrate Clb2 was
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strongly stabilized and present throughout the cell cycle in the absence of APC activity. These results are consistent with previous studies of overexpressed Acm1 stability
in G1-arrested cells harboring a conditional APC mutant allele [92, 94]. We conclude
that APCCdc20 is not sufficient for complete elimination of Acm1 in late mitosis and
that an APC-independent mechanism is also required. In the absence of APC activity this APC-independent mechanism is sufficient for complete Acm1 elimination
in late mitosis and G1. We therefore set out to characterize the APC-independent
proteolytic mechanism responsible for Acm1 degradation.
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Fig. 2.1.: APCCdc20 is neither necessary nor sufficient for complete Acm1
degradation at mitotic exit. A) dbf2-2 cells expressing endogenous chromosomally
tagged Clb5-3HA and Pds1-9Myc were released from a G1 arrest at 37 ◦ C and the
levels of Clb5, Pds1, and Acm1 monitored by immunoblotting over the indicated
time period. G6PD is a loading control. Numbers under each lane were obtained by
fluorescence microscopic analysis of at least 100 cells at that timepoint stained with
DAPI and scored for the presence of 2 segregated DNA masses indicative of the dbf22 late anaphase arrest point. cyc, asynchronous cycling cultures. B) Protein levels
were quantified from the immunoblots in panel A. The abundance of each protein was
plotted as a percentage of its maximal expression level. C) Extracts from synchronized
cultures of yBRT135 (Wild-type) and mutant strain yBRT159 lacking several subunits
of APC (apc2∆apc11∆cdc20∆cdh1∆pds1∆clb5∆SIC110x ) were generously provided
by David Toczyski [148], and were probed for Acm1, Clb2, and the loading control
G6PD by immunoblotting. The budding index under each lane, taken from [148], is
used as an indicator of cell cycle progression.

2.2.2

Acm1 is degraded by the 26S proteasome in vivo

Proteolysis of Acm1 in G1 can be blocked by the proteasome inhibitor MG132 [94], suggesting that Acm1 is a substrate of the proteasome. To more rigorously characterize proteasome dependence and rule out the possibility of off-target
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effects of MG-132 we compared Acm1 stability after MG-132 treatment with stability
in a collection of conditional proteasome mutant strains. We used wild-type Acm1,
which is unstable only in G1 cells, and an Acm1 mutant lacking Cdk phosphorylation
sites (Acm15A ), which is unstable throughout the cell cycle [94]. Consistent with
our previous results with wild-type Acm1, 3HA-Acm15A was strongly stabilized after
MG-132 treatment in a GAL1 promoter shutoff/cycloheximide chase assay (Figure
2.2A). Using the same assay, the stability of both 3HA-Acm1 and 3HA-Acm15A was
measured in G1-arrested pre1-1 pre2-2 cells harboring temperature-sensitive mutations in the β4 and β5 subunits of the 20S proteasome core particle [149]. Both
3HA-Acm1 and 3HA-Acm15A , as well as the control APC substrate Fin1-3HA were
highly unstable in wild type G1 cells but were strongly stabilized in the pre1-1 pre2-2
mutant strain (Figure 2.2B). These results confirm that Acm1 is degraded by the
proteasome in G1. We also tested Acm1 stability in a proteasome mutant strain,
cim3-1, with a temperature-sensitive defect in the Rpt6 ATPase subunit of the 19S
regulatory particle [150], which is primarily responsible for recognition and processing of poly-ubiquitinated proteins. The cim3-1 strain shows defective proteolysis of
ubiquitinated substrates at restrictive temperature [150]. 3HA-Acm1, 3HA-Acm15A ,
and Fin1-3HA were all strongly stabilized in G1-arrested cim3-1 cells (Figure 2.2C).
To ensure this was not an artifact of Acm1 overexpression from the GAL1 promoter
we also monitored the level of endogenous Acm1 in wild-type and conditional proteasome mutant strains at the restrictive temperature. The steady-state level of Acm1
was increased upon proteasome inactivation in both cim3-1 and pre1-1 pre2-2 cells
(Figure 2.2D). Collectively, these results demonstrate that Acm1 proteolysis requires
activity of the 26S proteasome, not just the 20S core particle, and suggested that
Acm1 is likely targeted to the proteasome via polyubiquitination. We therefore set
out to identify components of the ubiquitin system required for the APC-independent
Acm1 proteolysis.
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Fig. 2.2.: Acm1 degradation requires both the 20S core particle and the 19S
regulatory complex of the 26S proteasome. A) Strain YKA407 carrying plasmid
pHLP298 expressing 3HA-Acm15A from the GAL1 promoter was treated first with galactose to
induce 3HA-Acm15A expression, second with 50 µM MG-132 or a mock treatment, and third with
glucose and cycloheximide to terminate expression (Time = 0). The level of 3HA-Acm15A was then
monitored over time by immunoblotting with an HA antibody. G6PD is a loading control. B) and C)
The same experiment described in panel A was performed with wild-type (YWO0607 for B, MHY753
for C) or the indicated temperature-sensitive proteasome mutant strains (YWO0612 for B, MHY754
for C) carrying plasmids expressing either 3HA-Acm15A , 3HA-Acm1, or Fin1-3HA from the GAL1
promoter. Instead of MG-132 treatment, cultures were shifted to 37 ◦ C prior to terminating protein
expression. For 3HA-Acm1, and Fin1-3HA, cells were arrested first in G1. D) The same strains
from panels B and C were grown to exponential phase and shifted to the restrictive temperature to
compare the steady-state level of endogenous Acm1 by immunoblotting with an anti-Acm1 antibody.
G6PD was used as a loading control.

2.2.3

Acm1 proteolysis requires a functional ubiquitin conjugation system

To test if Acm1 proteolysis is generally dependent on the ubiquitin conjugation
system, we measured its stability in a strain harboring a conditional mutation, uba1-
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204, in the sole E1 ubiquitin activating enzyme in budding yeast [151]. A pulse of
3HA-Acm1 or Fin1-myc expression was induced from the GAL1 promoter in G1arrested wild-type and uba1-ts cells after shift to the non-permissive temperature of
37 ◦ C (Figure 2.3). Both 3HA-Acm1 and the control protein Fin1-myc were strongly
stabilized in uba1-ts cells compared to isogenic wild-type cells. Similar, although less
dramatic, results were obtained using a second conditional E1 allele, uba1-ts ( [152];
data not shown). We conclude that the APC-independent G1 degradation of Acm1
is dependent on a functional ubiquitin conjugation system.

Fig. 2.3.: Acm1 proteolysis requires a functional ubiquitin conjugation pathway. Expression of 3HA-Acm1 or Fin1-myc was induced with galactose in G1arrested wild-type (RJD3268) or uba1-204 (RJD3269) cells at room temperature.
Culture temperature was increased to 37 ◦ C prior to addition of glucose and cycloheximide. Cells were harvested at the indicated times after terminating expression
and protein levels monitored by immunoblotting with anti-HA or anti-myc antibodies.
G6PD is a loading control.

2.2.4

Acm1 proteolysis does not require individual E3 ligases or E2 conjugating enzymes

To identify the proteins directly responsible for Acm1 ubiquitination and proteolysis, we systematically screened a collection of yeast strains individually lacking
non-essential yeast E2 ubiquitin conjugating enzymes and E3 ubiquitin ligases (Table
2-1) for effects on Acm1 stability. We used the Acm15A mutant because it is constitutively unstable and does not require cell cycle arrest in G1 to monitor effects
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on stability. First, steady-state levels of 3HA-Acm15A expressed from the natural
ACM1 promoter in exponentially growing E2 and E3 mutant cultures were measured
by immunoblotting and compared to the level of wild-type 3HA-Acm1 in the parent
strain. Surprisingly, the level of Acm15A fluctuated widely in the mutant strains, and
in several cases was significantly elevated, suggesting that Acm1 stability might be
increased in the absence of these ubiquitin system components (Figure 2.8). However,
subsequent direct testing of stability using our inducible promoter and cycloheximide
chase system failed to reveal any strong effects of these gene deletions on Acm1 halflife (Figure 2.9). We suspect that the differences in steady-state expression from the
natural promoter were likely due to effects on transcription or cell cycle distribution since the ACM1 promoter is strictly cell cycle regulated [147]. Consistent with
this, analysis of wild-type Acm1 and Acm15A levels in G1-arrested cultures of these
deletion strains cells failed to reveal evidence of stabilization (data not shown).
To avoid problems with expression from the highly regulated ACM1 promoter
we re-screened the entire collection of E2 and E3 deletion strains using the GAL1
promoter stability assay and directly monitored stability of untagged Acm15A with
our Acm1 antibody. We also added strains lacking genes encoding predicted RING
domains without known E3 activity and other recently verified E3 ligases (Table 2-1).
Since inhibition of either the proteasome or Uba1 resulted in strongly stabilized Acm1
over the course of at least one hour in this assay, we compared the level of Acm1 at
0 and 60 minutes in each strain after addition of glucose and cycloheximide. In 47
known or putative E3 deletion strains and 10 E2 deletion strains we did not find a
single case where Acm1 was stabilized comparable to MG-132 addition (Figure 2.10
and data not shown). We also found no effect of the essential E3 enzymes Rsp5 and
Prp19 on Acm1 stability using strains from the tetracycline-repressible essential gene
library (data not shown). The essential E3 SCF was tested previously with negative
results [92] and we confirmed these results using conditional cdc4 and cdc53 alleles
(data not shown). We conclude that Acm1 proteolysis by the APC-independent
mechanism does not require any single E2-E3 modules, although we cannot rule out
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the possibility that multiple redundant E3 enzymes are capable of promoting Acm1
degradation or that an unknown E3 exists that was not tested.

2.2.5

Acm1 proteolysis does not require assembly of ubiquitin chains

In parallel with the uba1-204 experiment described above, we analyzed Acm1 stability after overexpressing a mutant ubiquitin in which all lysines have been replaced
with arginine (Ub-K7R, a gift from L. Hicke, Northwestern University). This mutant
blocks polyubiquitin chain extension when conjugated to a protein [153] and thereby
stabilizes ubiquitin proteasome substrates. The stabilities of Acm1 and the APC
substrates Fin1 and Clb2 were monitored in G1-arrested cells overexpressing either
mutant or wild-type ubiquitin. As expected, Fin1 and Clb2 were highly stabilized by
overexpression of Ub-K7R (Figure 2.4A). Their steady-state levels were also noticeably higher at time 0 in the presence of Ub-K7R compared to wild-type ubiquitin. In
contrast, the stability of Acm1 was unaffected by the overexpressed chain-terminating
Ub-K7R and the steady state level of Acm1 was similar at time 0 in both strains.
Similar results were observed with 3HA-Acm1 in a doa4∆ strain, which has a defect in
processing of ubiquitin precursors and therefore a lower level of endogenous ubiquitin
for Ub-K7R to compete with (Figure 2.4B). In this case, we terminated transcription
from the GAL1 promoter with glucose but did not add cycloheximide, allowing continuous synthesis and accumulation of Ub-K7R and wild-type ubiquitin. Surprisingly,
these experiments reveal that Acm1 proteolysis in G1 shows no apparent dependence
on assembly of poly-ubiquitin chains, a general requirement for ubiquitin-mediated
proteolysis.

2.2.6

Ubiquitin conjugation sites on Acm1 are not required for its proteolysis

To independently test the dependence of Acm1 proteolysis on ubiquitination, we
constructed a mutant ACM1 allele in which all 20 lysine codons were replaced with
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arginine codons. The mutant protein, 3HA-Acm1K0 , lacks all internal sites for ubiquitin conjugation and we added a 3HA epitope tag lacking lysines to block the native
N-terminus as a potential ubiquitin conjugation site. Despite the extensive mutagenesis, 3HA-Acm1K0 is fully functional as a Cdh1 inhibitor in vivo (Figure 2.5A)
because 3HAAcm1K0 overexpression suppressed the toxic effect of Cdh1 overexpression like wild-type 3HA-Acm1 [88–90,92]. Thus, the mutant is biologically functional
and does not suffer from global misfolding or severe structural differences compared
to wild-type Acm1. We compared the stability of galactose-induced pulses of 3HAAcm1K0 and 3HA-Acm1 in α-factor arrested G1 cells (Figure 2.5B). The absence of
lysines had no effect on the stability of Acm1 (Figure 2.5B), suggesting that ubiquitin
conjugation to Acm1 is not required for its proteolysis. Acm1 stability is dramatically increased by cyclin-dependent kinase phosphorylation [91,92,94] and as a result,
Acm1 is stable in S and M phase cells. To determine if the Acm1K0 mutant is still
regulated by phosphorylation like wild-type Acm1, we repeated the stability assay in
S phase cells. Both wild-type 3HA-Acm1 and 3HA-Acm1K0 were comparably stable
in hydroxyurea-arrested S phase cells compared to G1 (Figure 2.5C), suggesting that
the mutagenesis did not perturb normal phospho-regulation of Acm1 stability.
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Fig. 2.4.: Acm1 proteolysis does not require assembly of polyubiquitin
chains. A) YKA247 cells containing PGAL1 -driven plasmids pHLP391 (for Acm1),
pESCW-Fin1-Myc, or pHLP309 (for Clb2) and PCU P 1 -driven ubiquitin (Ub) overexpression plasmids LHP306 (for Ub-K7R mutant) or LHP308 (for wild-type Ub) were
grown to early exponential phase. Cells were arrested at G1 before expression of wildtype or mutant Ub was induced with 100 mM CuSO4 and Acm1, Fin1-myc, and Clb2
with galactose. Stability of Acm1, Fin1-Myc, and Clb2 were monitored with antiAcm1, anti-Myc, and anti-Clb2 antibodies, respectively. G6PD is a loading control.
NC, negative control without galactose induction. B) The same experiment described
in panel A was performed in doa4∆ cells to limit the abundance of endogenous ubiquitin, and only glucose was used to terminate expression, allowing continuous synthesis
of mutant or wild-type Ub. In this experiment pHLP212 was used to express 3HAAcm1, which was detected with an anti-HA antibody and Fin1-3HA was used as a
control.
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Since in rare cases proteins can undergo ubiquitination at nonlysine sites, we next
directly tested for ubiquitin conjugates on Acm1 in G1-arrested cells. Wild-type
3HA-Acm1 and 3HAAcm1K0 were compared in our stability assay with and without
proteasome inhibition. Consistent with results presented above, both proteins were
highly unstable in the absence of MG-132 but strongly stabilized in the presence of
MG-132 (Figure 2.5D). Acm1 has been proposed to undergo weak ubiquitination and
subsequent degradation mediated by APCCdh1 , the enzyme it inhibits [91]. Consistent
with this, we detected ubiquitin conjugates on wild-type 3HA-Acm1 in the presence
of MG-132 (Figure 2.5D). Under identical conditions, ubiquitin conjugates were undetectable on 3HA-Acm1K0 . Since these proteins have indistinguishable halflives in
G1 cells, the ubiquitin conjugates detected on wild-type Acm1 are not likely to contribute significantly to its proteolysis under normal conditions. Importantly, these
results argue that Acm1K0 is not targeted to the proteasome via unconventional ubiquitin linkages to non-lysine amino acids, or to the N-terminus.
Finally, we compared the levels of 3HA-Acm1 and 3HAAcm1K0 expressed from
the natural ACM1 promoter as a function of cell cycle stage in cdc15-2 cells (Figure
2.5E). Cells were arrested in G1 with α-factor, S with hydroxyurea, early M with
nocodazole, and late M by temperature shift to 37 ◦ C and Acm1 levels compared by
immunoblotting. In cycling cells and S and early M arrested cells the abundance of
3HA-Acm1 and 3HA-Acm1K0 was equivalent. In late M arrested cells, the abundance
of 3HAAcm1K0 was higher than 3HA-Acm1 and was equivalent to the level in early
M cells, consistent with the anaphase ubiquitin dependent proteolytic mechanism
mediated by APCCdc20 [91]. In support of our results from Figure 2.1, a portion of
the wild-type 3HA-Acm1 was still present in these late anaphase cells, demonstrating
that Acm1 is not completely eliminated by APCCdc20 . Importantly, 3HA-Acm1K0 was
undetected in G1 cells, similar to wild-type 3HA-Acm1. This strongly implies that the
APC-independent proteolytic mechanism that clears Acm1 completely during mitotic
exit and G1 does not involve conjugation of ubiquitin chains to Acm1.
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Fig. 2.5.: Acm1 proteolysis does not require ubiquitin acceptor sites on
Acm1. A) YKA247 cells carrying PGAL1 expression plasmids for 3FLAG-Cdh1, 3HAAcm1, HA-Acm1-ken, and 3HA-Acm1K0 in the indicated combinations were grown
until mid-exponential phase. 10-fold serial dilutions were spotted on selective media
containing either glucose or galactose. Plates were incubated at 30 ◦ C for 23 days. B)
and C) YKA247 cells carrying PGAL1 expression plasmids for 3HA-Acm1 (pHLP117)
or lysine-less 3HA-Acm1K0 mutant (pHLP330) were grown in YP-raffinose to early
exponential phase. Cells were arrested at G1 (panel B) or S phase (panel C). Stability of 3HA-Acm1 and 3HA-Acm1K0 was monitored over the indicated time period
by immunoblotting with anti-HA antibody. G6PDH is a loading control. D) Same
as panels B and C, except pdr5∆ cells were used and stability was monitored in the
presence and absence of MG-132 as indicated. Longer immunoblot exposures were
obtained for detection of ubiquitin (Ub) conjugates. E) cdc15-2 cells carrying centromeric plasmids expressing either wild-type 3HA-Acm1 or 3HA-Acm1K0 from the
natural ACM1 promoter were arrested at the indicated cell cycle stages as described
in Materials and Methods. The level of each protein was then compared by anti-HA
immunoblotting with G6PD as a loading control.
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2.2.7

An N-terminal putative disordered region of Acm1 contributes to
APC-independent degradation

To probe the biological significance of Acm1 degradation we needed a stable Acm1
mutant. We therefore sought truncated Acm1 variants that exhibited increased halflife in our G1 stability assay. We fused the ZZ domain of Protein A (ProtA) to
the Acm1 C-terminus (for equivalent immunoblot detection of all Acm1 constructs).
Full length Acm1-ProtA was highly unstable. Removal of 42 amino acids or less had
little effect on the rate of Acm1-ProtA degradation (Figure 2.6A). Strikingly, removal
of the 52 N-terminal amino acids strongly stabilized Acm1-ProtA in this assay and
longer truncations from the N-terminus were also stable.
Although clearly required for efficient Acm1 degradation in G1, the first 52 amino
acids of Acm1 were not sufficient to destabilize Protein A when fused to its N-terminus
(Figure 2.6B). This suggested that other regions of Acm1 might be important as well.
We found that the Acm1N ∆52 protein was unstable in the absence of the C-terminal
Protein A fusion (Figure 2.6C). Thus, stabilization of Acm1 in G1 required both loss
of the amino terminus and modification of the C-terminus. The N-terminal region
of Acm1 is predicted to be highly disordered using several secondary structure prediction algorithms (data not shown). The proteasome can directly recognize some
disordered proteins and catalyze their proteolysis in the absence of ubiquitin conjugation. We purified active 20S and 26S proteasomes from yeast but found no evidence
that a variety of recombinant Acm1 proteins purified from E. coli could be directly
recognized and degraded (Figure 2.11).
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Fig. 2.6.: Proteolysis of an Acm1-ProtA fusion protein in G1 requires
the N-terminal 52 amino acids of Acm1. A) YKA247 cells transformed with
PGAL1 constructs expressing ACM1, acm1N ∆42 , acm1N ∆52 , acm1N ∆60 , acm1N ∆72
or acm1N ∆80 fused to the ZZ domain of Protein A were arrested in G1 and protein
stability assayed over time by immunoblotting with anti-Protein A antibody. B) The
same assay as panel A with cells expressing Acm1 amino acids 152 fused to Protein A.
C) The stability of Acm1 and Acm1N ∆52 without the Protein A fusion were compared
using the same assay as in panel A, but with anti-Acm1 antibody for immunoblot
detection. G6PD is a loading control. G6PD loading controls were performed for all
blots in panels A and B as well (not shown).

2.2.8

Acm1N ∆52 is still cleared from cells at mitotic exit

We next used the stabilized Acm1N ∆52 protein to study the biological significance
of Acm1 proteolysis at mitotic exit. It is important to note that the N-terminus
of Acm1 also contains the Cdc20-specific D-box responsible for Acm1 recognition
by APCCdc20 [91]. Thus, the Acm1N ∆52 protein should be resistant to both known
proteolytic mechanisms. We predicted that failure to degrade Acm1 would prevent
or delay activation of APCCdh1 . To test this, strains harboring a PM ET 3 -CDC20
allele and expressing either Acm1 or Acm1N ∆52 -ProtA from the ACM1 promoter
were blocked at metaphase by methionine addition and then released in the absence
of methionine to undergo synchronous mitotic exit. The levels of Acm1 and the Cdh1
substrate Clb2 were monitored over time by immunoblotting (Figure 2.7A and 2.7B).
Surprisingly, there was little difference in the decay profiles of Acm1 and Acm1N ∆52 -

43
ProtA. Moreover, we did not observe significant differences in degradation of Clb2.
Similar results were observed with another Cdh1 target, Kip1 (data not shown).
Thus, although Acm1N ∆52 -ProtA is highly stabilized in G1-arrested cells, it is still
effectively cleared by cells during mitotic exit. Possible explanations for this are
discussed below.

2.2.9

Constitutive expression of stabilized Acm1N ∆52 impairs growth of
sic1∆ cells

Since the ACM1 promoter is cell cycle-regulated, loss of Acm1N ∆52 as cells exit
mitosis could be in part due to termination of ACM1 transcription. To test for defects
in APCCdh1 function in cells expressing stabilized Acm1N ∆52 we expressed ACM1 and
acm1N ∆52 alleles from the constitutive ADH promoter in a sic1∆ background. Either
Sic1 or Cdh1 is sufficient for Cdk inactivation and mitotic exit in budding yeast, however loss of both is lethal. Therefore, activation of Cdh1 becomes critically important
in sic1∆ cells. We observed a significant growth delay in sic1∆ cells constitutively
expressing Acm1N ∆52 compared to wild-type Acm1, both in liquid culture and on
agar plates (Figure 2.7C and 2.7D). This experiment supports the idea that clearance
of Acm1 from cells is required for timely and full activation of APCCdh1 at mitotic
exit and in G1.
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Fig. 2.7.: (Caption on next page)
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Fig. 2.7.: (Previous page)
Acm1N ∆52 is still cleared at mitotic exit, but constitutive expression impairs growth of sic1∆ cells. A) YKA859 cells carrying either pHLP117 (for
expression of 3HA-Acm1) or pHLP505 (for expression of Acm1N ∆52 -ProtA) were arrested at metaphase by methionine repression of PM ET 3 -CDC20 and then released in
the absence of methionine. Cells were collected at regular intervals and analyzed by
immunoblotting using antibodies against Acm1, Clb2, or G6PD (loading control). B)
Quantitation of chemiluminescent immunoblots from panel A. Data are the average
of 4 independent experiments. C) Growth of sic1∆ cells transformed with either an
empty vector, pHLP361 (PADH -Acm1-ProtA) or pHLP363 (PADH -acm1N ∆52 -ProtA)
were compared using a plate reader to measure absorbance at 600 nm. Data are the
average of three independent experiments with standard deviation error bars. D)
Serial 10-fold dilutions of the strains from panel C as well as isogenic wild-type and
cdh1∆ strains were spotted and grown on selective agar plates.

46

Fig. 2.8.: Screening of non-essential E2 conjugases and E3 ligases for effects
on 3HA-Acm15A expression level. 3HA-Acm15A was expressed from the natural
ACM1 promoter on a centromeric plasmid in BY4741 (WT) and deletion strains
lacking the genes indicated above each lane. The steady state level of 3HA-Acm15A
in asynchronous log phase cultures of each strain was compared to that of wildtype 3HA-Acm1 (labeled Reference) expressed from the same plasmid in BY4741 by
immunoblotting with anti-HA antibody. G6PDH is a loading control.
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Fig. 2.9.: Measurements of HA-Acm15A stability in selected strains lacking nonessential E2 conjugases and E3 ligases. Stability of HA-Acm15A was
monitored by GAL1 promoter stability assay as described in Materials and Methods
in asynchronous mid-log phase cultures of the indicated gene deletion strains harboring pHLP110. Anti-HA immunoblot profiles were compared to those from MG-132
treated cells and conditional proteasome mutant strains (not shown, see Figure 2.2).
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Fig. 2.10.: Screening of non-essential E2 conjugases and known and putative
E3 ligases for effects on Acm15A stability. Experiments performed as in Figure
2.9 but using an untagged Acm15A variant expressed from PGAL1 in pHLP392 in
an acm1∆ background. Only timepoints 0 and 60 minutes following glucose and
cycloheximide addition were compared. MG-132 treatment was used as a positive
control for Acm1 stabilization. Anti-Acm1 antibody was used to detect the Acm15A .
Only representative E3 deletion strains are shown in panel A, but all strains listed in
Table 2-1 were analyzed with similar results. Panel B shows E2 deletion strains
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Fig. 2.11.: Acm1 is not degraded by purified 20S or 26S proteasomes. A)
SDS-PAGE analysis of purified 20S (left) and 26S (right) proteasome preparations
visualized with Coomassie blue. M, molecular weight markers. Components of the
proteasomes were confirmed by mass spectrometry. B) Proteasome activities were
measured using the fluorogenic substrate, Suc-LLVY-AMC. The proteasome inhibitor
epoxomycin (Epox) was used to demonstrate specificity. Similar results were observed
with MG-132 (not shown). A standard curve of free AMC was used to convert
fluorescence signal to moles of product formed. 20S Ref is the specific activity value
reported previously for budding yeast 20S proteasome in reference 55 from the main
text. C) Immunoblot of recombinant purified GST-Acm1 incubated with purified 26S
proteasome over time. D) Immunoblot of recombinant 6His-Acm1 alone and after
incubation with purified proteasome (20S or 26S) with and without the inhibitor
epoxomicin. E) GST-Acm1 and free Acm1 generated by treatment of GST-Acm1
with 3C protease were incubated with purified 26S proteasome and analyzed by SDSPAGE and Coomassie blue staining.
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2.3

Discussion

2.3.1

Acm1 may be a novel ubiquitin-independent proteasome substrate

The 26S proteasome is a large ATP-dependent protease complex consisting of a
20S core particle with a 19S regulatory particle at both ends [154, 155]. It is the
primary enzymatic activity responsible for protein turnover in eukaryotic cells [156].
Although the vast majority of known proteasome substrates require ubiquitination for
proteolysis, proteins can also be recognized by the proteasome without ubiquitin conjugation [157–159]. The 20S core particle alone, which is likely the predominant form
of the proteasome in vivo, can recognize mis-folded or damaged proteins directly and
catalyze their proteolysis independent of ubiquitin conjugation and ATP hydrolysis.
In addition, the 26S holoenzyme can also recognize some proteins independent of ubiquitin. One recent study estimated that 20% of human proteins are subject to proteolysis by the proteasome independent of ubiquitin conjugation [160]. However, the extent to which any of this proteolysis is regulated is unclear and ubiquitin-independent
proteolysis is thought to largely constitute a basal protein turnover pathway and/or
a route to eliminate damaged or mis-folded proteins [158, 161].
The best-characterized ubiquitin-independent substrate of the 26S proteasome
is ornithine decarboxylase (ODC), which catalyzes the rate-limiting first step in
polyamine biosynthesis [162, 163]. ODC is targeted to the proteasome by a protein,
termed antizyme, in response to high polyamine levels. This regulated ubiquitinindependent proteolysis serves to maintain polyamine homeostasis in cells [164]. Antizyme
binding to ODC results in a conformational change that exposes a C-terminal degron
in ODC recognized by the 26S proteasome [165, 166]. Antizyme itself also enhances
recognition of ODC by the proteasome. The C-terminal tail of ODC may act as a
structural ubiquitin mimic since it competes with ubiquitin chains for binding to the
proteasome [166]. Interestingly, antizyme has also been linked to the ubiquitin independent proteasomal degradation of other proteins, including the cell cycle regulators
cyclin D1 [167] and Aurora A kinase [52]. Other proteins involved in aspects of cell
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cycle control with reported ubiquitin-independent proteolytic mechanisms include
p53 [168], p21Cip1 [169–172], and Rb [173, 174]. These proteins are also destroyed
by the conventional ubiquitin-proteasome pathway and it is often difficult to dissect the relative physiological contributions of ubiquitin-dependent and independent
mechanisms. In addition, for all of these cases it is unclear if, and how, ubiquitinindependent proteolytic mechanisms are regulated during cell division. One possible
exception to this may be human c-Fos, a proto-oncoprotein that functions as part
of the AP-1 transcription factor complex involved in control of cell proliferation and
other processes. c-Fos is sensitive to ubiquitin independent proteolysis and one report suggests that phosphorylation of a C-terminal degron sequence by MAP kinases
specifically at the G0/G1 transition inhibits this mechanism [175]. The importance
of this mechanism and its relevance in cycling cells is unclear, but it is reminiscent
of what we observe with Acm1, which is also stabilized at the G1/S transition by
phospho-dependent inhibition of seemingly ubiquitin-independent proteolysis.
Several features of Acm1s proteolytic mechanism reported here are reminiscent of
ubiquitin-independent proteolysis. First, Acm1 degradation is insensitive to inhibition of ubiquitin chain assembly (Figure 2.4). Second, Acm1 degradation does not
require acceptor lysines and does not appear to involve direct ubiquitin conjugation
(Figure 2.5). Third, no individual E3 ligase or E2 conjugating enzyme is required for
Acm1 proteolysis. The one notable exception is that Acm1 proteolysis does require a
functional E1, suggesting that the ubiquitin conjugation system is at least indirectly
required. Thus, Acm1 meets most, but not all, criteria for an ubiquitin-independent
proteasome substrate [158].

2.3.2

How is Acm1 recognized by the proteasome and what is the role of
the Acm1 N-terminus?

Additional work will be required to illuminate the biochemical mechanism by
which Acm1 is specifically targeted to the proteasome in its dephosphorylated state.
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Many ubiquitin independent proteasomal targets are thought to possess unstructured regions that mediate their direct recognition by the proteasome, much like a
mis-folded protein [158, 176]. The N-terminus of Acm1 is predicted to be largely
disordered (our unpublished observations) and contributes to its APC-independent
proteolysis (Figure 2.6). Phosphorylation at Cdk sites in and around the Acm1 Nterminus may promote a more structured conformation that prevents degradation.
Alternatively, Acm1 may interact with a proteasome targeting factor analogous to
the ODC-antizyme interaction that has high affinity for dephosphorylated Acm1 but
not for phosphorylated Acm1. This factor could itself be regulated by ubiquitination,
thereby explaining the E1 result and general requirement for the ubiquitin system.
The E1 requirement could also reflect a general role for ubiquitinated proteins in
activating the 26S proteasome, a phenomenon that has some recent support [177].
Another possibility is that the Acm1 N- and/ or C-terminus contain sequences that
are directly recognized by a component of the proteasome. Such a sequence could act
by mimicking ubiquitin as proposed for ODC, or interact with a completely distinct
proteasome structure.
Despite the strong stabilization of Acm1N ∆52 -ProtA in our GAL1 promoter stability assay (Figure 2.6, half-life .1 hour), it was still effectively cleared during mitotic
exit when expressed from the ACM1 promoter, with kinetics similar to wild-type
Acm1-ProtA. There are several possible explanations for this surprising result. Although the Cdc20-specific D-box is absent from Acm1N ∆52 it is possible that removal
of the N-terminal 52 amino acids makes the central D-box and/or KEN box that
inhibit Cdh1 accessible to Cdc20. Cdh1 was also proposed to catalyze a slow ubiquitination and proteolysis of Acm1 [91] that, coupled with the termination of ACM1
transcription, may contribute to clearance of endogenous protein. We confirmed
that the slow turnover of Acm1N ∆52 -ProtA in G1 cells is Cdh1-dependent (data not
shown). Finally, there may be some difference in conditions present in an α-factor
arrest compared to mitotic exit that affect the turnover rate of Acm1 by the APCindependent mechanism.
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2.3.3

Biological significance of Acm1 proteolytic mechanisms

Our results have confirmed the existence of two independent proteolytic mechanisms acting on Acm1. Acm1 is recognized by APCCdc20 in anaphase as described previously [91] and degraded via the conventional ubiquitin pathway. However, APCCdc20
is not sufficient to completely eliminate Acm1 and is not actually required for Acm1
levels to oscillate during the cell cycle (Figure 2.1). Consistent with this conclusion,
mutation of the D-box in Acm1 that is recognized by Cdc20 had no noticeable effect on Acm1 stability or cell cycle expression profile [89, 92]. The APC-independent
mechanism, which exhibits features of ubiquitin-independent proteolysis, is sufficient
to establish Acm1s cell cycle expression profile.
Why is APCCdc20 insufficient for complete Acm1 degradation and why is it necessary to have two independent proteolytic mechanisms? One possibility is that two
distinct cellular pools of Acm1 exist, one in the nucleus and one in the cytoplasm,
and Cdc20 can only access nuclear Acm1. Although admittedly speculative, a fair
amount of circumstantial evidence exists to support this possibility. Cdc20 is restricted primarily to the nucleus [178]. Cdh1, on the other hand, is restricted to
the cytoplasm by Cdk phosphorylation until the end of anaphase [178]. Since Acm1
binds tightly to Cdh1 in cells arrested in late anaphase [88], it is likely that at least
a portion of Acm1 remains cytoplasmic. Moreover, nuclear import of Acm1 is also
negatively regulated by Cdk phosphorylation [91]. Since Acm1 levels are much higher
than Cdh1 [88] a substantial pool of free Acm1 must exist that could be subject to
rapid nucleocytoplasmic shuttling. When Cdc14 is first activated by the FEAR network in early anaphase, dephosphorylation of the pool of free Acm1 could trap it in
the nucleus where it is recognized and targeted for degradation by APCCdc20 . The
Cdh1-bound pool of Acm1 would be resistant to APCCdc20 by virtue of its cytoplasmic localization. This pool of Acm1 could require the second ubiquitin-independent
proteolytic mechanism activated when Cdc14, released by the mitotic exit network,
reaches the cytoplasm and dephosphorylates both Cdh1 and Acm1. The complexity

54
of Acm1 regulation in late mitosis strongly implies that timely and complete removal
of Acm1 is essential for proper activation of APCCdh1 , completion of mitotic cyclin
degradation, and exit from mitosis. Our observation of a growth delay caused by
Acm1N∆52 expression in sic1∆ cells supports this.
A related question is why APCCdc20 action on Acm1 is required at all, especially
considering that in the absence of APC activity Acm1 levels still cycle apparently normally (Figure 2.1). The N-terminal D-box recognized by Cdc20 is highly conserved in
Acm1 orthologs, suggesting that APCCdc20 -mediated degradation must be important.
It may be that initial depletion of the abundance of free Acm1 by APCCdc20 preconditions Cdh1 for rapid activation at the appropriate time in late mitosis, maximizing
the efficiency, coordination, and robustness of the mitotic exit process.
Recently, Acm1 was proposed to act as a physiological buffer for Cdh1, precisely
controlling Cdh1 activity in combination with inhibitory Cdk phosphorylation to
allow proper multi-step assembly of a mitotic spindle [62]. In cells expressing a
Cdh1 mutant lacking inhibitory Cdk phosphorylation sites, bipolar spindle assembly
was ultra-sensitive to ACM1 gene dosage. In this context, very fine control of Acm1
level by the phosphorylation sensitive and constitutively active ubiquitin-independent
proteolytic mechanism could precisely control Acm1 abundance at a level representing
the maximal capacity for Cdk phosphorylation. Acm1 expressed above this level
would begin to exceed the capacity of Cdk to maintain it in a phosphorylated state
and result in rapid proteolysis of hypophosphorylated protein. This is consistent with
our unpublished observations that over-expression of Acm1 from the ADH and GAL1
promoters leads to only modest changes in steady-state level.

2.4

Conclusion
The APC-independent proteolysis of Acm1 appears to represent a unique example

of highly cell cycle-regulated proteasomal degradation independent of the canonical
polyubiquitin targeting system. This mechanism also reflects the existence of alter-
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native ways to establish cell cycle expression profiles other than via the SCF and
APC E3 ligases. Our work reinforces the cooperative interplay of transcriptional and
proteolytic control in establishing strict expression windows of cell cycle regulators
during cell division. Future research on this topic should reveal if the unique cell cycle proteolysis of Acm1 represents a general mechanism complementing the ubiquitin
proteasome system in governing cell cycle-dependent protein levels.

2.5

Materials and Methods

2.5.1

Strain and plasmid construction, and mutagenesis

All yeast strains used in this study, except those for screening ubiquitin system
mutants, are listed in Table 2. Ubiquitin system mutant strains are listed in Table 2-1.
All plasmids used in this study are listed in Table S3. Strain YKA468 was constructed
by recombinational insertion of a PCR product containing a 3HA epitope tag with
kl TRP1 selectable marker at the 3’ end of CLB5 and a 9MYC tag with HIS3MX6 selectable marker at the 39 end of PDS1 in the dbf2-2 strain using plasmids pYM22 and
pYM19 as templates as described [179]. Strain YKA469 was constructed by standard
recombinational replacement of the ACM1 coding sequence with a PCR-generated
KanMX4 selectable marker. YKA859 was constructed from FM1175 by deleting
ACM1 using PCR-mediated integration of the KanMX4 marker and then inserting a
6HA:NatNT2 tag at the 39 end of KIP1 using pYM17 [179]. YKA404 was generated
from Y7092 [180] by PCR-based deletion of ACM1 with the Nat1 nourseothricin resistance cassette. E3 and E2 deletion strains for screening stability of untagged Acm15A
were generated by crossing YKA404 to the appropriate MATa KanMX4 gene deletion strains from Open Biosystems as described [180]. Plasmid pHLP317 expressing
3HA-Fin1 from the GAL1 promoter was constructed by subcloning the BamHI-SalI
fragment from pESCW-Fin1-Myc into pESCLeu-3HA (both gifts from H. Charbonneau, Purdue University). The acm1K0 mutant allele was created in pBluescript by
site-directed mutagenesis using the QuikChange Multi kit (Stratagene) and, amplified
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Table 2.1: Yeast deletion strains screened for effects on Acm1 stabilization
Non-essential E3s
Non-essential E2s
ASI3
PEX12
UBC2
ASR1
PIB1
UBC4
BRE1
PSH1
UBC5
CUL3
RAD5
UBC6
CUL8
RAD16
UBC7
DMA1
RAD18
UBC8
DMA2
RCO1
UBC10
ETP1
RKR1
UBC11
FAP1
RTC1
UBC12
FAR1
SAN1
UBC13
HEL1
SLX5
HEL2
SLX8
HRD1
SNT2
HUL4
SSM4
HUL5
TOM1
IRC20
TUL1
ITT1
UBR1
MAG2
UBR2
MOT2(NOT4)
UFD2
NFI1
UFD4
PEP3
ULS1
PEP5
VPS8
PEX2
YBR062C
PEX10

Essential E3s
RSP5
PRP19
SCF*
APC*

For all non-essential genes, deletion strains were obtained from the Open Biosystems gene deletion
library and crossed to YKA404 to generate combined deletions with acm1∆::KanMX4.
For essential genes RSP5 and PRP19, tetracycline-repressible strains were obtained from the Open
Biosystems Tet-promoter collection.
*Effects of SCF on Acm1 stability were tested using conditional cdc34 and cdc53 mutant strains
(not shown and [162]). No effect was found. Lack of dependence on APC can be found in Figure
2.1 and [161].
Strains in bold were tested in both Figure 2.8 and Figure 2.10 screens. Non-essential E3 and E2
strains not in bold were only tested in the Figure 2.10 screen.
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by PCR, and subcloned into the XhoI sites of pHLP117 [88] to create pHLP328 or
subcloned into the SacII and XhoI sites of p415GAL1 to create pHLP329. The one
lysine codon in the 3HA sequence of pHLP329 was altered to an arginine codon to
create pHLP330. The 3HA-acm1K0 alleles in pHLP328 and pHLP330 were confirmed
by DNA sequencing. pHLP298 was constructed by sub-cloning the 3HA-ACM15A
sequence from pHLP209 into p415GAL1. Plasmids for Acm1 stability experiments
were constructed by first ligating the PCR-amplified ZZ domain of Protein-A into the
HindIII and XhoI sites of p415GAL1 and then ligating the appropriate ACM1 PCR
fragments into the PstI and HindIII sites. All plasmid constructs were confirmed by
DNA sequencing.

2.5.2

Cell growth and cell cycle arrest

Standard yeast growth conditions and media were used. For G1 arrest, α-factor
peptide (GenScript) was added to cultures at a final concentration of 5 mg/ml for
BAR1 or 50 mg/l for bar1∆ strains. For S phase arrest, solid hydroxyurea (Sigma
Aldrich) was added directly to cultures at 10 mg/ml. For G2/M arrest, nocodazole
(Sigma Aldrich) was added at a final concentration of 15 mg/ml from a 1.5 mg/ml
stock in DMSO. For telophase arrest, strains harboring temperature-sensitive MEN
mutants cdc15-2 or dbf2-2 were grown initially at 23 ◦ C and then shifted to 37 ◦ C. For
all temperature sensitive strains, 23 ◦ C was used as permissive and 37 ◦ C as restrictive
temperatures. For synchronous growth from G1 to telophase, α-factor treated cdc152 or dbf2-2 cells were released from arrest by extensive washing using a vacuum
filtration device and resuspension in fresh medium pre-warmed to 37 ◦ C. Growth was
continued at 37 ◦ C and samples were removed at the indicated times for analysis.
Extracts of synchronized yBR135 and yBR159 cultures for analyzing Acm1 levels
in the absence of APC activity [148] were generously provided by David Toczyski
(U. California San Francisco). For metaphase block and release, FM1175 and its
derivatives were grown in SD-Met-Leu media (50 mL) then transferred to YPD (120
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mL) supplemented with 5 mM methionine and grown for 4 hours at 30uC. Cells
were then released into 120 mL of selective media (SD-Met-Leu) following vacuum
filtration onto a membrane disk (0.8 mm) and washing with 100 mL of SD-Met-Leu
media. Cell cycle arrests were confirmed by microscopic analysis of cell morphology
and flow cytometry. Flow cytometry analysis was performed exactly as described
[88] using an Accuri C6 flow cytometer (BD Biosciences). Cell cycle stage in the
synchronous growth experiments was determined by 49,6-diamidino-2-phenylindole
(DAPI) staining of formaldehyde-fixed cells and fluorescence microscopy to monitor
nuclear division. Images were captured on an Olympus BX51 fluorescence microscope
using Metamorph software (Molecular Devices, Inc.) and percentage of cells with
segregated DNA masses quantified (minimum 100 cells per timepoint).

2.5.3

Immunoblotting

The following antibodies were used. Monoclonal anti-HA 12CA5 and anti-Myc
9E10 were from Roche Applied Science (catalog numbers 11666606001 and 11667149001,
respectively) and were used at concentrations of 0.5 mg/ml (1:10,000 dilution) and 1
mg/ml (1:5,000 dilution), respectively. Rabbit anti-glucose-6-phosphate-dehydrogenase
(G6PD) and rabbit anti-Protein A were from Sigma (catalog numbers A9521 and
P3775, respectively) and were used at concentrations of 3 ng/ml (1:10,000 dilution) and 0.6 ng/ml (1:50,000 dilution), respectively. Rabbit anti-Clb2, used at 40
ng/ml (1:5,000 dilution) was from Santa Cruz Biotechnology (catalog numbers sc9071). Horseradish peroxidase-conjugated donkey anti-rabbit and anti-mouse were
from Jackson Immuno Research (catalog numbers 111-035-003 and 115-035-003, respectively) and were used at concentrations of 80 ng/ml each. Immunoblots were developed using ECL plus (GE Healthcare) or Luminata (Millipore) detection reagents.
For Acm1 polyclonal antibody production and purification, the complete ACM1
open reading frame was cloned into pGEX6P-1 (GE Healthcare) for overexpression
in E. coli as an N-terminal GST-fusion protein. The majority of GST-Acm1 is found
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in the insoluble fraction of bacterial cell extracts. Insoluble proteins were pelleted by
centrifugation and resolubilized in 8 M urea, separated by SDS-PAGE and stained
with Coomassie blue. The predominant band was GST-Acm1 and was excised and
submitted to Pacific Immunology for polyclonal antibody production. Total Rabbit
IgG was purified from serum using Protein A-agarose resin (Sigma Aldrich). Subsequently, anti-Acm1 antibodies were affinity purified using a GST-Acm1 affinity column generated by crosslinking recombinant GST-Acm1 to glutathione-agarose with
disuccinimidyl suberate (Thermo Scientific). Acm1 antibody was eluted from the
affinity column with 50 mM glycine pH 1.9 and immediately neutralized by addition
of Tris-HCl pH 8.0 to 100 mM. Antibody specificity was tested by immunoblotting
of yeast whole cell extracts using acm1D cells as a control. 1:5,000 dilutions of the
affinity purified antibody were used for all immunoblots. Quantification of chemiluminescent immunoblots was performed using a Bio-Rad Laboratories ChemiDoc XRS+
digital imager and ImageLab software. Images obtained following incubation of blots
with chemiluminescent reagent were analyzed using the Image Lab software. Signals
were normalized to the G6PD load control signal and then to the 0 min timpoint.

2.5.4

Protein stability assays

Measurements of protein stability were performed by GAL1 promoter shutoff/
cycloheximide chase assays as described [94]. Unless stated otherwise, expression
was induced with 2% galactose and terminated by addition of 2% glucose and 0.5
mg/ml cycloheximide. For experiments in proteasome mutants (cim3-1 and pre1-1
pre2-2 ), cells were first arrested with α-factor at 23 ◦ C and then protein expression
induced for 30 min prior to shift to 37 ◦ C. For ubiquitin mutant overexpression
experiments, actively growing cells were arrested with α-factor in early exponential
phase (OD600 =0.4) and then CuSO4 was added to 100 mM to induce overexpression
of mutant or wild-type ubiquitin from the CUP1 promoter. After 30 min 2% galactose
was added to induce expression of the Acm1 or control proteins. To measure stability
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of endogenous Acm1, mid-exponential phase cells were treated only with 0.5 mg/ml
cycloheximide to terminate expression. For MG-132 treatment, a pdr5∆ strain was
used to maximize efficacy [181] and cultures were treated with 50 µM MG-132 (from
10 mM stock in DMSO) for 30 min prior to terminating expression.
For synchronized mitotic exit experiments, Acm1 or Acm1N 52 -ProtA were expressed from the natural Acm1 promoter on CEN plasmids (pHLP117 or pHLP505,
respectively) in a PM ET 3 -CDC20 background. Cultures were arrested in mitosis by
Cdc20 depletion as described above and protein levels monitored over time by quantitative immunoblotting.
Screening of ubiquitin system mutant strains Yeast strains individually lacking
all known non-essential E2 ubiquitin conjugating enzymes, E3 ubiquitin ligases, and
proteasome components were obtained from the Open Biosystems yeast deletion library (Table 2-1). Relative levels and stability of wild type Acm1 and the Acm15A
mutant [94] were measured by immunoblotting as described above. For screening
of essential E3 genes, strains from the Tet-repressible essential gene library (Table
2-1) containing pHLP209 expressing 3HA-Acm15A from the ACM1 promoter were
grown until mid-exponential phase and then treated with 2µg/ml doxycycline for 2
hrs before processing for immunoblotting.

2.5.5

In vivo APC inhibition assay

Inhibition of APCCdh1 in vivo was measured exactly as described previously [88].
Spotting growth assay.
Cultures of sic1∆ cells transformed with either p415ADH, pHLP361 (PADH -Acm1ProtA) or pHLP363 (PADH -acm1N ∆52 -ProtA) as well as isogenic wild-type and cdh1∆
strains transformed with p415ADH were grown to mid-exponential phase selective
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Table 2.2: Yeast strains used in this study.
Strain
BY4741
W303
doa4∆
MHY753
MHY754
YKA247
YKA404
YKA407
YWO0607
YWO0612
YKA468
YKA469
yBR135
yBR159
RJD3268
RJD3269
FM1175
YKA859
sic1∆
cdh1∆
RPN11-TAP
SDL135

Genotype
MATa his3∆1 leu2∆0 met15∆0 ura3∆0
MATa ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1 can1-100
(BY4741) MATa doa4::KanMX4
MATa his3-∆200 leu2∆1 ura3-52 lys2-801 trp1-63 ade2-101
MATa his3-∆200 leu2∆1 ura3-52 lys2-801 trp1-63 ade2-101
cim3-1
(W303) bar1 ::URA3 acm1 ::KanMX4
MAT acm1 ::Nat1 can1 ::STE2pr-his5 lyp1∆ his3∆1 leu2∆0
ura3∆0 met15∆0
(BY4741) MATa bar1::hisG acm1 ::KanMX4 pdr5 ::URA3
MATa ura3 leu2-3,112 his3-11,15 CanS Gal+
MATa ura3 leu2-3,112 his3-11,15 CanS Gal+ pre1-1 pre2-2
MATa ura3∆ leu2∆ ade2∆ his3∆ trp1∆ dbf2-2 CLB53HA:TRP1 PDS1-9MYC:HIS3
(W303) MATa cdc15-2 GFP-TUB1:URA3 acm1 ::KanMX4
(W303) MATa pds1 ::LEU2 clb5 ::HIS3 trp1-1 ::SIC1:TRP110x
(W303) MATa pds1 ::LEU2 clb5 ::HIS3 trp1-1 ::SIC1:TRP110x
apc2∆ apc11∆ cdc20∆ cdh1∆
(W303) MATa uba1 ::KanMX pRS313-UBA1
(W303) MATa uba1 ::KanMX pRS313-uba1-204
(W303) MATa PM ET 3 -CDC20-HA::TRP1
(FM1175) acm1 ::KanMX4 KIP1-6HA:NatNT2
(BY4741) MATa sic1 ::KanMX4
(BY4741) MATa cdh1 ::KanMX4
(BY4741) MATa RPN11-TAP:HIS3MX
MATa lys2-801 leu2-3,112 ura3-52 his3-∆200 trp1-1
pre1 ::PRE1-TEVProA:HIS3

Source
Open Biosystems
Open Biosystems
[150]
[150]
[88]
This study
[94]
Dieter H. Wolf
Dieter H. Wolf
This study
This study
[148]
[148]
Ray Deshaies
Ray Deshaies
Foong May Yeong
This study
Open Biosystems
Open Biosystems
Open Biosystems
Daniel Finley
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Table 2.3: Yeast plasmids used in this study.
Name
LHP306
LHP308
pESCTrp-Fin1
pHLP110
pHLP117
pHLP123
pHLP209
pHLP212
pHLP231
pHLP298
pHLP309
pHLP317
pHLP328
pHLP330
pHLP391
pHLP392
pHLP397
pHLP399
pHLP400
pHLP401
pHLP402
pHLP403
pHLP413
pHLP414
pHLP415
pHLP416
pHLP417
pHLP503
pHLP504
pHLP505
pHLP361
pHLP363

Expressed Protein
Ub-K7R
Ubiquitin
Fin1-Myc
HA-Acm15A
3HA-Acm1
HA-Acm1ken
3HA-Acm15A
3HA-Acm1
3FLAG-Cdh1
3HA-Acm15A
Clb2
Fin1-3HA
3HA-Acm1K0
3HA-Acm1K0
Acm1
Acm15A
Acm1-ProtA
Acm1N ∆42 -ProtA
Acm1N ∆52 -ProtA
Acm1N ∆60 -ProtA
Acm1N ∆72 -ProtA
Acm1N ∆80 -ProtA
Acm11−18 -ProtA
Acm113−30 -ProtA
Acm125−42 -ProtA
Acm137−54 -ProtA
Acm149−66 -ProtA
Acm11−52 -ProtA
Acm112−52 -ProtA
Acm1N ∆52 -ProtA
Acm1-ProtA
Acm1N ∆52 -ProtA

Backbone
YEp352
YEp352
pESC-Trp
p415GAL1
p415ADH
p415GAL1
p415ADH
p415GAL1
pNC219
p415GAL1
P415GALL
pESC-Leu
p415ADH
p415GAL1
P415GAL1
p415GAL1
p415GAL1
p415GAL1
p415GAL1
p415GAL1
p415GAL1
p415GAL1
p415GAL1
p415GAL1
p415GAL1
p415GAL1
p415GAL1
p415GAL1
p415GAL1
p415GAL1
p415ADH
p415ADH

Marker
URA3
URA3
TRP1
LEU2
LEU2
LEU2
LEU2
LEU2
TRP1
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2
LEU2

Origin
2µm
2µm
2µm
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
2µm
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS
CEN/ARS

Promoter
CUP1
CUP1
GAL1
GAL1
ACM1
GAL1
ACM1
GAL1
GAL1
GAL1
GALL
GAL1
ACM1
GAL1
GAL1
GAL1
GAL1
GAL1
GAL1
GAL1
GAL1
GAL1
GAL1
GAL1
GAL1
GAL1
GAL1
GAL1
GAL1
ACM1
ADH1
ADH1

Source
[153]
[153]
[94]
[94]
[88]
[89]
[94]
[94]
[94]
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
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media, then washed and resuspended in sterile TE to OD600 of 1.0. Serial 10-fold
dilutions were spotted onto SD-Leu agar plates and grown at 37 ◦ C for 2 days.
Growth rate measurements.
Growth rates were measured by diluting exponentially growing cultures to an OD600
of 0.05 in selective media and growing in 96-well plates at 30 ◦ C with shaking in a
BioTek Synergy 2 plate reader. Absorbance measurements at 600 nm were taken
every 60 minutes.
Proteasome activity assays.
Proteasomes were purified from yeast soluble whole cell extracts by IgG-agarose
(Sigma-Aldrich) affinity chromatography using a protocol described previously. For
26S proteasomes, a strain expressing an RPN11-TAP fusion was used and for 20S
proteasomes a strain expressing a PRE1-TEVProA fusion was used. To assay general
activity of proteasome preparations, the fluorogenic substrate Suc-LLVY-AMC (Peptides International, Inc.) was used as described [55] at 100 mM in reaction buffer (50
mM Tris-HCl pH 7.4, 5 mM MgCl2 , 10% glycerol, and 1 mMATP). Fluorescence of
the hydrolyzed AMC moiety was measured at excitation and emission wavelengths of
380 and 440 nm, respectively. Specific activities of purified 26S proteasome and 20S
proteasomes were measured as described [55]. Values for the 20S proteasome were
comparable to that observed in other studies [55]. We did not find reports of specific
activities for the budding yeast 26S proteasome on the Suc-LLVY-AMC substrate
under similar conditions.
GST-Acm1 and 6His-Acm1 were purified from E. coli as described previously
[89, 129]. The GST tag was cleaved off Acm1 with PreScission (3C) protease (GE
Life Sciences). To assay degradation of purified GST-Acm1 by the 26S proteasome
preparation, 200 mg of GST-Acm1 and 500 mg proteasome were mixed in 500 ml of
reaction buffer with 100 mM NaCl at 30 ◦ C and samples were collected over time and
analyzed by western blot using anti-Acm1 antibody. Degradation of 6His-Acm1 by
26S and 30 ◦ C20S proteasomes was assayed similarly for 30 min at 30 ◦ C. Free Acm1
was generated by pre-treatment of GST-Acm1 with 3C protease before mixing with

64
26S proteasome and proceeding as above. 5 mM epoxomicin (Peptides International,
Inc.) was used where indicated to specifically inhibit the proteasome.
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3. CDC14 PHOSPHATASE SUBSTRATE SELECTIVITY
IS BROADLY CONSERVED DURING EVOLUTION
3.1

Introduction
Cdc14 is somewhat unique among phosphatases involved in the regulation of the

cell cycle. Unlike mitotic serine/threonine phosphoprotein phosphatases (PPPs), it
does not function as part of a large protein complex [95]. It is currently unclear
if Cdc14 has conserved functions in evolutionarily distant species. As discussed in
Chapter 1, there is little conservation of Cdc14’s role in regulating the cell cycle. One
method to address this current lack of knowledge is to biochemically characterize
the enzyme to attempt to identify protein substrates. If one is able to define a
substrate sequence preference for the enzyme in vitro, it would be possible to predict
likely physiological substrates as has been demonstrated in budding yeast [110]. The
extent to which the structural conservation of the active site results in conservation
of substrates is also currently not understood.
Budding yeast Cdc14 possesses strict selectivity for phosphoserine Cdk phosphorylation sites (Ser/Thr-Pro) [110, 129]. Furthermore, substrates with multiple basic
residues C-terminal to the phosphoserine are preferred. The features that determine
this substrate selectivity appear to be present near the enzyme active site, in contrast to other multisubunit mitotic PSPs, whose selectivity is a product of regulatory
subunit association [95]. Alanine (A285) in the active site confers selectivity for phosphoserine over phosphothreonine by steric clash with the methyl group on the phosphothreonine side chain of substrates [129]. In silico molecular dynamics modeling
of peptide binding to hCDC14B also suggests that the preference for substrates with
a +3 basic residue is a result of a cation-π interaction with solvent exposed aromatic
residues proximal to the active site [110]. While several key determinants of Cdc14
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specificity are well-defined, specificity has not yet been comprehensively defined. For
example, possible contributions of residues N-terminal to the phosphoamino acid towards substrate recognition have not been explored. The experiments in this study
aim to improve the understanding of Cdc14 substrate selectivity, mostly by defining
its conservation across diverse eukaryotic species. This understanding will elucidate
the extent of substrate and functional conservation across these species. Differences
in substrate selectivity can also be explored in investigating divergence in function as
well as in the development of inhibitors that are selective among Cdc14 enzymes.
The main goal of this project were to compare the substrate sequence selectivity
of Cdc14 protein phosphatases from a diverse set of organisms and to search for
additional substrate specificity determinants. The basis of this line of experiments
was the discovery that budding yeast Cdc14 demonstrates preference for a subset of
Cdk substrates characterized by utilizing phosphopeptide as well as whole protein
substrates [129, 130, 182]. In the experiments presented below, I have expanded on
the amino acid sequences that constitute optimal Cdc14 substrates. Furthermore, I
have investigated the extent to which substrate selectivity observed in budding yeast
Cdc14 is conserved among Cdc14 enzymes from various organisms. To this end,
the substrate selectivity of Cdc14 from the fission yeast Schizosaccharomyces pombe
(Clp1, Flp1), the plant pathogenic fungus Fusarium graminearum (FgCdc14) and the
two paralogs of human CDC14 (hCDC14A and B) were investigated and compared
to budding yeast Cdc14 using phosphopeptide substrates.
This chapter aims to investigate ScCdc14 substrate selectivity in more detail by
analyzing the effects of changes in sequence on the kinetics of phosphopeptide substrate dephosphorylation. The extent to which Cdc14 selectivity is conserved across
an evolutionarily diverse set of organisms is also explored. Given the Cdc14 active
site conservation, I hypothesize that Cdc14 substrate selectivity is conserved among
enzymes from evolutionarily distant species.
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3.2

Results

3.2.1

Determination of kinetic parameters of Saccharomyces cerevisiae
Cdc14

This study built on these previous results. Phosphopeptide variants based on the
sequences of known Cdc14 substrates (Acm1pS3 and Acm1pS31 listed in Table 3.7)
were used to perform steady state kinetic measurements. Unsurprisingly, the strict
preference of Cdc14 for phosphoserine containing peptides was observed by the lack
of catalytic activity towards phosphothreonine containing substrates in the context
of both phosphopeptide sequences (Figure 3.1, Table 3.1). ScCdc14 was also highly
sensitive to mutations at the +1 position C-terminal to the phosphoserine (Figure
3.1) confirming that Cdc14 was selective for proline-directed phosphorylation sites.
Removal of all C-terminal basic residues (+3 to +5 positions) resulted in a drastic
reduction of catalytic efficiency of ScCdc14 (Figure 3.1).
Figure 3.3, panel A and Table 3.1 demonstrated that, in the case of the Acm1pS31
phosphopeptide, Cdc14 was not sensitive to single mutations to basic residues at positions +4 and +5 C-terminal to the site of phosphorylation given that the substrate
contains a lysine at +3. The requirement of a +3 basic residue was strongly demonstrated by the reduction in activity towards substrates lacking any basic residue at
+3 (Figure 3.2 and Table 3.1). The data also demonstrated that the identity of the
basic residue at +3 had a significant effect on Cdc14 activity, Arg being significantly
less favorable to Lys. Simultaneous mutation of the +4 and +5 basic residues significantly reduced Cdc14 catalytic efficiency (Figure 3.3 panel B, Table 3.1). This
reduction in activity resulted from the increase in Km .
These observations were in agreement with Cdc14 substrate selectivity previously
observed [129, 130] and provided a basis for comparing any deviations in selectivity
of Cdc14 from other organisms.
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Table 3.1: Steady-state kinetic parameters for phosphopeptide substrates
dephosphorylated by S. cerevisiae Cdc14. Steady state kinetic parameters,
kcat and Km , were determined by measuring initial velocity as a function of peptide
substrate concentration and fitting the Michaelis-Menten equation to the data using
nonlinear regression. The mean ± standard deviation from three independent trials
are presented. The sequence variation column shows the nomenclature for each peptide variant of the peptide provided in the sequence column (full sequences given in
Table 3.7).

Sequence

Sequence

kcat

Km

kcat /Km

variation

(s−1 )

(µM)

(M−1 /s−1 )

0.06 ± 0.015

14 ± 34

4699

pT

0.009 ± 0.003

615 ± 535

15.3

+3A

1.0 ± 0.05

1285 ± 133

781

+4A

0.078 ± 0.006

16 ± 12

4951

+5A

0.12 ± 0.02

20 ± 9.8

4512

+3R

0.82 ± 0.03

388 ± 209

325

+4A,+5A

0.1 ± 0.01

121 ± 48

882

+3R,+4A,+5A

0.16 ± 0.03

600 ± 224

266

+3A,+4A,+5A

0.018 ± 0.001

1376 ± 240

12.9

0.12 ± 0.04

193 ± 74

624

pT

0.005 ± 0.0003

234 ± 69

23

+1A

0.03 ± 0.002

2293 ± 355

13

+3A

0.057 ± 0.003

1250 ± 159

45

VKGNELRpSPSKRRSQI

MIpSPSKKRTI
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Fig. 3.1.: Budding yeast Cdc14 was highly selective for phosphoserine containing phosphopeptide substrates An in vitro dephosphorylation reaction was
performed as described in the experimental procedures section. Rate of phosphopeptide dephosphorylation was plotted as a function of peptide concentration. The data
were fit to the Michaelis-Menten equation using GraphPad Prism and steady-state kinetic parameters, kcat and Km , were obtained. For assays where substrate saturation
was not achieved, a linear fit was generated and kcat /Km was estimated as described
in the experimental procedures section. These values are reported in Table 3.1. Data
represent the mean of 3 independent experiments and error bars show standard deviation of the mean. Mutations of pSer to pThr, +1 Pro and removal of all C-terminal
basic residues led to a significant reduction of Cdc14 activity against phosphopeptide
substrates derived from known Cdc14 substrates.
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Fig. 3.2.: Loss of lysine three residues C-terminal to Ser(P) drastically
reduced budding yeast Cdc14 activity. Mutation of the +3 lysine in two previously characterized substrates led to a significant reduction in Cdc14 activity. Rate
of phosphopeptide dephosphorylation was plotted as a function of peptide concentration. The data were analyzed as described in Figure 3.1 and the kinetic parameters
are reported in Table 3.1
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Fig. 3.3.: Budding yeast Cdc14 efficiently dephosphoryalted phosphopeptides substrates containing a single basic residue C-terminal to phosphoSer
Individual mutation of basic residues at +4 and +5 residues C-terminal to the phosphoserine (Panel A) or changing +3 lysine to Arginine (Panel B) had a major effect
on the activity of Cdc14. Rate of phosphopeptide dephosphorylation was plotted as
a function of peptide concentration. The data were analyzed as described in Figure
3.1 and the kinetic parameters are reported in Table 3.1
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3.2.2

The Fusarium graminearum Cdc14 (FgCdc14) Substrate selectivity was similar to S. cerevisiae Cdc14

F. graminearum Cdc14 (FgCdc14) shares the sequences that define the Cdc14 substrate binding site with S. cerevisiae Cdc14 (Figure 1.5, [102]) predicted to contribute
to substrate selection based on modeling studies [110, 129]. Hence, the substrate selectivity observed in budding yeast was hypothesized to be conserved for FgCdc14
As expected, FgCdc14 demonstrated a high degree of selectivity for phosphoserine
containing phosphopeptides over those with either phosphothreonine or phosphotyrosine (Figures 3.4 (panels B and C) and 3.5, Tables 3.3 and 3.2). FgCdc14 was also
very sensitive to the absence of a lysine at the +3 position and mutations at the +1
proline (Figures 3.4 (panel C) and 3.5 ). Complete lack of a C-terminal basic residue
(between +3 and +5) led to a drastic reduction in catalytic efficiency. Lysine was also
the preferred basic residue at +3 both in the context of the original peptide sequence
and when it was the sole basic residue between positions +3 and +5. Changes to the
sequence N-terminal to phosphoserine (-1 and -2 positions) have very little effect. The
effects of peptide sequence mutations described above were observed with all the peptides substrates tested. The F. graminearum Cdc14 catalytic domain (FgCdc14cat )
had reduced overall enzymatic activity but the trends in substrate selectivity observed
with the full length protein also apply (Figure 3.6, Table 3.3).
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Fig. 3.4.: FgCdc14 enzyme displays substrate selctivity similar to S. cerevisiae Cdc14. Mutations of the +4 and +5 basic residues (Panel A), +3 lysine
(Panel B), +1 proline and phosphoserine (Panel C) lowered FgCdc14 activity towards phosphopeptide substrates. Rate of phosphopeptide dephosphorylation was
plotted as a function of peptide concentration. The data were analyzed as described
in Figure 3.1 and the kinetic parameters are reported in Table 3.2
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Table 3.2: Steady-state kinetic parameters for FgCdc14 catalyzed dephosphorylation of phosphopeptides. Steady state kinetic parameters, kcat and Km ,
were determined by measuring initial velocity as a function of peptide substrate concentration and fitting the Michaelis-Menten equation to the data presented in figure
3.4 using nonlinear regression. The mean ± standard deviation from three independent trials are presented. The sequence variation column shows the nomenclature for
each peptide variant of the peptide provided in the sequence column (full sequences
given in Table 3.7).

Sequence

Sequence

kcat

Km

kcat /Km

variation

(s−1 )

(µM)

(M−1 /s−1 )

0.76 ± 0.04

107 ± 23

6542

pT

N/A

N/A

4.1a

+3A

N/A

N/A

56a

+3R

N/A

N/A

98a

+3R, +4A,+5A

N/A

N/A

71a

+4A

0.46 ± 0.05

359 ± 93

1950

+5A

0.31 ± 0.03

219 ± 56

3196

+4A,+5A

0.3 ± 0.04

815 ± 196

859

+3A,+4A,+5A

N/A

N/A

19a

0.7 ± 0.04

122 ± 25

5737

pT

N/A

N/A

9.9a

+1A

N/A

N/A

21.6a

+3A

N/A

N/A

36.2a

VKGNELRpSPSKRRSQI

MIpSPSKKRTI

a

Steady state parameters could not be calculated for these peptides because Vmax was not reached at the [s] used.

The slope of the line fit to the V vs. [S] curve was applied to equation 3.4.

76

Fig. 3.5.: Estimated kcat /Km values for F. graminearum Cdc14 obtained
from initial velocity measurements Initial reaction velocity measurements at
low concentrations (below Km , 100µM) phosphopeptides series of Acm1pS3 (panel
A) and Cdh1pS239 (panel B) and 75nM of FgCdc14 were used to estimate apparent kcat /Km by applying equation 3.4. The first bar in each panel represents the
phosphopeptide whose sequence was shown. The labels on the x axis represent the
substitutions made at the positions (relative to the pSer). Data are the average of
three independent experiments and error bars represent standard deviation of the
mean. Apparent kcat /Km are reported in Table 3.3
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Fig. 3.6.: Estimated kcat /Km values for the catalytic domain of F. graminearum Cdc14 obtained from initial velocity measurements Initial reaction
velocity measurements at low concentrations (below Km , 100µM) using phosphopeptide series of Acm1pS3 (panel A) and Cdh1pS239 (panel B) and 600nM of
FgCdc14cat were used to estimate apparent kcat /Km by applying equation 3.4. The
first bar in each panel represents the phosphopeptide whose sequence was shown.
The labels on the x axis represent the substitutions made at the positions (relative
to the pSer). Data are the average of three independent experiments and error bars
represent standard deviation of the mean. Apparent kcat /Km are reported in Table
3.3
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Table 3.3: Catalytic efficiency (kcat /Km ) estimates of purified FgCdc14. Catalytic efficiency was estimated from initial velocity measurements at low substrate
concentration (Figures 3.5 and 3.6) by applying equation 3.4. The mean ± standard
deviation of three independent trials are presented. The sequence variation column
shows the nomenclature for each peptide variant of the peptide provided in the sequence column (full sequences given in Table 3.7).
Sequence

MIpSPSKKRTI

LLpSPGKQFRQ

FgCdc14
Estimated
kcat /Km
(M−1 S−1 )

FgCdc14cat
Estimated
kcat /Km
(M−1 S−1 )

pT
pY
+1A
+3A
+3R
-2G,-1D
+4A,+5A
+3R,+4A,+5A
+3N,+4A,+5A

3674 ± 189
5±1
74 ± 2
21 ± 2
48 ± 19
524 ± 9
2313 ± 92
920 ± 17
115 ± 5
8±1

214 ± 7
0.29 ± 0.03
18.2 ± 0.6
12.4 ± 0.2
11.5 ± 0.4
150 ± 8
165 ± 10
183 ± 4
22 ± 1
2.5 ± 0.3

pT
+1A
+2K
+3A
+3R
-2G,-1D
+4K
+5R

219 ± 6
4.4 ± 0.4
4.5 ± 0.3
2414 ± 75
9.9 ± 0.4
17 ± 1
174 ± 3
1007 ± 37
213 ± 8

73 ± 2
1.1 ± 0.1
0.97 ± 0.02
311 ± 12
2.9 ± 0.1
7.4 ± 0.2
65 ± 1
208 ± 8
74 ± 3

Sequence
variation
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3.2.3

Human Cdc14A (hCDC14A) displayed substrate selectivity similar
to S. cerevisiae Cdc14

The substrate selectivity observed in to ScCdc14 and FgCdc14 was similar for
hCDC14A. The selectivity for phosphoserine over phosphothreonine containing phosphopeptide substrate, the necessity of a basic residue at +3 position and the requirement of a +1 proline are conserved (Figures 3.7, Table 3.4). Although Arg at +3,
as the sole basic C-terminal residue was able to support Cdc14 activity, the catalytic
efficiency observed was significantly attenuated (Figure 3.7).
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Table 3.4: Steady-state kinetic parameters for hCDC14A catalyzed dephosphorylation of phosphopeptides. Steady state kinetic parameters, kcat and Km ,
were determined by measuring initial velocity as a function of peptide substrate concentration and fitting the Michaelis-Menten equation to the data using nonlinear
regression. The mean ± standard deviation from three independent trials are presented. The sequence variation column shows the nomenclature for each peptide
variant of the peptide provided in the sequence column (full sequences given in Table
3.7).

Sequence

Sequence

kcat

Km

kcat /Km

variation

(s−1 )

(µM)

(M−1 /s−1 )

0.08 ± 0.01

51.2 ± 5.1

1616.7

pT

N/A

N/A

4.3a

+3A

0.06 ± 0.01

1500 ± 538

39.3

+4A

0.11± 0.02

113 ± 10

934.8

+5A

0.09 ± 0.03

167 ± 25.3

566.3

+3R

0.82 ± 0.05

142 ± 30

720.5

+3R,+4A,+5A

0.148 ± 0.007

398 ± 65

372.3

+3A,+4A,+5A

N/A

N/A

7.3a

0.098 ± 0.003

93.86 ± 13.73

1046

pT

N/A

N/A

3.4a

+1A

N/A

N/A

11a

+3A

0.032 ± 0.003

353 ± 121

90.1

VKGNELRpSPSKRRSQI

MIpSPSKKRTI

a

Steady state parameters could not be calculated for these peptides because Vmax was not reached at the [s] used.

The slope of the line fit to the V vs. [S] curve was applied to equation 3.4.
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Fig. 3.7.: hCDC14A displayed substrate selectivity similar to Sc. Cdc14
A. Mutation of pSer to pThr, mutation of +1 pro, and B. +3 Lys led to reduction
in hCDC14A activity. Rate of phosphopeptide dephosphorylation was plotted as a
function of peptide concentration. The data were analyzed as described in Figure 3.1
and the kinetic parameters are reported in Table 3.4
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Fig. 3.8.: Mutations of +4 and +5 basic residues had an intermediate effect on hCDC14A activity Individual mutations of +4 and +5 basic residues and
change of the +3 Lys to Arg lead to a reduction in hCDC14A activity but the effect
was not as severe as complete loss of +3 basic residue. Rate of phosphopeptide dephosphorylation was plotted as a function of peptide concentration. The data were
analyzed as described in Figure 3.1 and the kinetic parameters are reported in Table
3.4

3.2.4

Schizosaccharomyces pombe Cdc14 (Clp1) displayed substrate selectivity similar to ScCdc14

In initial velocity assays performed using Clp1, the S. pombe orthologue of ScCdc14, similar substrate selectivity features were observed. There was a strict preference for phosphoserine residues over phosphothreonine (Figure 3.9, Table 3.5). Loss
of the +3 Lys and +1 Pro drastically reduced catalytic efficiency. Mutation of basic
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residues C-terminal to the site of phosphorylation negatively impacts Clp1 activity
towards both phosphopeptide substrates tested (Figure 3.9). As was the case for the
other Cdc14 enzymes tested thus far, Lys was preferred at the +3 position over Arg.
Table 3.5: Catalytic efficiency (kcat /Km ) estimates of purified Clp1. Catalytic efficiency was estimated from initial velocity measurements at low substrate
concentration by applying equation 3.4. The mean ± standard deviation of three
independent trials are presented. The sequence variation column shows the nomenclature for each peptide variant of the peptide provided in the sequence column (full
sequences given in Table 3.7).
Sequence

Sequence
variation

pT
+3A
+4A
VKGNELRpSPSKRRSQI +5A
+3R
+4A,+5A
+3R,+4A,+5A

MIpSPSKKRTI

3.2.5

pT
+1A
+3A

Clp1 estimated kcat /Km
(M−1 S−1 )
374 ± 44
14.5 ± 17
6.5 ± 14
125 ± 43
160 ± 24
108 ± 18
60 ± 10
38 ± 26
163 ± 24
17 ± 7
6.2 ± 5.2
10 ± 7

There are no major variations in Cdc14 substrate selectivity between species

The data presented in previous sections were generated using phosphopeptides
that contained a limited number of changes, based on previous observations about
Cdc14 selectivity. While this revealed major determinants for specificity, it is possible
that other amino acids and other positions near the phosphoamino acid could influence
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substrate recognition as well. Hence, an unbiased positional scanning approach was
undertaken to identify substrate positions and residues that influence dephosphorylation of the phosphopeptide substrate Cdh1pS239 (LLpSPGKQFR). This substrate
has previously been shown to yield intermediate Cdc14 activity [129] and was ideal
for observing increases as well as reductions in activity that result from changes in
the peptide sequence. The quality of the phosphopeptide array was assayed by use
of the Mn2+ -dependent λ protein phosphatase with activity towards phosphorylated
serine, threonine and tyrosine residues (New England Biolabs). All peptides in the
array are efficiently dephosphorylated by λ phosphatase (Figure 3.10).
The phosphopeptide array results using ScCdc14 reconfirm the observations presented in the previous section that +1 Pro was essential for high activity. Mutations
of the +3 position also led to a significant drop in activity (Figure 3.11). One substantial observation was that most mutations of the +2 Gly to other amino acids led to a
slight increase in activity but Pro and Val were poorly tolerated at this position. In
agreement with previous results, introduction of additional Lys at +4 and +5 raised
activity, a trend not observed for Arg. An interesting observation was that there were
mutations in the N-terminal positions that slightly enhanced activity. Val introduction at both -1 and -2 was favorable. Tyr at position -2 led to the highest increase
in activity. The reasons for the observed increases for mutations at positions -1 and
-2 could be that the original amino acids at those positions are disfavored because
there were multiple mutations that led to an increase in activity. This suggests that
sequence immediately upstream of pSer-Pro could modulate substrate recognition to
some degree. Identifying other trends in substrate selectivity was a challenge because
there were no common amino acid properties, like R group charge, length, or aromaticity, that indicate a particular feature was preferred at any given position. This
is an indication that there were no other major determinants of substrate selectivity
that were not previously observed.
The phosphopeptide array results using Clp1 also illustrated the preference of +1
Pro and +3 Lys (Figure 3.12). However, there was activity, higher than the original
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sequence, observed for changes at both +1 and +3 positions. Notably, changes to Gly
and Trp at +1 and Gly at +3 led to a greater than four-fold and two-fold increase,
respectively, over the starting sequence. As was observed with ScCdc14, Pro and Val
at +2 were disfavored and most mutations away from the original sequence at this
position led to increased activity. In agreement with previous results, introduction of
additional Lys at +4 raised activity by more than three-fold as did the introduction
of Gly, with Arg not being particularly favored. However, unlike ScCdc14, Arg introduction at +5 led to a greater than five-fold increase in activity whereas Lys had
a relatively small effect. Changes in the N-terminal positions also enhance activity.
Gly and Pro at -2 and Gln and Val at -1 resulted in a greater than five-fold increase
in activity over the original sequence.
Assays with FgCdc14 also illustrated the requirement of +1 Pro and +3 Lys
(Figure 3.13). Surprisingly, Gly at +1 was actually preferred over the original Pro.
Pro and Val at +2 are disfavored and all mutations away from the original sequence led
to more than a doubling in activity. In agreement with previous results, introduction
of additional Lys at +4 raises activity, but unlike ScCdc14, Arg at this position also
led to an increase. As observed with Clp1, Arg introduction at +5 also led to a
greater than doubling in activity whereas Lys has a relatively small effect. Changes
in the N-terminal positions also enhanced activity. Pro, Thr, and Tyr at -2 and Val
and Gln at -1 resulted in a greater than four-fold increase in activity over the original
sequence.
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Fig. 3.9.: Estimated kcat /Km values of Clp1 from initial velocity measurement assays Initial reaction velocity measurements at low concentrations (below
Km ) using phosphopeptide series of Acm1pS31 (panel A) and Acm1pS3 (panel B)
were used to estimate apparent kcat /Km by applying equation 3.4. The first bar in
each panel represents the phosphopeptide whose sequence is shown. The labels on the
x axis represent the substitutions made at the positions (relative to the pSer). Data
are the average of three independent experiments and error bars represent standard
deviation from the mean.
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There was generally low enzyme activity observed with the human Cdc14A paralog (hCDC14A) which limits the ability to make conclusions about mutations that
lowered enzyme activity. Assays with hCDC14A showed that Gly and Trp at +1
position resulted in activity greater than four-fold over the original sequence, and 8
of the 18 residue changes supported as much activity as the original sequence (Figure
3.14). Lys and Ser at +2 are highly favorable, greater than four-fold, over the original sequence. In agreement with previous results, introduction of additional Lys at
+4 raised activity, but unlike ScCdc14, Arg at this position also led to an increase.
Introduction of Lys at +5 had little effect on hCDC14A activity. Changes in the
N-terminal positions also enhanced activity; Pro and Gly at -2 and Gln at -1 resulted
in a greater than four-fold increase in activity over the original sequence.
Similar to hCDC14A, enzyme activity was very low for hCDC14B. Mutation at
the +1 position to Gly and Trp resulted in an increase of hCDC14B activity greater
than eight-fold over the original sequence, and 8 of the 18 residue changes supported
at least as much activity as the original sequence (Figure 3.15). Changes in the +3
Lys are also less detrimental, as changes to ala, Gly, Met, Pro, and Trp result in an,
at least, 85% increase in activity, relative to the original sequence. This is a relatively
small effect and is unlikely to be a true preference for these residues over Lys at +3.
The increase in activity observed for mutation of +3 Lys to Ala is surprising because
loss of the +3 Lys has been shown to drastically reduce activity of hCDC14B in an
end point assay [129]. The Pro at +2 was unfavorable but all other mutations raised
activity, with Asp, Glu, and Lys resulting in a greater than ten-fold increase over the
original sequence. In agreement with previous results, Lys was the most favorable
residue at +4. Arg at +5 also led to an increase in activity and its effect was greater
than that of Lys. Pro at -2 and Gln at -1 were the most favorable residues at each
position and led to an increase in activity greater than 13 and 20-fold, respectively,
relative to the original sequence.

Fig. 3.10.: λ phosphatase dephosphorylates all peptides in the phosphopeptide array. Amount of dephosphorylated
peptide (nmol) by λ phosphatase illustrates that all peptides in the phosphopeptide array are equivalently and efficiently
dephosphorylated. Each cell is shaded to reflect the amount of dephosphorylated peptide (red, high; white, low) and data
are an average of two trials. The original peptide sequence is highlighted by the green box. Each position is represented by
a row and is numbered relative to the phosphoserine residue. Each column represents the amino acid incorporated.
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Fig. 3.11.: kcat /Km estimates of ScCdc14 from initial velocity measurement assays. A summary of the estimated
catalytic efficiency against a positional scanning mutant phosphopeptide library is presented. Each cell is shaded to reflect
the relative activity observed (brown, high; white, low) and data are an average of two independent trials. The original
peptide sequence is highlighted by the red box. Each position is represented by a row and is numbered relative to the
phosphoserine residue. Each column represents the amino acid incorporated.
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Fig. 3.12.: kcat /Km estimates of Clp1 from initial velocity measurement assays. A summary of the estimated
catalytic efficiency against a positional scanning mutant phosphopeptide library is presented. Each cell is shaded to reflect
the relative activity observed (brown, high; white, low) and data are an average of two independent trials. The original
peptide sequence is highlighted by the red box. Each position is represented by a row and is numbered relative to the
phosphoserine residue. Each column represents the amino acid incorporated.
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Fig. 3.13.: kcat /Km estimates of FgCdc14 from initial velocity measurement assays. A summary of the estimated
catalytic efficiency against a positional scanning mutant phosphopeptide library is presented. Each cell is shaded to reflect
the relative activity observed (brown, high; white, low) and data are an average of two independent trials. The original
peptide sequence is highlighted by the red box. Each position is represented by a row and is numbered relative to the
phosphoserine residue. Each column represents the amino acid incorporated.
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Fig. 3.14.: kcat /Km estimates of hCDC14A from initial velocity measurement assays. A summary of the estimated
catalytic efficiency against a positional scanning mutant phosphopeptide library is presented. Each cell is shaded to reflect
the relative activity observed (brown, high; white, low) and data are an average of two independent trials. The original
peptide sequence is highlighted by the red box. Each position is represented by a row and is numbered relative to the
phosphoserine residue. Each column represents the amino acid incorporated.
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Fig. 3.15.: kcat /Km estimates of hCDC14B from initial velocity measurement assays. A summary of the estimated
catalytic efficiency against a positional scanning mutant phosphopeptide library is presented. Each cell is shaded to reflect
the relative activity observed (brown, high; white, low) and data are an average of two independent trials. The original
peptide sequence is highlighted by the red box. Each position is represented by a row and is numbered relative to the
phosphoserine residue. Each column represents the amino acid incorporated.
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3.3

Discussion
The main contribution of this work is the demonstration that Cdc14 substrate

selectivity is conserved across multiple diverse species. The hypothesis that conservation of the active site and residues thought to contribute to substrate selectivity
would result in similar substrate preference was supported by the results. The data
presented in this section further expand the understanding of Cdc14’s kinetic characteristics. The existence of several major determinants for substrate selectivity first
observed in budding yeast Cdc14 was conserved in all the Cdc14 enzymes tested. I
repeatedly observed a strong preference for phosphoserine over phosphothreonine or
phosphotyrosine containing substrates. The requirement for a +1 proline as well as
a +3 lysine was also observed in all enzymes. The data presented in this chapter
analyzing budding yeast Cdc14 also build on the work previously performed in the
Hall and Charbonneau labs characterizing substrate selectivity [129, 130]. The results strengthen the observation by demonstrating selectivity was independent of the
source of the sequence chosen to design the phosphopeptide substrates. The kinetic
data reveal that the substrate preference is driven both by changes in kcat and Km .
Substrates that do not contain a +3 Lys show a very large increase in Km suggesting
a large role for this Lys in substrate binding.
There were some subtle differences in the effects observed for changes in the Cterminal basic residues in the dephosphorylation of Acm1pS31. Clp1 and hCDC14A
were much less sensitive to mutations of the +3 Lys to Arg in contrast to FgCdc14
and ScCdc14. These differences were observed both when the mutation is made in the
context of the starting sequence (Acm1pS31) or when Arg was the sole basic reside
in the +3 to +5 region. ScCdc14 activity was less sensitive to mutations of the +4
and +5 Arg residues than the FgCdc14, Clp1 or hCDC14A, although this difference
is not very significant(Table 3.6).
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Table 3.6: Comparison of catalytic efficiency of Cdc14 enzymes reveals that
substrate selectivity is conserved. Catalytic efficiency (kcat /Km ) of Sc. Cdc14,
FgCdc14 and hCDC14A towards each peptide variant of the peptide provided in the
sequence column (full sequences given in Table 3.7) are compared.

Sequence

Sc. Cdc14

FgCdc14

hCDC14A

Sequence

kcat /Km

kcat /Km

kcat /Km

variation

(M−1 /s−1 )

(M−1 /s−1 )

(M−1 /s−1 )

4699

6542

1616.7

pT

15.3

4.1

4.3

+3A

781

56

39.3

+4A

4951

1950

934.8

+5A

4512

3196

566.3

+3R

325

98

720.5

+3R,+4A,+5A

266

71

372.3

+3A,+4A,+5A

12.9

19

7.3

624

5737

1046

pT

23

9.9

3.4

+1A

13

21.6

11

+3A

45

36.2

90.1

VKGNELRpSPSKRRSQI

MIpSPSKKRTI

The data obtained from the phosphopeptide positional scanning library experiment presented revealed that there are novel negative determinants of substrate selectivity. Introduction of proline and valine at +2 and glycine at +4 is not tolerated.
A summary of Cdc14 enzyme selectivity features conserved across multiple species is
summarized in Figure 3.16. Beyond the major determinants of selectivity, there are
some residues like proline at -2, valine at -1 and tryptophan at +6 that could be minor
contributers to selectivity. Arginine at -2 is disfavored for a majority of the enzymes
tested. There are also some subtle differences in selectivity observed. Mutations of
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the +2 position show that there are differences in Cdc14 response. For instance, Alanine at +2 is favored for most of the enzymes tested except for hCDC14A. FgCdc14
and Clp1 have a preference for His at +2 whereas the other Cdc14 enzyme do not.
Thr at this position also results in enhancement of activity except for ScCdc14 and
hCDC14A. Histidine preference at position +5 also varies as Clp1 and FgCdc14 don’t
tolerate this mutation where as other enzymes do not show an effect. The effects of
these mutations need to be investigated in more detail before any firm conclusions
can be made.

Fig. 3.16.: Updated optimal substrate motif for Cdc14. An improved substrate
sequence motif based on the summary of Cdc14 dephosphorylation activity towards
phosphopeptide substrates. Residues in Red are essential. Residues in blue enhance
activity and those in black dashes are novel negative determinants of Cdc14 activity.
Residues in gray have minor enhancing effects.

The data obtained from the phosphopeptide positional scanning library experiment does not allow for a complete determination of sequence preference of all the
Cdc14 enzymes tested. One significant issue is that the amount of enzyme used for
the assays was not normalized to yield equal activity towards the original peptide
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(Cdh1pS239). This led to a low general enzyme activity against the starting phosphopeptide for all enzymes used, except ScCdc14 and FgCdc14. This error limits
the ability to identify amino acids that are unfavorable. A solution is to utilize more
enzyme in the assay or a more sensitive experimental approach with a larger dynamic
range, like quantitative mass spectrometry, which could help alleviate the issue.
The extent to which the physiological Cdc14 substrates are conserved across the
species tested is not yet clearly understood. The improved understanding of substrate
selectivity presented here raises the possibility of predicting optimal substrates. This
approach was applied to the F. graminearum Cdc14, which is important for pathogenesis, and proposed a set of potential substrates that could play a role in plant
infection [183]. A similar approach can be applied to identify potential Cdc14 substrates for multiple organisms. This analysis could shed light on cellular processes in
which Cdc14 might play a role.

3.4

Experimental Procedure

3.4.1

Cdc14 purification

His6 -tagged Saccharomyces cerevisiae Cdc14 and the catalytic domain of Fusarium
graminearum Cdc14 (FgCdc14cat , residues 1-433) were expressed in Escherichia coli
and affinity-purified using HisPur nickel-NTA resin (Life Technologies). Schizosaccharomyces pombe Cdc14 (Clp1, kind gift from Dr. Kathy Gould), Fusarium graminearum Cdc14 (FgCdc14) and the catalytic domains of human CDC14 (hCDC14A,
residues 1-379 and hCDC14B, residues 1-418) were expressed as N-terminally tagged
glutathione S-transferase (GST) fusion proteins. The FgCdc14 ORF and it’s catalytic
domain (FgCDC14cat ) were amplified from the first-strand cDNA by PCR, cloned into
the Gateway entry vector pENTR/D-TOPO (Life Technologies), verified by DNA sequencing, and then transferred to the Gateway destination vectors (Life Technologies).
pDEST15 (FgCDC14) and pDEST17 (FgCDC14cat ) were used to introduce an Nterminal glutathione S-transferase (GST) fusion or an N-terminal 6x histidine fusion,
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respectively. GST-FgCDC14 expression was performed by transformation of BL21
(DE3) cells followed by induction with 0.4 mM isopropyl -D-thiogalactopyranoside
(IPTG) for 16 hours at 25 ◦ C. The His6 -FgCdc14cat fusion was induced in BL21
AI cells (Life Technologies) with 0.2% L-arabinose. Sources of expression constructs
are listed in Table 3.8 and expression of ScCdc14, Clp1 and hCDC14 A/B were as
previously described [129].
Purification of all His6 -tagged proteins was performed as follows. Bacteria were
lysed on ice for 30 minutes in 10 cell pellet volumes of buffer A (25 mM Tris-HCl
pH 7.5, 500 mM NaCl) supplemented with 0.1% Triton X-100, 10 mM imidazole,
1 mM phenylmethylsulfonyl fluoride (PMSF), 1 µM pepstatin, 10 µM leupeptin, 1
mg/ml lysozyme, and incubated for 30 minutes. Lysate was then sonicated to reduce
viscosity. For His6 FgCdc14cat , in place of sonication, 25 Units/ml Universal Nuclease
(Thermo Fisher) were added to the lysis mixture at the same time lysozyme was
added. Lysate was then clarified as described above, and the soluble extract was
incubated with 1 ml HisPur nickel-NTA resin for 1 hour at 4 ◦ C with agitation. After
batch washing sequentially with 15 ml buffer A containing 10 mM, 25 mM, and finally
40 mM imidazole, protein was eluted with 5 1 ml aliquots of buffer B containing 250
mM imidazole, collecting 1 ml fractions. Elution fractions containing high protein
concentration, as determined by using a Bradford assay, were combined and dialyzed
into 1L of storage buffer (25 mM Tris-HCl pH 7.5, 300 mM NaCl, 2 mM EDTA,
0.1% 2-mercaptoethanol, 40% glycerol) overnight at 4 ◦ C. The resulting recombinant
proteins were analyzed by SDS-PAGE and stored in small aliquots at -80 ◦ C.
Purification of all GST-tagged proteins was performed as follows. Bacteria were
lysed in 5 cell pellet volumes of buffer B (25 mM Tris-HCl pH 7.5, 500 mM NaCl, 2
mM EDTA, 0.1% Triton X-100, and 0.1% 2-mercaptoethanol) supplemented with 1
mM PMSF, 1 µM pepstatin, and 10 µM leupeptin. Cells were lysed for 30 minutes
on ice with 1 mg/ml lysozyme and PMSF was added to lysate to 1mM. Lysate was
then sonicated to reduce viscosity. Soluble extract was prepared by centrifugation at
35,000 x g for 30 minutes at 4 ◦ C. Meanwhile, 1 ml glutathione agarose resin (EMD
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Biosciences) was pre-equilibrated with buffer A. The resulting soluble extract was
then incubated with glutathione resin for 1 hour at 4 ◦ C on a rocking platform. Resin
was collected by centrifugation (700 x g, 2 minutes, 4 ◦ C) and then washed three times
with 10 ml buffer A with rocking for 5 minutes at 4 ◦ C. GST-tagged proteins were
eluted by incubating the resin several times with 1 mL lysis buffer A supplemented
with 10 mM reduced glutathione at 4 ◦ C for 5 minutes followed by centrifugation.
Elution fractions containing high protein concentration were pooled and dialyzed as
described above. The resulting recombinant proteins were analyzed by SDS-PAGE
and stored in small aliquots at -80 ◦ C.

3.4.2

Phosphopeptide synthesis

Phosphopeptides (Table 3.7) were synthesized using CLEAR-Amide resin (Peptides International) at 50 µmol scale by solid-phase Fluorenylmethyloxycarbonyl chloride (Fmoc) chemistry on a Prelude peptide synthesizer (Protein Technologies, Inc.).
Fmoc-protected amino acids and other peptide synthesis reagents were obtained from
AnaSpec Inc. (Fremont, CA, USA). Fmoc-protected amino acid monomers dissolved
at 100µM in dimethylformamide (DMF) were added to CLEAR-Amide resin being
mixed with glass beads under bubbling of N2 gas. Each amino acid was coupled to
the growing peptide for 30 minutes followed by two rounds of deprotection (2 minutes
each) with a mix of 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (95mM)/N-methylmorpholine (200mM)(HCTU/NMM). The coupling time was increased to the C-terminal Fmoc-protected amino acid monomers as
described previously [184]. The only modification was that coupling times for phosphorylated amino acids was increased to 3 hours to improve incorporation. Upon
completion of synthesis, peptides were cleaved from resin and resuspended in 5%
acetonitrile(ACN)/0.1% Trifluoroacetic acid(TFA).
Phosphopeptide substrates (Table 3.7) were also obtained from a commercial
source in crude form from Genscript Inc.
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3.4.3

Phosphopeptide Substrate Purification

Crude peptides were desalted using Sep-Pak C18 cartridges (Waters Corporation)
as described [185]. The concentrations of phosphopeptide stocks were measured with
an ashing procedure and malachite green-ammonium molybdate dye as described
previously [186].
Phosphopeptides in the peptide library were obtained from Genscript as desalted
lyophilized aliquots. Each peptide was resuspended in water with a target concentration of 20mM, based on molecular weight, and phosphopeptide concentration was
quantified using an alkali hydrolysis procedure adopted from [187]. A 10 µl aliquot
of a 100-fold dilution of each peptide stock was mixed with 100 µl of 2M NaOH and
heated at 100 ◦ C for 30 minutes. The mixture was allowed to cool to room temperature then neutralized with 100 µl of 4.7N HCl. Hydrolyzed inorganic phosphate
was quantified by adding 400 µl of the malachite green based phosphate detection
reagent, BIOMOL greenT M (Enzo Life Sciences), incubating for 30 minutes at room
temperature and measuring the absorbance (A620 ). Inorganic phosphate in each well
was quantified by using a standard curve prepared using sodium hydrogen phosphate
(Na2 HPO4 ) and processed identically as above. The standard curve was found to be
linear up to 250 µM Na2 HPO4 .

3.4.4

In vitro dephosphorylation assays

Phosphopeptide dephosphorylation reactions (50 or 20 µl) were performed in 25
mM HEPES pH7.5, 0.1% 2-mercaptoethanol, 1mM EDTA, 150mM NaCl. For most
reactions Cdc14 concentrations used were 50 nM (ScCdc14), 75 nM (FgCdc14, Clp1,
hCDC14A and hCDC14B), and 600nM (FgCdc14cat ). These concentrations were increased for poor phosphopeptide substrates. Reactions were incubated for 30 minutes
at 24 ◦ C (FgCdc14 and FgCdc14cat ), 30 ◦ C (ScCdc14 and Clp1), or 37 ◦ C (hCDC14A
and hCDC14B). Reactions were stopped and dephosphorylation of substrates was
measured by detecting the release of inorganic phosphate by adding 2 times reac-
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tion volume of BIOMOL GreenT M reagent (ENZO Life Sciences). Absorbance at 620
nm was measured on a microplate reader and the amount of phosphate released was
calculated from a standard curve generated with Na2 HPO4 under identical solution
conditions (Standard curve was linear upto 200 µM of phosphate).

3.4.5

An unbiased in vitro analysis of sequences affecting Cdc14 selectivity

In order to identify phosphopeptide sequences affecting Cdc14 activity, a test of
Cdc14 activity was performed on a positional scanning phosphopeptide series. The
phosphopeptide series was generated based on a shortened version of a known Cdc14
substrate (Cdh1pS239, LLpSPGKQFR, phosphorylated residue shown in bold) by
individual mutation of each position (excluding pSer) to all possible amino acids
(except cysteine). This resulted in a panel of 145 phosphopeptides.
λ phosphatase (New England Biolabs) was used to test the quality of each phosphopeptide in the phosphopeptide array. 4 Units of λ phosphatase was used to dephosphorylate 1 nmol of each peptide. The reactions were performed in 20 µl volume
with buffer (25 mM HEPES pH7.2, 0.1% BME, 1 mM EDTA, 0.01% BSA, 100 mM
NaCl, 1 mM MnCl2 ) and incubated at 30 ◦ C for 1 hour. Reactions were then terminated by adding 40 µl of BIOMOL GreenT M reagent (ENZO Life Sciences). Release
of inorganic phosphate was then determined by measuring absorbance at 620 nm
(A620 ) and utilizing a standard curve generated with sodium phosphate.
The panel of phosphopeptides was then used for in vitro assays to measure the
activity of all available Cdc14 enzymes. The reactions were performed in 20 µl volume
with buffer (25 mM HEPES pH7.2, 0.1% BME, 1 mM EDTA, 0.01% BSA, 100 mM
NaCl), 100 µM of each phosphopeptide and Cdc14 (50 nM of ScCdc14 or Clp1 or
75 nM of hCDC14A, hCDC14B or FgCdc14). Reactions were then incubated either
at 30 ◦ C (ScCdc14, FgCdc14 and Clp1) or 37 ◦ C (hCDC14A and hCDC14B). Reactions were then terminated by adding 40 µl of BIOMOL GreenT M reagent (ENZO
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Life Sciences). Release of inorganic phosphate was then determined by measuring
absorbance at 620 nm (A620 ) and utilizing a standard curve generated with sodium
phosphate.

3.4.6

Determination of steady state kinetic parameters (kcat /Km )

To establish the assay conditions, the response of the enzyme activity to changes
in reaction time was tested. The assay was found to be linear over a 1 hour period
and 30 minutes was selected as an appropriate reaction time. All assays were also
performed such that enzyme concentration was kept at least a 100-fold lower than
that of substrate and substrate consumption was kept below 10% which allowed us
to make steady-state assumptions.
Two approaches were employed to determine kinetic parameters for the assayed enzymes. The enzyme was assumed to obey Michaelis-Menten kinetics. When possible,
peptide substrate was varied to establish a full substrate saturation curve. The outcome of these experiments was fit with a standard Michaelis-Menten curve (Equation
3.1, using GraphPad 3) to determine Vmax and Km values. kcat was calculated using
Equation 3.2. These results were used to calculate the catalytic efficiency (kcat /Km )
of the enzyme.

Equation 3.1
v = Vmax

[S]
Km +[S]

(3.1)

Equation 3.2
Vmax = [E]t kcat i.e. kcat =

Vmax
[E]t

(3.2)

where v represents the reaction velocity at a given substrate concentration ([S]).
For cases when a full Michaelis-Menten curve could not be generated, assays were
performed such that the substrate concentration was well below the Km . The equation
below was utilized to determine the kcat /Km from the best fit line plot.
Under conditions in which [S]  Km , equation 3.2 simplifies to
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Equation 3.3
v ≈ Vmax K[S]m →Vmax K1m ≈

v
[S]

(3.3)

Equation 3.3 can then be combined with Equation 3.2 to give Equation 3.4, which
can be used to determine kcat /Km .

Equation 3.4
kcat
Km

=

Vmax 1
[E]t Km

≈

v 1
[S] [E]t

(3.4)

104

Table 3.7: Phosphopeptide sequences utilized in phosphatase assays for analyzing
Cdc14 substrate selectivity
Peptide Name
Sequence variation
Sequence
Acm1pS3
MIpSPSKKRTI
Acm1pS3-pS3pT
pT
MIpTPSKKRTI
Acm1pS3-pS3pY
pY
MIpYPSKKRTI
Acm1pS3-P4A
+1A
MIpSASKKRTI
Acm1pS3-K6A
+3A
MIpSPSAKRTI
Acm1pS3-K6R
+3R
MIpSPSRKRTI
Acm1pS3-NT
-2G,-1D
GDpSPSKKRTI
Acm1pS3-KAA
+4A,+5A
MIpSPSKAATI
Acm1pS3-RAA
+3R,+4A,+5A
MIpSPSRAATI
Acm1pS3-NAA
+3N,+4A,+5A
MIpSPSNAATI
Acm1pS31
VKGNELRpSPSKRRSQI
Acm1pS31-pS31pT
pT
VKGNELRpTPSKRRSQI
Acm1pS31-K34A
+3A
VKGNELRpSPSARRSQI
Acm1pS31-R35A
+4A
VKGNELRpSPSKARSQI
Acm1pS31-R36A
+5A
VKGNELRpSPSKRASQI
Acm1pS31-K34R
+3R
VKGNELRpSPSRRRSQI
Acm1pS31-35A36A
+4A,+5A
VKGNELRpSPSKAASQI
Acm1pS31-RAA
+3R,+4A,+5A
VKGNELRpSPSRAASQI
Acm1pS31-AAA
+3A,+4A,+5A
VKGNELRpSPSAAASQI
Cdh1pS239
LLpSPGKQFRQ
Cdh1pS239-pS239pT
pT
LLpTPGKQFRQ
Cdh1pS239-P4A
+1A
LLpSAGKQFRQ
Cdh1pS239-G5K
+2A
LLpSPKKQFRQ
Cdh1pS239-K6A
+3A
LLpSPGAQFRQ
Cdh1pS239-K6R
+3R
LLpSPGRQFRQ
Cdh1pS239-Q7K
+4K
LLpSPGKKFRQ
Cdh1pS239-F8R
+5R
LLpSPGKQRRQ
Cdh1pS239-NT
-2G,-1D
GDpSPGKQFRQ
Bold letters indicate a phosphoryalted residue. Residues mutated from the
parental sequence at the top of each group of peptides are underlined
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Table 3.8: Plasmids used in this study
Name
SB021
pHLP486
pHLP524
KG2333

Expressed Protein
His6 -ScCdc14
GST-FgCdc14
His6 -FgCdc14cat
GST-Clp1

Backbone
pET15b
pDEST15
pDEST17
pGEX4T1

Marker
Amp
Amp
Amp
Amp

Promoter
T7
T7
T7
tac

pGSTHCA379
pGSTHCB418

GST-hCDC14A(1379)
GST-hCDC14B(1418)

pETGST
pETGST

Amp

T7

Amp

T7

Source
[129]
This study
This study
Gift from
Dr. Kathy
Gould
[129]
[129]
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4. CDC14 PHOSPHATASE INHIBITOR DEVELOPMENT
4.1

Introduction

4.1.1

Phosphatases are targets for inhibition

Protein phosphatases are categorized based on their substrate specificity into serine/threonine phosphatases (STPs), protein histidine phosphatases (PHPs), protein
tyrosine phosphatases (PTPs), and dual specific phosphatases (DSPs) [188]. These
categories of phosphatases have characteristic mechanisms of catalysis and active site
structures which can be exploited during the design of class specific inhibitors [189].
The major difference in the catalytic mechanism between STPs and PTP/DSPs is
that STPs utilize an activated water to directly hydrolyze the substrate phosphoester bond whereas PTPs/DSPs use a cysteine as the initial nucleophile to form a
thiophosphate intermediate which is then hydrolyzed by water in a subsequent step.
The active sites also differ in that PTP/DSPs have a deeper active site pocket to
accommodate the large aromatic phosphotyrosine [190]. The invariable active site
cysteine also has a very low pKα which means it is predominantly in the thiolate ion
form at neutral pH, which allows it to be an effective nucleophile but also exposes it
to oxidation.
Strategies to design clinically relevant PTP/DSP phosphatase inhibitors have been
much more successful than those for STPs. Most strategies use non-hydrolyzable
phosphotyrosine analogs like difluorophosphono-methylphenylalanine (F2 Pmp) groups
[189]. One study was able to incorporate F2 Pmp into a hexameric peptide and develop a potent inhibitor of the insulin receptor [191]. Based on the peptide sequence
of optimal PTP 1B substrates, this study was able to achieve IC50 values of 100µM
by replacing the phosphotyrosine with the non-hydrolyzable mimic F2 Pmp.
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Cdc25, a potent regulator of the cell cycle, is the prototypical phosphatase target
for pharmacologically relevant inhibitor design. Cdc25 is a dual specificity phosphatase (DSP) responsible for removing the inhibitory phosphorylation to activate
Cdk1 [192]. Cdc25 enzymes are inactivated by the DNA damage checkpoint which
leads to inactivation of Cdk1 [192]. Cdc25 phosphatases are found in all eukaryotic
organisms, except in plants, and there are three paralogs of Cdc25 (A, B and C) in
mammals. These paralogs are largely conserved except for their regulatory subunits.
Cdc25 over-expression is also strongly associated with poor prognosis in various cancers [193]. The search for Cdc25 inhibitors has identified a wide variety of classes
of molecules including quinonoids which are likely irreversible inhibitors of Cdc25
and result in cell cycle arrest [194]. Large molecules containing phosphate mimetic
moieties have also been identified as potent Cdc25 inhibitors [194].
High throughput screening (HTS) strategies have been employed to identify phosphatase inhibitors. One such effort is the identification of a specific inhibitor of the
STP phosphoserine phosphatase from Mycobacterium tuberculosis [195]; the causative
pathogen of tuberculosis (TB). In an effort to combat the multi-drug resistance being observed, attempts to target essential bacterial metabolic pathways have led to
identification of inhibitors required of L-serine biosynthesis [195]. A similar approach
for identifying Cdc14 inhibitors could yield potent inhibitors.

4.1.2

Cdc14 is an ideal candidate for active site binding inhibitors

Ser/Thr protein phosphatases usually have highly generic active sites with little
intrinsic substrate selectivity [95]. Their substrate selectivity is usually a function of
regulatory subunits that define their substrate association as well as their sub-cellular
localization [95]. Cdc14, a member of the dual specificity phosphatase (DSP) family
of phosphatases, is unique in this respect. The determinants of substrate interaction
appear to be contained within or near the active site of the enzyme [102].
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Although the role of the Cdc14 phosphatase in the cell cycle has been studied
extensively, it is only recently that studies into its mechanism and substrate specificity have been conducted [103, 129, 130]. S. cerevisiae Cdc14 has been shown to
prefer multicyclic aryl phosphates when provided non-physiological small molecule
substrates [103]. The catalytic efficiency difference observed among these substrates
appears to be a function of differences in Km rather than kcat which indicates the active site can discriminate among substrates based on substrate affinity [103]. Cdc14
has also been shown to have a strict preference for phosphoserine containing peptide and protein substrates over those with either phosphotyrosine or phosphothreonine [129, 130]. Phosphopeptide substrates containing multiple basic residues Cterminal to the phosphoserine, particular Lys at +3 are also preferred. Taken together, Cdc14 enzymes are ideal candidates for the development of small molecule
inhibitors that take advantage of the active site selectivity. And given the conservation of the enzyme structure, inhibitors developed against ScCdc14 will likely be
effective against Cdc14 enzymes in multiple species.
Selective Cdc14 inhibitors have a variety of potential applications. One such application would be in the study of Cdc14 function in cells. The ability to inhibit
Cdc14 function in cells would make studying Cdc14’s role in organisms with multiple paralogs of the enzyme more feasible. The effort to study Cdc14 function in
higher eukaryotes has been limited due to the challenges in genetically eliminating all
Cdc14 function. We have also recently shown that Cdc14 function is essential for the
pathogenicity of the plant pathogenic fungus F. graminearum [196]. Cdc14 inhibitors
are potential fungistatic agents that could be used to combat crop loss.
In an attempt to identify specific Cdc14 inhibitors, a high throughput screen
(HTS) was carried out.
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4.1.3

Choice of Chemical library for HTS

The HTS for Cdc14 inhibitors was carried out using commercially available small
molecule libraries on hand at the Drug Discovery Center at the Bindley Biosciences
Facility (Purdue University, West Lafayette, IN).

The LOPAC chemical library
The LOPAC chemical library, available from Sigma Life Science, is a collection of
1,280 pharmacologically active compounds.

ChemBridge DIVERSetT M collection
This library is a collection of 20,000 molecules intended to cover a wide variety of
chemical classes.
A custom Cherry-pick chemical library from Life Chemicals curated for biological
activity was also used.

4.2

Results

4.2.1

Cdc14 demonstrates product inhibition

As presented in the previous chapter, Cdc14 is highly selective for substrates containing a phosphoserine, a +1 proline, and a +3 basic residue. Cdc14 steady-state
kinetic profiles using an optimal peptide substrate exhibit substrate inhibition [129].
These observations raised the possibility that Cdc14 activity could be inhibited by
molecules that mimic high affinity substrate features. To explore this, I first used a
non-phosphorylated peptide (Acm1pS3) that contains an optimal substrate sequence
and tested its ability to inhibit the dephosphorylation of the phosphorylated form of
the same sequence (Acm1pS3). This peptide is able to inhibit Cdc14 activity (Figure
4.1) with an IC50 of 183 (±23)µM and ki of 120µM. This result suggests that an un-
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phosphorylated peptide containing an optimal substrate sequence is able to effectively
compete with substrate for Cdc14 binding. The peptide is a less effective inhibitor
of Cdc14 when compared to sodium tungstate, a general inhibitor of phosphatases,
which has an IC50 of 1.24 (±0.4)µM and ki of 0.82µM (Figure 4.2).
The observation that Cdc14 activity can be inhibited by a product peptide raised
the question about which sequence elements are important for inhibition. Any changes
to the unphosphorylated Acm1S3 peptide sequence away from on optimal substrate
sequence eliminate its ability to inhibit Cdc14 (Figure 4.3). Peptides with mutation
of the serine to threonine, +1 proline, +3 lysine or downstream basic residues are
severely compromised as inhibitors compared to Acm1S3. Effective inhibition, at
least in the case of Acm1S3, is only achieved when the inhibitor peptide is in excess
of the substrate and contains optimal substrate sequences.

4.2.2

Small molecule inhibitors of Cdc14 were identified

The substrate selectivity of Cdc14 and the ability to inhibit its activity with peptides that contain the optimal substrate sequence raised the possibility of identifying
small molecule inhibitors of Cdc14 that are competitive inhibitors. The ideal inhibitor would be able to take advantage of the same enzyme features that result in
Cdc14 selectivity to specifically bind to the enzyme active site and/or the substrate
interaction interface. A high throughput screen with ∼50,000 small molecules, was
performed via an endpoint assay, using a photometric readout, at fixed concentrations
of substrate (100µM, Acm1pS3) and inhibitor (40µM). The screen identified a total
of 116 inhibitors that were able to inhibit >70% of Cdc14 activity and some of the
identified inhibitors have been characterized in more detail (Table 4.1, Figure 4.4). A
detailed list of molecules identified by the HTS not yet manually confirmed are also
listed in the Appendix.
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Fig. 4.1.: Acm1S3 is an effective Cdc14 inhibitor An unphosphorylated peptide
containing an optimal substrate sequence inhibits Cdc14 activity with an IC50 of 183
µM and ki of 120 µM. Rate of phosphopeptide (Acm1pS3, 100µM) dephosphorylation is plotted as a function of inhibitor peptide concentration. Each bar represents
activity observed and data are an average of three independent trials and error bars
show standard deviation of the mean. Data were fit with a sigmoidal dose response
curve using GraphPad Prism, as described in the methods section, to obtain IC50
values.
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Fig. 4.2.: Sodium tungstate inhibits Cdc14 activity with a ki of 0.82µM
A general phosphatase inhibitor (sodium tungstate) inhibits Cdc14 activity with an
IC50 of 5 ±1.7µM and ki of 3.3µM. Rate of phosphopeptide (Acm1pS3, 100µM)
dephosphorylation is plotted as a function of inhibitor peptide concentration. Each
point represents activity observed and data are an average of three independent trials
and error bars show standard deviation of the mean. Data were fit to a sigmoidal
dose response curve (Equation 4.1) using GraphPad Prism to obtain IC50 values.
The Hill slope for this fit is -0.12. Observing complete inhibition of Cdc14 activity is
a challenge in this photometric assay.
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Fig. 4.3.: Mutations away from the ideal substrate sequence abolish ability
of peptides to inhibit Cdc14 activity Mutations that change serine to threonine
(panel A), +1 Proline (panel B), or basic residues (+3 to 5, Panels C-E) eliminate
the ability of the unphosphorylated peptide to inhibit Cdc14 activity. Each point
represents activity observed and data are an average of three independent trials and
error bars show standard deviation of the mean.
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Fig. 4.4.: A likely significant number of the molecules identified as Cdc14
inhibitors are pan assay interference compounds (PAINS). The Kekulé structures of small molecule inhibitors of Cdc14 activity are presented. These molecules
belong to classes of compounds like alkylidene barbituates and quinones known to be
non specific protein modifiers [197]. The number below each structure is the molecule
identification number and the number in parentheses is the % inhibition of Cdc14
activity at 40µM of inhibitor.
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Table 4.1: Small molecule Cdc14 inhibitors have been identified. The chemical formulae, IUPAC names and % inhibition observed for inhibitors selected for
further analysis are listed
Numbera Formula
5117227
C10 H5 O5 S.N a
5130983

C10 H6 N6 O2

5175170

C20 H12 O3

5174626

C18 H14 N2 O3

5224815

C14 H14 N2 O3

5256251

C14 H10 N4 O4

Name
Sodium-3,4-dioxo-3,4-dihydro-1naphthalenesulfonate
1H-indene-1,2,3-trione
2-(1Htetrazol-5-ylhydrazone)
2’-hydroxy-1,1’-binaphthalene-3,4dione
1-benzyl-5-benzylidene2,4,6(1H,3H,5H)-pyrimidinetrione
5-(4-isopropylbenzylidene)2,4,6(1H,3H,5H)-pyrimidinetrione
N-(6-anilino-4,7-dioxo-4,7dihydro-2,1,3-benzoxadiazol-5yl)acetamide

% inhibition
97.7
97.37
90.15
75.83
75.2
74

a

numbers represent the identification number used by the commercial source (ChemBridge)

Small molecule inhibitors have ki values in the low µM range
The subset of the small molecule inhibitors identified were analyzed to determine
their IC50 values. It was found that four of the small molecules significantly inhibited
Cdc14 activity at low µM concentrations. Activity of Cdc14 at a fixed [S] and varying
[I] were plotted for these four inhibitors (Figures 4.5, 4.6, 4.7, and 4.8). The IC50s
for each of the characterized inhibitors are listed in table 4.2. These inhibitors had ki
values in the low µM range. Two of the six potential inhibitors identified in the HTS
were not effective during the confirmatory tests.
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Table 4.2: Determination of ki for Cdc14 inhibitors. IC50 values were determined by fitting data as described in Figures 4.5-4.9. ki was calculated using the
equation
IC50
where [S] = 100 µM and km = 193 µM (from Chapter 3).
ki =
1 + k[S]
m
Numbera
5224815
5175170
5117227
5256251

IC50(µM)
3 ± 1.9
6.5 ± 1.3
3.3 ± 0.8
8 ± 12

ki (µM)
1.9
4.2
2.1
3.3

a

numbers represent the identification number used by the commercial source. Standard deviation of IC50 is indicated.

A large number of pan assay interference compounds (PAINS) were observed to inhibit Cdc14 activity
A large proportion of the inhibitors identified by the high throughput screen are
molecules that have been reported as non-specific covalent protein modifiers [198].
These compounds, which include alkylidene barbiturates and quinones represented in
Figure 4.4, can non-specifically react with nucleophiles found on the substrate peptide
or Cdc14 to lead to the observed inhibition. It is very unlikely that these compounds
can serve as the basis for developing specific Cdc14 inhibitors. In an initial attempt
to investigate the mechanism of inhibition, assays were performed at a fixed inhibitor
concentration and with increasing substrate concentration. ScCdc14 was first incubated with inhibitor for 5 minutes prior to substrate addition. It was expected that if
the inhibitors were reversible, a higher substrate concentration would lead to higher
enzyme activity. Although all four inhibitors were competed with increasing substrate
concentration (Figure 4.9), it is unlikely that they are true reversible inhibitors. It
is not yet possible to determine the mechanism of inhibition based on the results
observed.
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Small molecule inhibitors are less effective against other Cdc14s
The ability of small molecule inhibitors of ScCdc14 were tested for activity against
FgCdc14. IC50 values could not be determined because data could not be fit to a
sigmoidal dose response curve (Figures 4.10 4.11). Given the conservation of substrate
selectivity, specific Cdc14 inhibitors would be expected to be similarly effective against
multiple Cdc14 enzymes. The inconsistent effect of these inhibitors against FgCdc14
and hCDC14A is a strong indication that the tested inhibitors are in fact non specific
PAINS because the observed conservation of substrate selectivity would suggest a
true competitive inhibitor should affect all enzymes equivalently.

Fig. 4.5.: Molecule #5224815 inhibits Cdc14 activity with a ki of 1.3µM.
Phosphopeptide dephosphorylation at a fixed substrate concentration is plotted as a
function of inhibitor concentration. Activity observed without inhibitor is normalized
to 100%. Data presented are an average of three independent trials and error bars
shows standard deviation of the mean. Data were fit to a sigmoidal dose response
curve (Equation 4.1) using GraphPad Prism to obtain IC50 values. The Hill slope
for this fit is -0.13.
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Fig. 4.6.: Molecule #5175170 inhibits Cdc14 activity with a ki of 5.6µM.
Phosphopeptide dephosphorylation at a fixed substrate concentration is plotted as a
function of inhibitor concentration. Activity observed without inhibitor is normalized
to 100%. Data presented are an average of three independent trials and error bars
shows standard deviation of the mean. Data were fit to a sigmoidal dose response
curve (Equation 4.1) using GraphPad Prism to obtain IC50 values. The Hill slope
for this fit is -0.34.

Fig. 4.7.: Molecule #5117227 inhibits Cdc14 activity with a ki of 5.6µM.
Phosphopeptide dephosphorylation at a fixed substrate concentration is plotted as a
function of inhibitor concentration. Activity observed without inhibitor is normalized
to 100%. Data presented are an average of three independent trials and error bars
shows standard deviation of the mean. Data were fit to a sigmoidal dose response
curve (Equation 4.1) using GraphPad Prism to obtain IC50 values. The Hill slope
for this fit is -0.74.
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Fig. 4.8.: Molecule #5256251 inhibits Cdc14 activity with a ki of 12.5µM.
Phosphopeptide dephosphorylation at a fixed substrate concentration is plotted as a
function of inhibitor concentration. Activity observed without inhibitor is normalized
to 100%. Data presented are an average of three independent trials and error bars
shows standard deviation of the mean. Data were fit to a sigmoidal dose response
curve (Equation 4.1) using GraphPad Prism to obtain IC50 values. The Hill slope
for this fit is -0.08.

Fig. 4.9.: Cdc14 inhibitors display an indeterminate inhibitory mechanism. Cdc14 inhibitors can be competed
with increasing substrate activity A.5224815 B.5117227 C.5175170 D.5256251. Phosphopeptide dephosphorylation at a fixed
inhibitor concentration is plotted as a function of substrate concentration. Activity observed without inhibitor is normalized
to 100%. Data presented are an average of three independent trials and error bars shows standard deviation of the mean.
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Fig. 4.10.: Small molecule inhibitors are less potent inhibitors of F. graminearum Cdc14 A.5117227 B.5175170
C.5224815 D.5256251. Phosphopeptide dephosphorylation at a fixed substrate concentration is plotted as a function of
inhibitor concentration. Activity observed without inhibitor is normalized to 100%. Data presented are an average of three
independent trials and error bars shows standard deviation of the mean. IC50 values could not be determined because data
could not be fit a sigmoidal dose response curve.
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Fig. 4.11.: Small molecule inhibitors are less potent inhibitors of hCDC14A A.5117227 B.5175170 C.5224815 and
D. 5256251. Phosphopeptide dephosphorylation at a fixed substrate concentration is plotted as a function of inhibitor concentration. Activity observed without inhibitor is normalized to 100%. Data presented are an average of three independent
trials and error bars shows standard deviation of the mean. IC50 values could not be determined because data could not be
fit a sigmoidal dose response curve.
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4.3

Discussion
Observations that the area around the Cdc14 active site contains multiple docking

sites for substrate features which provide specificity raised the possibility of identifying
or developing selective small molecule inhibitors. Ideally, an initial Cdc14 inhibitor
lead compound would be a competitive active site binder. This lead compound could
be optimized by adding functional groups with features that interact with the adjacent
substrate docking sites to create a high affinity, high specificity inhibitor. A peptide
containing optimal Cdc14 substrate sequence was shown to be an effective Cdc14
inhibitor demonstrating in principal that one can use substrate docking features in
the inhibitor design process. A high throughput screen using portions of two chemical
libraries (50,000 compounds) was also employed to identify Cdc14 inhibitors. A small
number of molecules (116) were found to inhibit >70% of Cdc14 activity. This HTS
approach is yet to result in the identification of specific Cdc14 inhibitors. Many of
the inhibitors are likely non-specific, belonging to classes of pan assay interference
compounds (PAINS) [197].
Efforts to identify specific Cdc14 inhibitors will require removal of known PAINS
from the list of inhibitors. Utilization of a virtual screening approach, in combination with a PAINS eliminating step might increase the likelihood of identifying true
inhibitors. This strategy would involve only pursuing molecules that do not have
chemical groups that are known to inhibit enzyme activity in a non specific manner [197]. A recent study employed such an approach to discover selective inhibitors
of the histone methyltransferase SET7 [199]. If molecules that bind in the Cdc14
active site can be identified, additional functional groups could be added onto these
molecules to fit either in the proline binding site or the acidic groove near the active
site, thus improving affinity. This approach will most likely involve molecular combination methods that add functional groups to the lead compound in order to improve
inhibitor binding to the Cdc14 substrate binding pocket.
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Selective Cdc14 inhibitors have the potential to be useful in multiple applications.
One major use for these molecules would be in understanding Cdc14 function in
humans. The effort to study Cdc14 function in higher eukaryotes has been limited
due to the challenges in genetically eliminating all Cdc14 function. The effects of
inhibitors in live cells can be tested in budding yeast because elimination of Cdc14
activity has a clear observable phenotype, in which cells arrest during late mitosis in
a telophase like state with large buds and segregated DNA. This phenotype can easily
be assayed with microscopy techniques and would allow for efficient identification of
inhibitors selective for Cdc14. The ability to inhibit Cdc14 in cultured human cells
with a rapidly acting small molecule would make studies into Cdc14 function much
more feasible.
Cdc14 inhibitors could have applications beyond the study of Cdc14 function.
We recently showed that Cdc14 function is essential for pathogenicity of the wheat
blight fungus F. graminearum [183]. The development of effective Cdc14 inhibitors
could prove useful in the search for fungistatic agents. This possibility is made much
more attractive because plants do not have Cdc14 orthologs and fungistatic agents
would only be effective against the fungus. There is also a potential for using Cdc14
inhibitors in cancer therapy as supplements to DNA damaging drugs. Inhibiting
Cdc14, previously demonstrated to play a role in DNA damage repair [200, 201],
would impair the ability of tumor cells to recover following treatment with DNA
damaging chemotherapeutics, potentially making the treatments more effective.

4.4

Experimental Procedure

4.4.1

Purification of Cdc14

Recombinant His6 -Cdc14 was purified as described in chapter 3 with modifications. An additional anion exchange purification step was added prior to dialysis into
the storage buffer. Following pooling of 250 mM imidazole elution fractions, the pool
was applied manually, using a syringe, to a 5 ml HiTrap desalting column (GE Life
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Sciences) pre-equlibrated with desalting buffer (25 mM HEPES pH 7.4, 25 mM NaCl,
0.1% BME) and 1.7 ml fractions were collected. The column was washed with additional desalting buffer and fractions collected until protein was undetectable using
a bradford assay. Desalted fractions with highest protein concentration were then
pooled and applied to a 1 ml HiTrap Q Anion exchange column (GE Life Sciences)
pre-equlibrated with desalting buffer. The column was then washed with 10 ml of
desalting buffer. Protein was then eluted with 10 ml stepwise increases of salt concentration to 224.5 mM, 248.25 mM, 262.5 mM, 272 mM, and 500 mM of NaCl. Elution
was collected in 1.5 mL fractions and assayed for protein concentration. Fractions
with highest protein content were pooled and dialyzed into storage buffer (25 mM
Tris-HCl pH 7.5, 300 mM NaCl, 2 mM EDTA, 0.1% 2-mercaptoethanol, 40% glycerol)
overnight at 4 ◦ C. The resulting recombinant proteins were analyzed by SDS-PAGE
and stored in small aliquots at -80 ◦ C.

4.4.2

Peptide substrate preparation

Acm1pS3 (MIpSPSKKRTI) was synthesized by Genscript Inc. in crude form and
purified using Sep-Pak C18 cartridges (Waters Corporation) as described in chapter
3 [185]. The concentrations of phosphopeptide stocks were measured with an ashing
procedure and malachite green-ammonium molybdate dye as described previously
[186].

4.4.3

Unphosphorylated peptide inhibitors

The ability of unphosphorylated peptides to inhibit Cdc14 activity was tested
using a standard 20 µl enzyme assay described in the Experimental Procedure section
of Chapter 3. The peptides listed in Table 4.3 were added at defined concentrations
before the addition of peptide substrate (Acm1pS3). In one set of experiments, the
effects of increasing Acm1S3 concentration was investigated. The effects of changing
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the sequence of Acm1S3 was also investigated by comparing the effects of peptides
at a fixed concentration.
Table 4.3: Unphosphorylated peptides tested as inhibitors
Peptide Name
Acm1S3
Acm1T3
Acm1S3 P4A
Acm1S3 K6A
Acm1S3 K6R
Acm1S3 7A8A
Acm1S3 AAN

Sequence variation
0T
+1A
+3A
+3R
+4A, +5A
+3A, +4A, +5N

Sequence
MISPSKKRTI
MITPSKKRTI
MISASKKRTI
MISPSAKRTI
MISPSRKRTI
MISPSKAATI
MISPSAANTI

Mutations are underlined.

4.4.4

High-throughput inhibitor screen

The following protocol was performed by utilizing purified ScCdc14 and Acm1pS3
in an in vitro reaction in which candidate inhibitors were included. The release of
phosphate was quantified using a colorimetric assay. The screen was performed in
two microplate formats (384 or 1536 well).

384 well format: These assays contained 75 nM ScCdc14, 100 µM Acm1pS3
substrate and screened compounds at 40 µM in a reaction volume of 50 µl. Reactions were set up by dispensing 40 µl of the enzyme mix in reaction buffer (25 mM
HEPES pH7.5, 0.1 % BME, 1mM EDTA, 150mM NaCl) into wells of a 384 well
plate. Candidate chemical inhibitors were dispensed at a volume of 200 nl/well from
a stock at 10 mM in DMSO, using a pinning tool, for a final concentration of 40 µM.
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Reactions were then initiated by adding 10 µl of Acm1pS3 at 500 µM, diluted using
reaction buffer, into each well and incubated for 30 minutes at room temperature.
Reactions were terminated by adding 10 µl of the Malachite Green Phosphate Assay
mix (BioAssay Systems) prepared as directed by the manufacturer. Following incubation for 30 minutes, the release of inorganic phosphate was calculated by using a
standard curve generated with sodium phosphate under identical solution conditions.
1536 well format: These assays contained 75 nM ScCdc14, 100 µM Acm1pS3
substrate and screened compounds at 40 µM in a reaction volume of 5 µl. Reactions
were set up by dispensing 4 µl of the enzyme mix in reaction buffer (25 mM HEPES
pH7.2, 0.1% BME, 1mM EDTA, 100mM NaCl, 0.01% BSA) at 93.75 nM into wells
of a 1536 well plate. Candidate chemical inhibitors were dispensed at a volume of 20
nl/well from a stock at 10 mM, using a pinning tool, for a final concentration of 40
µM. Reactions were then initiated by adding 1 µl of Acm1pS3 at 500 µM, diluted
using reaction buffer, into each well and incubated for 1 hour at 4 ◦ C. Reactions were
terminated by adding 1 µl of the Malachite Green Phosphate Assay mix (BioAssay
Systems) prepared as directed by the manufacturer. Following incubation for 30
minutes, the release of inorganic phosphate was calculated by using a standard curve
generated with sodium phosphate under identical solution conditions.

4.4.5

Determination of small molecule inhibitor IC50

Before a more stringent analysis of inhibitor IC50 values, the ability of the molecules
to inhibit Cdc14 activity was confirmed with a manual enzyme assay in which 50nM
Cdc14 and 40 µM of each inhibitor were first combined and incubated for 5 minutes.
Then 100 µM phosphopeptide substrate was added in a final reaction volume of 20µl.
Compounds confirmed to be inhibitors were then analyzed to determine IC50 values.
Cdc14 enzyme assays with 50nM Cdc14 and 100 µM Acm1pS3 substrate were set up
with varying concentrations of Cdc14 inhibitors from 0.1 to 100 µM. Reactions were
set up to a final volume of 20µl and incubated at 30 ◦ C for 30 minutes. IC50 values

128
were estimated by comparing the observed enzymatic activity to that of an uninhibited reaction and fitting the data with a sigmoidal response curve, with a variable
slope (Equation 4.1), using GraphPad Prism.

Eq.4.1
B+(T −B)
(4.1)
Y = 1+10((log(IC50)−X)∗h)

where X is log[inhibitor]; Y is % activity at log[inhibitor]; B is lowest % activity
(initially set to 0%) ; T is highest % activity (initially set to 100%) and h is the Hill
slope
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5. SUMMARY AND FUTURE DIRECTIONS
5.1

Summary
The experimental results presented in this thesis address two mechanisms that

regulate mitotic exit. One process is that of proteasomal degradation and the other
is dephosphorylation of proteins by mitotic phosphatases. I have presented the results investigating the non-canonical mechanism by which the budding yeast protein,
Acm1, is degraded by the proteasome, in a cell cycle regulated manner. I have also
presented results of experiments characterizing the substrate selectivity of the mitotic
phosphatase Cdc14 from an evolutionarily diverse set of organisms. In addition I have
presented progress in the development of Cdc14 inhibitors. Below I will summarize
the major findings and will discuss follow-up experiments.

5.1.1

Non-canonical mechanism for proteasomal degradation

When starting this project, work in the Hall lab and by others had shown that
Acm1 degradation during G1 is independent of the APC and requires the proteasome
[92, 94]. At the time, it was not clear how Acm1 gets targeted for proteasomal
degradation and if polyubiquitination is required. My work has shown that Acm1
degradation in G1 does not require Acm1 polyubiquitination but the activity of the
ubiquitin activating E1 enzyme is necessary. However, no single E2 or E3 ligase
has been identified as an essential factor for Acm1 degradation. Acm1 degradation
also requires the N-terminal, putative disordered region (Figure 5.2). Removal of
this region leads to stabilization of Acm1 in G1. This N-terminal sequence is not a
sufficient degron suggesting the requirement for additional factors. I have also shown
that failure to effectively degrade Acm1 has a negative effect on cell growth. It is not
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yet clear how Acm1 is targeted for degradation but the mechanism is not consistent
with canonical mechanisms of proteasomal degradation. A proposed model for Acm1
degradation is given in Figure 5.1.

Fig. 5.1.: Updated model for Acm1 degradation. The model proposed for Acm1
degradation based on the current experimental evidence. This model accounts for E1
and 26S proteasome requirement for degradation. No individual E2 or E3 enzymes
are required. Therefore, the model accounts for the possibility of redundant E2s or
E3s that could be involved downstream of the E1 enzyme. General lysine linked
ubiquitin chain attachment is not required and Acm1 lacking all ubiquitin accepter
lysines is degraded normally. This observation, however, does not rule out the unlikely
possibility that Acm1 can be monoubiquitinated at unconventional residues. The
herpevirus E3 ligase, mK3, has been reported to mediate the degradation of the
major histocompatibility complex I heavy chain (MCH1) by attaching ubiquitin at
cysteine, serine or threonine residues [202, 203] although such an E3 is yet to be
described in yeast. There is also the possibility that an adapter protein, reminiscent
of Antizyme, could target Acm1 for degradation when monoubiquitinated.

5.1.2

Conservation of Cdc14 substrate selectivity

Phosphopeptide substrate-based characterization of Cdc14 substrate selectivity
has been an effective tool in understanding the substrate sequence preference of Cdc14
and in predicting physiological protein substrates [129, 130]. In chapter 3, I have
presented my work on investigating the extent to which the selectivity observed in
S. cerevisiae is conserved in other species, including S. pombe, F. graminearum, and
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humans. These analyses show that there is a high degree of conservation in Cdc14
substrate selectivity among this diverse set of organisms. All tested enzymes have a
strict preference for phosphoserine containing substrates with +1 proline and basic
residues C-terminal to the phosphorylation site. These analyses also identified novel
determinants of selectivity previously not observed (Figure 3.16). Introduction of
proline and valine at +2 and glycine at +3 is not tolerated.

5.1.3

Development of Cdc14 inhibitors

The substrate selectivity observed for Cdc14 enzymes raised the possibility that
specific inhibitors can be identified. Chapter 4 presented the progress made towards
identifying Cdc14 inhibitors. One major observation made is that a peptide containing optimal substrate sequence is able to inhibit Cdc14 activity. This observation
indicated the possibility that inhibitors can be designed to take advantage of the active site features to yield selective and high affinity competitive inhibitors. A high
throughput screen employed to discover such inhibitors led to the identification of
inhibitors which show ki values in the µM range. The majority of the most effective inhibitors are likely non-specific, belonging to classes of pan assay interference
compounds (PAINS) [197].

5.2

Future Directions

5.2.1

Understanding Acm1 degradation

The observations made about Acm1 degradation in G1 make it an interesting
case study of an unconventional proteasomal degradation mechanism. As proposed
in the model for Acm1 degradation (Figure 5.1), the possibility exists that an adapter
protein, analogous to antizyme, binds to Acm1 and targets it to the proteasome.
Identification of this adapter protein would require stabilization of the complex by
inhibiting the proteasome in G1 cells and immunopurifying the complex. A mass
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spectrometric analysis of this complex could reveal any copurifying proteins. This
would be followed by investigating the requirement of the adapter, by deleting the
gene. The possibility of this new binding factor mediating the degradation of other
proteins can also be investigated by purifying any complexes containing this protein
that are enriched when the proteasome is inhibited. The effects of the gene deletion on
the degradation of copurifying proteins can also elucidate if this mechanism is utilized
for the degradation of other proteins. The possibility of unconventional ubiquitin
attachment to Acm1 can be investigated by mutating the single Cysteine (C107),
each Serine (23 in total) or Theronine (11 in total) .
The requirement of the N-terminal region of Acm1 could be due to the requirement
of a disordered region to promote translocation into the proteasome active site. This
possibility can be explored by replacing this region with another disordered protein
sequence of similar length. The PONDR R algorithm also predicted the C-terminal
region of Acm1 is disordered (Figure 5.2). The effects of removing this region could
also be investigated to shed light on the contribution of this region to degradation, if
any such effect exists.

5.2.2

Utility of degradation resistant Acm1 in understanding APCCdh1

Questions about what exactly distinguishes an APCCdh1 substrate from a pseudosubstrate inhibitor remain to be answered. There is clear evidence that the sequence
motifs that allow substrates to bind Cdh1 are also necessary for Acm1 binding [89].
However, there is a divergence of the fate of proteins that interact with Cdh1. One
of the hypotheses put forward is that Acm1 contains additional sequence elements
that result in higher binding affinity, compared to substrates, which interfere with the
ability of APCCdh1 to ubiquitinate Acm1. There is also a possibility that there are
sequences within Acm1 that prevent ubiquitination, independent of binding affinity.
In addition, the effects of mutations in Acm1N ∆52 , the degradation resistant mutant,
that destabilize the protein can be investigated in the full length protein.
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The list of APCCdh1 substrates is by no means exhaustive. Currently the presence
of the degron sequences (D and KEN boxes) in a protein is used as an indicator that
the protein is an APC substrate. This definition seems incomplete, because the likelihood of any given protein containing a D or KEN box (RXXL or KEN) sequence
is fairly high and clearly not all proteins that contain these sequences are APCCdh1
substrates. There are also APCCdh1 substrates that contain no clearly recognizable
degron. Taken together, these observations point to, as of yet, unidentified protein features characteristic of an APC substrate. Being able to identify additional
APCCdh1 substrates would improve the likelihood of finding new sequences that define a substrate. A degradation resistant Acm1 that is stable in G1, when APCCdh1
is active, is beneficial in identifying substrates, regardless of recognition mechanism.
Ability to inhibit the degradation of said protein by overexpressing Acm1N ∆52 will be
a strong indication that the protein is an APCCdh1 substrate.

5.2.3

Cdc14 substrate selectivity

The results from the positional scanning peptide library assay have identified new
phosphopeptide positions that influence substrate selectivity (Figure 3.16). Additional experiments are required to further investigate these effects. Determination of
steady state kinetic parameters, by measuring dephosphorylation rates as a function
of substrate concentration, for peptides listed in Table 5.1 would serve to more clearly
characterize the influence of changes at these positions (-2,-1, and +6). Any differences in the magnitude of effects at each position could reveal variations in substrate
preferences that exist among the Cdc14 enzymes tested. The effect of these mutations should also be investigated by using different phosphopeptide substrates. The
effects of residues further N-terminal to the phosphoserine can also be investigated
using another positional scanning library approach with a longer Cdh1pS239 peptide (DSKQLLLpSPGKQFRQ) and mutating individual residues between positions
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-6 and -4. Mutations that enhance activity could then be followed up by experiments
to determine the effects on kinetic parameters.
Table 5.1: Phosphopeptide sequences for testing effects of novel substrate
determinants.
Sequence variation

Sequence

-2P
-2G
-1V
-1Q
+2P
+2V
+4G
+6W

LLpSPGKQFRQ
PLpSPGKQFRQ
GLpSPGKQFRQ
LVpSPGKQFRQ
LQpSPGKQFRQ
LLpSPPKQFRQ
LLpSPVKQFRQ
LLpSPGKGFRQ
LLpSPGKQFWQ

Residues in bold are phosphorylated and changes in sequence are
underlined.

As previous work and the data presented in Chapter 3 demonstrate, Cdc14 has
a very strict selectivity. Bremmer et al. have been able to demonstrate that the
Alanine 285 in the Cdc14 active site is a significant driver of phosphoserine over
phosphothreonine selectivity [129]. In addition, a hypothesis has been put forward,
based on the crystal structure of hCDC14B, that an acidic groove adjacent to the
active site and solvent exposed aromatic amino acids are responsible for the preference
for downstream basic residues and +3 lys, respectively [102, 130]. This hypothesis
could be tested by mutation studies and the effects of mutating the residues that
make up the acidic groove on substrate selectivity could help identify Cdc14 sequence
features that drive selectivity. The effects of mutant Cdc14 with altered selectivity
on cell cycle progress can also be investigated in vivo. This could further reveal the
role for Cdc14 selectivity in defining the order of substrate dephosphorylation during
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mitosis. Perturbing this order may result in the premature dephosphorylation of
substrates that are normally dephosphorylated in late mitosis. An example would be
Orc6 which could lead to premature origin relicensing or Iqg1 which could result in
cytokinesis defects.
The improved understanding of Cdc14 substrate sequence preference from multiple organisms presents the possibility of identifying novel protein substrates for
Cdc14, both in budding yeast as well as in organisms in which Cdc14 function is not
well studied. The substrate selectivity can be applied to predict potential protein
substrates using in silico searches of the organism proteome for proteins that contain
matching sequences. This would make efforts to identify physiologically relevant substrates more efficient and would shed light on the role of Cdc14 in these organisms.
As a demonstration of this, Yen1, a holiday junction resolvase in budding yeast was
identified using a similar approach [130]. Potential substrates that could shed light on
F. graminearum Cdc14 requirement for pathogenicity have also been compiled [183].
This same approach can be taken to elucidate hCDC14 function.

5.2.4

Development of Cdc14 inhibitors

The small molecules identified in the HTS as being Cdc14 inhibitors require careful analysis. Inhibitors that are likely non-specific, belonging to classes of pan assay
interference compounds (PAINS) need to be removed from compounds selected for
further development. Software tools like Pipeline Pilot (Pipeline Pilot; Accelrys Software Inc., San Diego, CA) will prove useful in streamlining this process [199]. An
alternate approach would be to perform HTS with multiple Cdc14 enzymes and only
pursue molecules that are effective against multiple enzymes. A structure-activity
relationship analysis will help identify common molecular structures that are represented among the inhibitors. This analysis could identify a structure that can be used
as a starting point for designing inhibitors that bind with higher affinity. This ap-
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proach would most likely involve synthesis of derivative molecules that add functional
groups that may improve inhibitor binding.
Given the challenges of using HTS with commercially available libraries that contain a large number of PAINS, an alternate approach for developing Cdc14 inhibitors
might be the preferred strategy. One option is to employ a structure guided design
of inhibitors that can make substrate like interactions with the enzyme active site.
Peptidomimetics that contain side-chains similar to optimal substrates and altered
sequences where the phosphoSer is mutated to Glu could prove useful. Main-chain
substituted peptidomimetics might be better suited for use in live cells as natural peptides have issues with stability against proteolysis and poor bioavailability [204]. An
alternative strategy for exploring molecules that can make multiple contacts with an
enzyme active site is to start with a molecule known to bind in a phosphatase active
site, like sulfonates, and explore molecule fragments that can improve binding [205].
The effects of Cdc14 inhibitors on other protein tyrosine phosphatases (PTPs) is
an important indicator of inhibitor selectivity since PTPs share an oxidizable active
site Cysteine, as part of the CX5 R domain. Testing inhibitor effect on PTPs like
Cdc25 (Mih1) or PTP1 would help exclude inhibitors that are general oxidizers. Some
human PTPs have been purified from bacteria (Figure 5.3) (expression constructs
were a kind gift from Dr. Zhong-Yin Zhang).

5.2.5

Application of Cdc14 inhibitors

If any selective Cdc14 inhibitors can be identified, they might have multiple applications. One major use for these molecules would be the study of Cdc14 function in
organisms that have previously been difficult to study. The challenge of accounting
for multiple paralogs of the enzyme and the lack of knowledge in their functional
redundancy has limited the success of efforts to study Cdc14 in higher eukaryotes.
The ability to inhibit all Cdc14 activity in human cells would allow a significant
progress in the understanding of Cdc14 function. The effects of inhibitors in vivo can
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be tested in budding yeast because loss of Cdc14 leads to arrest in a telophase like
state with cells having large buds which can easily be observed under a microscope.
One challenge with using yeast in such an assay is the yeast cell wall, which creates a
physical barrier for inhibitor entry into cells. This might require zymolyase treatment
to improve inhibitor permeability. If a cell permeable Cdc14 inhibitor is identified, it
would allow for a new method of arresting yeast cells in late mitosis. This would be
an alternative method to the shifting of cultures to 37 ◦ C to arrest cdc14-1 cells.
Cdc14 inhibitors could have applications beyond the study of Cdc14 function. It
has recently been demonstrated that Cdc14 function is essential for pathogenicity
of the wheat blight fungus F. graminearum [183]. Identification of Cdc14 inhibitors
has the potential to lead to the development of fungistatic agents that would be
selective for the fungus because plants do not have Cdc14. The ability of an identified
Cdc14 inhibitor that is also effective against purified FgCdc14 can be tested for its
ability to prevent plant infection by F. graminearum. This application may have some
limitations because use of these molecules in food crops might result in unintended
exposure for those consuming the crops.
There is also a therapeutic potential for using Cdc14 inhibitors in cancer treatment as supplements to DNA damaging drugs. hCDC14A and B have previously
been demonstrated to play redundant roles in DNA damage repair [201]. Employing
a therapeutic approach that causes DNA damage and simultaneously inhibits the
recovery mechanism, would impair the ability of tumor cells to survive treatment.
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Fig. 5.2.: Prediction of Acm1 disordered regions. In silico prediction of Acm1
structural disorder using PONDR R . The VL3 algorithm is used for the prediction
and the application is available via the Internet at http://pondr.com/.
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Fig. 5.3.: Purification of PTPs. Human protein tyrosine phosphatases were purified from bacteria and will be useful in determining selectivity of inhibitors for Cdc14.
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Mitotic Exit Leads to Tumor Regression In Vivo: Modulation by Cdk1, Mastl,
and the PP2A/B55α,δ Phosphatase,” Cancer Cell, vol. 18, no. 6, pp. 641–654,
2010.
[139] K. L. Sackton, N. Dimova, X. Zeng, W. Tian, M. Zhang, T. B. Sackton, J. Meaders, K. L. Pfaff, F. Sigoillot, H. Yu, X. Luo, and R. W. King, “Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C,” Nature, vol. 514,
no. 7524, pp. 646–649, 2014.
[140] F. Bassermann, D. Frescas, D. Guardavaccaro, L. Busino, A. Peschiaroli,
and M. Pagano, “The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damageresponse checkpoint.,” Cell, vol. 134, pp. 256–67, jul 2008.

150
[141] U. Bc and J.-M. Peters, “SCF and APC: the Yin and Yang of cell cycle regulated
proteolysis,” Curr. Opin. Cell Biol., pp. 759–768, 1998.
[142] H. C. Vodermaier, “APC/C and SCF: Controlling each other and the cell cycle,”
Curr. Biol., vol. 14, no. 18, pp. 787–796, 2004.
[143] A. R. Willems, M. Schwab, and M. Tyers, “A hitchhiker’s guide to the cullin
ubiquitin ligases: SCF and its kin,” Biochim. Biophys. Acta - Mol. Cell Res.,
vol. 1695, no. 1-3, pp. 133–170, 2004.
[144] J. W. Harper, J. L. Burton, and M. J. Solomon, “The anaphase-promoting
complex: it’s not just for mitosis any more.,” Genes Dev., vol. 16, pp. 2179–
206, sep 2002.
[145] J.-M. Peters, “The anaphase promoting complex/cyclosome: a machine designed to destroy,” Nat. Rev. Mol. Cell Biol., vol. 7, pp. 644–656, sep 2006.
[146] J. a. Pesin and T. L. Orr-weaver, “Regulation of APC/C activators in mitosis
and meiosis.,” Annu. Rev. Cell Dev. Biol., vol. 24, pp. 475–99, jan 2008.
[147] P. T. Spellman, G. Sherlock, M.
P. O. Brown, D. Botstein, and
cell cycle-regulated genes of the
hybridization.,” Mol. Biol. Cell,

Q. Zhang, V. R. Iyer, K. Anders, M. B. Eisen,
B. Futcher, “Comprehensive identification of
yeast Saccharomyces cerevisiae by microarray
vol. 9, pp. 3273–97, dec 1998.

[148] B. R. Thornton and D. P. Toczyski, “Securin and B-cyclin/CDK are the only
essential targets of the APC.,” Nat. Cell Biol., vol. 5, no. 12, pp. 1090–1094,
2003.
[149] W. Heinemeyer, a. Cruhler, V. Mohrle, Y. Mahe, and D. H. Wolf, “PRE2, highly
homologous to the human major histocompatibility complex- linked Ring10
gene, codes for a yeast proteasome subunit necessary for chymotryptic activity
and degradation of ubiquitinated proteins,” J. Biol. Chem., vol. 268, no. 7,
pp. 5115–5120, 1993.
[150] M. Ghislain, a. Udvardy, and C. Mann, “S. cerevisiae 26S protease mutants
arrest cell division in G2/metaphase.,” Nature, vol. 366, no. 6453, pp. 358–362,
1993.
[151] N. Ghaboosi and R. J. Deshaies, “A conditional yeast E1 mutant blocks the
ubiquitin-proteasome pathway and reveals a role for ubiquitin conjugates in
targeting Rad23 to the proteasome,” Mol. Biol. Cell, vol. 18, pp. 1953–1963,
2007.
[152] R. Palanimurugan, H. Scheel, K. Hofmann, and R. J. Dohmen, “Polyamines
regulate their synthesis by inducing expression and blocking degradation of
ODC antizyme.,” EMBO J., vol. 23, no. 24, pp. 4857–4867, 2004.
[153] J. Terrell, S. Shih, R. Dunn, and L. Hicke, “A function for monoubiquitination in
the internalization of a G protein-coupled receptor.,” Mol. Cell, vol. 1, pp. 193–
202, jan 1998.
[154] D. Voges, P. Zwickl, and W. Baumeister, “The 26S proteasome: a molecular
machine designed for controlled proteolysis.,” Annu. Rev. Biochem., vol. 68,
pp. 1015–68, jan 1999.

151
[155] D. H. Wolf and W. Hilt, “The proteasome: A proteolytic nanomachine of
cell regulation and waste disposal,” Biochim. Biophys. Acta - Mol. Cell Res.,
vol. 1695, no. 1-3, pp. 19–31, 2004.
[156] K. L. Rock, C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang,
and A. L. Goldberg, “Inhibitors of the proteasome block the degradation of
most cell proteins and the generation of peptides presented on MHC class I
molecules.,” Cell, vol. 78, pp. 761–71, sep 1994.
[157] M. a. Hoyt and P. Coffino, “Ubiquitin-free routes into the proteasome.,” Cell.
Mol. Life Sci., vol. 61, pp. 1596–600, jul 2004.
[158] I. Jariel-Encontre, G. Bossis, and M. Piechaczyk, “Ubiquitin-independent
degradation of proteins by the proteasome.,” Biochim. Biophys. Acta, vol. 1786,
pp. 153–77, dec 2008.
[159] M. Orlowski and S. Wilk, “Ubiquitin-independent proteolytic functions of the
proteasome, Arch,” Biochem. Biophys., vol. 415, pp. 1–5, 2003.
[160] J. M. Baugh, E. G. Viktorova, and E. V. Pilipenko, “Proteasomes can degrade
a significant proportion of cellular proteins independent of ubiquitination.,” J.
Mol. Biol., vol. 386, pp. 814–27, feb 2009.
[161] G. Asher, N. Reuven, and Y. Shaul, “20S proteasomes and protein degradation
”by default”,” BioEssays, vol. 28, no. 8, pp. 844–849, 2006.
[162] S. Gandre and C. Kahana, “Degradation of ornithine decarboxylase in Saccharomyces cerevisiae is ubiquitin independent.,” Biochem. Biophys. Res. Commun., vol. 293, pp. 139–44, apr 2002.
[163] Y. Murakami, S. Matsufuji, T. Kameji, S. Hayashi, K. Igarashi, T. Tamura,
K. Tanaka, and A. Ichihara, “Ornithine decarboxylase is degraded by the 26S
proteasome without ubiquitination,” Nature, vol. 360, pp. 597–599, 1992.
[164] P. Coffino, “Regulation of cellular polyamines by antizyme.,” Nat. Rev. Mol.
Cell Biol., vol. 2, no. 3, pp. 188–194, 2001.
[165] X. Li and P. Coffino, “Degradation of ornithine decarboxylase: exposure of
the C-terminal target by a polyamine-inducible inhibitory protein.,” Mol. Cell.
Biol., vol. 13, no. 4, pp. 2377–2383, 1993.
[166] M. Zhang, C. M. Pickart, and P. Coffino, “Determinants of proteasome recognition of ornithine decarboxylase, a ubiquitin-independent substrate.,” EMBO
J., vol. 22, pp. 1488–96, apr 2003.
[167] R. M. Newman, A. Mobascher, U. Mangold, C. Koike, S. Diah, M. Schmidt,
D. Finley, and B. R. Zetter, “Antizyme targets cyclin D1 for degradation: A
novel mechanism for cell growth repression,” J. Biol. Chem., vol. 279, no. 40,
pp. 41504–41511, 2004.
[168] G. Asher, P. Tsvetkov, C. Kahana, and Y. Shaul, “A mechanism of ubiquitinindependent proteasomal degradation of the tumor suppressors p53 and p73,”
Genes Dev., vol. 19, no. 3, p. 316, 2005.

152
[169] X. Chen, Y. Chi, A. Bloecher, R. Aebersold, B. E. Clurman, and J. M.
Roberts, “N-acetylation and ubiquitin-independent proteasomal degradation of
p21 Cip1,” Mol. Cell, vol. 16, no. 5, pp. 839–847, 2004.
[170] X. Chen, L. F. Barton, Y. Chi, B. E. Clurman, and J. M. Roberts, “UbiquitinIndependent Degradation of Cell-Cycle Inhibitors by the REGγ Proteasome,”
Mol. Cell, vol. 26, no. 6, pp. 843–852, 2007.
[171] X. Li, L. Amazit, W. Long, D. M. Lonard, J. J. Monaco, and B. W. O’Malley,
“Ubiquitin- and ATP-Independent Proteolytic Turnover of p21 by the REGγProteasome Pathway,” Mol. Cell, vol. 26, pp. 831–842, jun 2007.
[172] R. J. Sheaff, J. D. Singer, J. Swanger, M. Smitherman, J. M. Roberts, and
B. E. Clurman, “Proteasomal Turnover of p21 Cip1 Does Not Require p21
Cip1 Ubiquitination,” Components, vol. 5, pp. 403–410, 2000.
[173] R. F. Kalejta and T. Shenk, “Proteasome-dependent, ubiquitin-independent
degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein.,” Proc. Natl. Acad. Sci. U. S. A., vol. 100, no. 6,
pp. 3263–3268, 2003.
[174] P. Sdek, H. Ying, D. L. F. Chang, W. Qiu, H. Zheng, R. Touitou, M. J. Allday, and Z. X. Jim Xiao, “MDM2 promotes proteasome-dependent ubiquitinindependent degradation of retinoblastoma protein,” Mol. Cell, vol. 20, no. 5,
pp. 699–708, 2005.
[175] P. Ferrara, E. Andermarcher, G. Bossis, C. Acquaviva, F. Brockly, I. JarielEncontre, and M. Piechaczyk, “The structural determinants responsible for
c-Fos protein proteasomal degradation differ according to the conditions of expression.,” Oncogene, vol. 22, no. 10, pp. 1461–1474, 2003.
[176] A. Forster and C. P. Hill, “Proteasome degradation: enter the substrate,”
Trends Cell Biol., vol. 13, pp. 550–553, nov 2003.
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Appendix: Comparison of Cdc14 catalytic efficiencies

Fig. A.1.: Comparison of catalytic efficiencies of Cdc14 enzymes. Catalytic
efficiencies of Cdc14 enzymes are normalized to that observed for the starting sequence
(Green box) for each enzyme. Each box contains the activity observed (in order from
left to right) for Sc.Cdc14, FgCdc14, Clp1, hCDC14A and hCDC14B and each value
is shaded to reflect activity (dark,high-white,low).
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Appendix: Cdc14 inhibitors
A list of Cdc14 inhibitors identified by a high throughput screen is provided below.
There are two sets of inhibitors organized by the chemical library in which they are
found. The inhibitors are also ranked based on the observed % inhibition of Cdc14
activity. Molecules selected for manual confirmation and detailed characterization
are indicated by green shading.
The first set of molecules are from the DIVERSet commercial chemical library
available from ChemBridge.
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The molecules below are from a custom library of small molecules.

168

169

170

171

172

VITA

173

VITA

Michael Melesse
Personal Data
email:
CellPhone:
Linkedin:
Address:

mmelesse@purdue.edu
(503) 750-1838
www.linkedin.com/in/mmelesse/
Department of Biochemistry, Purdue University
1203 West State St., West Lafayette, IN 47907

Education
December 2015

Ph.D. in Biochemistry, Purdue University
West Lafayette, IN
Advisor: Dr. Mark C. Hall
May 2008 B.A. in Biochemistry and Molecular Biology,
Reed College, Portland, OR
Advisor: Dr. Ronald W. McClard

PUBLICATIONS
Melesse M., Choi E., Hall H., Walsh M.J., and Hall M.C., Timely activation of
budding yeast APCCdh1 involves degradation of its inhibitor, Acm1, by an unconventional proteolytic mechanism, PLoS One, 9(7): e103517. doi:10.1371/journal.pone.0103517
Powers B.L., Melesse M., Eissler C.E., Charbonneau H., and Hall M.C., Measuring activity and specificity of protein phosphatases, Methods in Molecular Biology.,
2016; Vol. 1342:221-35. doi:10.1007/978-1-4939-2957-3
Li C., Melesse M., Zhang H, Hao C., Wang C., Zhang H., Hall M.C., Xu
J.R., FgCDC14 regulates cytokinesis, morphogenesis, and pathogenesis in Fusarium graminearum, Molecular Microbiology, 2015 Aug. doi: 10.1111/mmi.13157.
In Preparation
Qin L., Melesse M., Guimaraes D., Hall M.C., Reevaluation of APCCdh1 degron
sequences
Iliuk A., Li L., Melesse M., Hall M.C. and Tao W.A., Multiplexed imaging of
protein phosphorylation on membrane based on Ti(IV) functionalized nanopolymer,
Angewandte Chemie

174
RESEARCH EXPERIENCE
Current Ph.D. Candidate
Department of Biochemistry,

Purdue

University,

West

Lafayette, IN

• Topic: Cell cycle regulation, protein degradation.
Identification of the degradation mechanism of the Saccharomyces cerevisiae protein Acm1.

PI: Dr. Mark C. Hall.
• Topic: Cell cycle regulation, protein phosphorylation.
Determination of the substrate selectivity of a cell cycle regulated phosphatase, Cdc14.

PI: Dr. Mark C. Hall

Research Assistant
- Oregon Health and Sciences University, Portland, OR
Summer 2009
• Research assistant for project entitled “ Identification of
ligands of Anaplastic lymphoma kinase in Mus musculus”. Biochemical characterization of protein substrates.
PI: Dr. Joseph Weiss
Fall 2008

Fall 2007 Undergraduate Research Assistant
to Chemistry Department, Reed College, Portland, OR
Summer 2008
• Undergraduate year long thesis project entitled “Sitedirected mutation of the Saccharomyces cerevisiae
OPRTase flexible loop: potential application to structural studies”.
PI: Dr. Ronald W. McClard.

Summer 2007 Undergraduate Summer Research Assistant
Chemistry Department, Reed College, Portland, OR

• Worked on a summer research project towards the organic synthesis of a pH switch for selective delivery of
radioactive iodine into cancerous cells.
PI: Dr. Patrick G. McDougal.

175
HONORS AND AWARDS
Aug. 2015 Bird Stair Fellowship award, Department of Biochemistry, Purdue
University

April 2015 Outstanding Teaching Assistant Award, Department of Biochemistry, Purdue University

Feb. 2015 Bird Stair Fellowship award, Department of Biochemistry, Purdue
University

April 2014 Henry Weiner Travel Award, Department of Biochemistry, Purdue
University

Sept. 2009 Ross Fellowship, Purdue Graduate School, Purdue University
In progress Graduate Teacher Certificate, Center for Instructional Excellence,
Purdue University

Aug. 2004 National Honors Society, International Community School of Addis
Ababa

Aug. 2004 International Baccalaureate diploma International Community
School of Addis Ababa

TEACHING EXPERIENCE
Fall
Summer
Spring
Fall
Spring
Fall
Spring
Spring
Spring

2015
2015
2015
2014
2014
2013
2013
2012
2011

BCHM221
BCHM309
BCHM100
BCHM100
BCHM100
BCHM309
BCHM695
BCHM307
BCHM309

Small Molecule Biochemistry
Biochemistry Lab
Introduction to Biochemistry
Introduction to Biochemistry
Introduction to Biochemistry
Biochemistry Lab (2 sections)
Macromolecules
Biochemistry
Biochemistry Lab (2 sections)

Dr. Steven S. Broyles
Dr. Orla Hart
Dr. Vikki Weake
Dr. Clint C. Chapple
Dr. Vikki Weake
Independent
Dr. Ann L. Kirchmaier
Dr. James C. Clemens
Dr. James T. Henderson.

MENTORING
Summer
Spring
Summer
Summer
to Spring
Spring
to Fall
Summer

2014
2014
2013
2012
2013
2012
2013
2011

Denise Ward, NSF Research Experience for Undergraduate (REU) program
Ryan Chaparian, Biochemistry undergraduate student
Perla Cruz, Summer Undergraduate Research Foundation (SURF) program
Mercedes Leland, Biochemistry undergraduate student
Michael Walsh, Biochemistry undergraduate student
George Habib, Summer Undergraduate Research Foundation (SURF) program

Spring and Matt Berret, Biochemistry undergraduate student
Fall 2011

176
PROFESSIONAL ACTIVITIES
Chair • Graduate student invited lecture committee, Biochemistry
department, Purdue University (Fall 2013)

Poster judge • REU (Research Experience for Undergraduates) / SURF
(Summer Undergraduate Research Fellowships) Program,
Purdue University (July 25, 2013)

• Biochemistry department research retreat,Turkey Run State
•
Member •
•
•
•
•

Park, (September 24, 2011)
SURF Program, Purdue University (August 3, 2011)
Graduate student advisory board, College of Agriculture, Purdue University (Spring 2012 - Present)
Grades appeal committee, College of Agriculture, Purdue University (Fall 2012, Fall 2013-Spring 2014)
Graduate student invited lecture committee, Biochemistry
department, Purdue University (Spring 2012)
Awards committee, College of Agriculture, Purdue University
(Fall 2012)
Graduate student invited lecture committee, Biochemistry
department, Purdue (Fall 2010)

SEMINARS AND POSTER PRESENTATIONS
Aug. 21, 2015 Cdc14 phosphatase substrate selectivity is conserved
Biochemistry Department Annual Retreat, Poster

Nov. 12, 2014 Identification of Cdc14 phosphatase inhibitors and applications to cancer
Purdue Cancer Center Research Retreat, Poster

Oct. 17, 2014

Understanding and exploiting Cdc14 substrate selectivity
Biochemistry Departmental Graduate student and Postdoc seminar series, Purdue University, Seminar

July 13-18, 2014

Towards the design of Cdc14 phosphatase inhibitors
FASEB Yeast Chromosome Structure, Replication and Segregation, Poster

Nov. 15, 2013

Characterization of the mechanism and biological function
of Acm1 degradation
Biochemistry Departmental Graduate student and Postdoc seminar series, Purdue University, Seminar

Sept. 28-29, 2013

Determining the function of Acm1 degradation
Midwestern Yeast Meeting, Northwestern University, Poster

April 19, 2013

A cell cycle regulated proteolytic mechanism independent
of ubiquitin conjugation to the substrate
Ubiquitination Processes and Their Role in Cancer, MiniSymposium and Poster Session, Purdue University, Poster

177
SEMINARS AND POSTER PRESENTATIONS (cont.)
Aug. 17, 2012

Determining the mechanism for Acm1 (APCCdh1 modulator
1) degradation
Biochemistry Department Annual Retreat, Turkey Run state
park, Poster

March 9, 2012

Characterization of Acm1 degradation
Biochemistry Departmental Graduate student and Postdoc seminar series, Purdue University, Seminar

Dec. 11, 2011

Polyubiquitination independent degradation of Acm1
Cell cycle regulation group meeting, Purdue University, Seminar

Sep. 24, 2011

Identification of proteins required for degradation of the
APC inhibitor Acm1
Biochemistry Department Annual Retreat, Turkey Run state
park, Poster

Nov. 12, 2010

Characterization of the proteasome mediated degradation
of Acm1
Biochemistry Departmental Graduate student and Postdoc seminar series, Purdue University, Seminar

Oct. 2, 2010

Identification of proteins required for degradation of the
APC inhibitor Acm1
Biochemistry Department Annual Retreat, Turkey Run state
park, Poster

TECHNICAL SKILLS
Biochemistry Protein purification, (co-)immunopurification, pulse-chase
analysis, high-throughput chemical screening, enzymatic assays (experimental and data analysis).
Analytical Flow cytometry, MS (MALDI-TOF), chromatography (thin
layer, ion exchange, SEC, HPLC, RPC), quantitative western blot, titrations, photo-spectrophotometry, Agarose and
PAGE electrophoresis.
Molecular biology Cloning: primer design, restriction digest analysis, ligations, transformation, RNA extraction, reverse transcription, PCR, DNA purification, DNA quantification and extraction, TOPO R and Gateway R cloning, genetic modification of yeast (gene deletion, genomic tagging).
Cellular biology liquid and solid culture of yeast and bacteria, cell cycle synchronization; microscopy: fluorescence and light.

178
OTHER ACTIVITIES
Safety committee
Peer mentor
Co-founder and
president
Intern

Member, lab safety committee Bindley Biosciences Center
(BBC), West Lafayette, IN (July 2014 - Present).
Peer mentor program, Reed College, Portland, OR (August 2005
- May 2008).
International Students Union, Reed College, Portland, OR
(Aug. 2005 - May 2008).
Multicultural Resources Center, Reed College, Portland, OR
(Jan. 2005 - May 2006).

